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The overall aim of this PhD is to use a multidisciplinary approach to determine the 
function of Ulcerative Colitis (UC) associated SNPs, to help understand the role of SNPs in 
the pathogenesis of UC in general and in a patient specific context.  
UC is a chronic, relapsing inflammatory disease of the large bowel for which the aetiology 
is thought to be a trifecta of 1) dysregulation of the immune system in response to 2) an 
environmental trigger in a 3) genetically susceptible host. Genetic susceptibility or 
susceptibility loci for UC have been identified by Genome Wide Associations Scanning and 
subsequent fine mapping and deep sequencing.   
This work intended to further characterise these susceptibility loci at a global level and a 
patient specific level using both a systems biology approach and experimental validation 
of the in-silico work. Using publicly available datasets non exonic UC associated SNPs were 
functionally annotated to regulatory regions within the genome. Exonic SNPs were also 
analysed looking at impacts in protein linear motifs and splice enhancement motifs. 
Bioinformatics was used to identify interacting proteins and create a UC-interactome 
network. This suggested that UC was a disease of fine regulators as opposed to a disease 
of specific target proteins.  
Analysis of the UC-interactome identified the focal adhesion complex (FAC) that is 
involved in regulating wound healing as major component of the network. One member 
of the FAC, Leupaxin (LPXN), was identified as a potential target for validation.  Using 
CRISPR-Cas9 technology, LPXN overexpressing cell lines and knock out cell lines were 
created. Wound healing assays and cytokine analysis identified that overexpression of 
LPXN impaired wound healing and reduced the secretion of MCP-1.  In addition, using 
genotyped colonic biopsies from UC patients and control patients in a polarised in vitro 
organ culture (pIVOC) system we show that the LPXN risk allele may impact on cytokine 
production.  
Finally, UKIBD genetics consortium data was used to access a pilot dataset of 58 patients’ 
SNP profiles from Immunochip data who were patients at the Norfolk and Norwich 
University Hospital to create patient-specific UC-interactomes. Analysis of these 
footprints identified convergent interacting proteins affected by multiple SNPs and novel 
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The gastrointestinal (GI) tract compromises a number of hollow organs from the mouth 
to the anus whose function includes digestion of food, absorption of nutrients, water and 
electrolyte balance and excretion of waste.   The GI tract can be divided into two regions, 
based on embryonic origins of the foregut or midgut. The upper GI tract consists of the 
mouth, pharynx, stomach and duodenum. The lower GI tract consists of the remainder of 
the small intestine (jejunum and ileum), the colon and the anus (Figure 1-1).  In order for 
digestion to occur, other visceral organs are required e.g. the liver, pancreas , gallbladder. 
 
Figure 1-1 Anatomy of the human GI tract. Schematic representation of GI tract from oesophagus to rectum. 
(Adapted from Servier Medical Art, 2016) 
The GI tract along its length is essentially a hollow tube comprising four layers (Figure 1-2), 










Figure 1-2 Layers of the GI tract. Schematic of the four layers of the GI tract; mucosa, submucosa, muscularis 
and serosa.(Adapted from Servier Medical Art).  
Although each layer of the GI tract wall is present, each part of the GI tract has anatomical 
features and functions unique to that section. An example of this is the stomach wall 
epithelium containing parietal cells to produce the hydrochloric acid required for the 
chemical breakdown of food bolus or the small intestine having villi to increase the surface 
area available for nutrient absorption.  
The function of the healthy colon is to reabsorb fluid and electrolytes from the stool and 
propulsion of intestinal contents towards the anal canal.  The colon also plays a significant 
function in the induction of mucosal tolerance to gut microbiota. The human intestine 
contains over 100 trillion microorganisms, which live in symbiosis and homeostasis with 
the human host, providing a role in extracting energy, mineral and bioactive compounds 
from food.  The gut associated lymphoid tissue (GALT) is the largest immune system in the 
body, which is continuously stimulated by gut microorganisms who provide natural 
antigens to induce mucosal immune tolerance (local and systemic immune 
unresponsiveness) to innocuous antigens (1). A functioning GALT is necessary to prevent 
acute proinflammatory immune responses against commensal microbiota (2).  Tolerance 
to colonic microbiota attenuates local immune responses but not systemic immune 
responses, this is appropriate as an E. coli which is part of the common microbiota, may 




Inflammatory bowel disease is an umbrella term used to describe chronic or recurring 
inflammation of the gastrointestinal tract. It is a comprised of two major clinical entities. 
Crohn’s disease (CD) – characterised by patchy inflammation of the gastrointestinal tract 
(GIT) which can occur anywhere between the mouth and the anus and has multiple 
phenotypes associated with the advent of stricturing of the bowel, perianal disease, or 
the formation of fistulae (abnormal connections between two hollow viscous or the bowel 
and the skin). This is opposed to Ulcerative Colitis (UC), which is characterised by 
continuous superficial ulceration of the large bowel from the rectum proximally, which 
can extend to involve the entire large bowel.  
Classical histological features characterising CD are chronic inflammation comprising 
increased lamina propria, plamacytosis in association with chronic architectural distortion 
and patchy neutrophilic inflammation, cryptitis, crypt abscesses or erosions; skip lesions 
of focal, patchy erosions, vertical fissures and fistulas; transmural inflammation with 
multiple lymphoid aggregates; granulomas and submucosal fibrosis and neuromuscular 
hyperplasia of submucosa. This is in comparison to features of UC which also comprise 
alteration of crypt architecture, basal plasmacystosis, neutrophilic cryptitis, crypt 
abscesses; inflammation is typically limited to the mucosa and submucosa. The use of 
immunosuppressive medication can cloud the histological picture, making initial diagnosis 
and distinguishing between CD and UC more difficult. 
UC has a bimodal age distribution with the first peak of diagnosis in the first and second 
decade of life and a second incidence peak occurring after the sixth decade of life. The 
annual incidence of UC in Europe is 24.3 per 100,000 person years (prevalance 505 per 
100,000 person years), 6.3 per 100,000 person years in Asia and Middle East (prevalance 
249 per 100,000 person years), 19.2 per 100,000 person years in North America. 
Within Europe, extensive review of incidence figures indicate and estimate of 178,000 
new cases of UC across Europe per year, with the prevalence expected to increase due to 
the early age of onset and low mortality of UC patients. 
UC can affect the large bowel from the rectum extending proximally. The site, extent and 
severity of the disease dictate therapeutic management strategies. The site can be that 
which affects only the rectum (proctitis), that affecting the rectosigmoid 
(proctosigmoiditis also known as distal colitis), that affecting up to the splenic flexure (left 
23 
 
sided colitis), and intermediary of that affecting around to the transverse colon 
(‘extensive’) and that affecting the whole large bowel (pancolitis).    
In the IBSEN cohort (3), the distribution of disease extent was 32% patients had proctitis, 
35% had left sided colitis (above the rectum to the splenic flexure) and 33% had extensive 
(past the splenic flexure to pan colitis).  Interestingly 28% of the patients with proctitis 
had disease that progressed proximally with 10% extending to extensive colitis over the 5 
years follow up period.  
There are additional phenotypes which include those patients who development 
extraintestinal manifestations (EIMs) (Table 1-1).  The classification of EIMs is wide and 
can be broadly characterised into complications of the disease and or treatment e.g. 
osteoporosis or dermatological manifestations of nutritional deficiencies, or diseases that 
are associated with a patient’s HLA status e.g. ankylosing spondylosis, psoriasis, vitiligo, 
or “inflammatory processes” that follow the inflammatory course of the IBD e.g. 
seronegative arthritis, reactive dermatological lesions, and ocular manifestations. 
Extraintestinal manifestations are seen in 25-40% of patients with inflammatory bowel 
disease, why they occur in some patients but not others are not always clear.  There is 
also a subset of patient with UC who develop Primary Sclerosing Cholangitis(PSC) – 
inflammation and scarring of the bile ducts which can progress to liver cirrhosis requiring 
the patient to potentially undergo a liver transplant and predisposes to the development 
of bile-duct carcinoma. The severity of PSC is well documented to be inversely 





Table 1-1 Extraintestinal manifestations of UC 
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Treatment of UC is dependent on severity as determined by the Truelove and Witt 
criteria(4) (Table 1-2) and to some degree the extent of the disease in the milder cases 
(Figure 1-3). As shown by the flow charts below, mild to moderate flares are treated 
depending on the site of the disease to bring the acute symptoms under control. Patient 
tolerability and side effects of drugs also play a significant part in medical management. 
 
Table 1-2 Truelove and Witt Criteria for disease severity 
 
Figure 1-3 Flow chart of treatment for mild to moderate flares (adapted from NICE Guidelines for the 
Management of UC) 
For acute severe flares, a different strategy is required to rapidly bring the inflammation 
under control in an inpatient setting, this includes intravenous drug administration and 
close monitoring (Figure 1-4). The font size is reference to the most frequent 




Figure 1-4 Flow chart for the treatment of acute severe UC flare (adapted from NICE guidelines for the 
management of UC) 
Once the flare is under control, the aim of ongoing management is to prevent further 
flares or maintain the patient in remission. Maintenance therapy, like treatment of flares, 
is site specific and functions, like the WHO Analgesia ladder, in terms of starting with the 
‘gentler’ therapies first and escalating though increasing immunosuppression to 









The side effect profile of 5Amino salicylic acids (5ASAs) are not insignificant, but affect a 
minority of patient with 11.1 reports per million prescriptions of interstitial nephritis (5, 
6) and 7.5 reports per million prescriptions of pancreatitis (5). 50% of UC patients treated 
with 5ASAs require escalation of treatment.  The first rung of maintenance therapy 
escalation is to the thiopurines; purine analogs which halt DNA replication in actively 
replicating cells (such as T and B cells). Consequently, bone marrow suppression and 
hepatoxicity are dose-dependent side effects of thiopurines.  Other side effects that have 
been reported by multivariate pharmacosurveillance include pancreatitis, anaemia, cell 
lysis and nephrotoxicity (7). Thiopurines are associated with an increased risk of 
lymphoma and non-melanoma skin cancer (8). Patients requiring further escalation of 
therapy to monoclonal antibody use, are at risk of serious and opportunistic infections , 
such as pneumonia, sepsis, fungal infections and tuberculosis (TB) (9) (10). A variety of 
infections have been reported in patients treated with Anti-TNF monoclonal antibodies 
including candidiasis, varicella zoster, herpes zoster, EBV, CMV, herpes simplex, Listeria 
infections and Pneumocystis jirovecii. Reactivation of infectious diseases that are dormant 
is also a risk, including TB and Hepatitis B (11). Other adverse events for Anti-TNFs include 
infusion reactions which are characterised by arthralgia, myalgia, urticarial rash, fever and 
or malaise, injection site reactions, skin lesions, lupus like syndrome, demyelinating 
disease, heart failure, melanoma and cervical dysplasia. Combination therapies such an 
anti-TNFs and thiopurines, may be associated with marginally higher rates of TB, 
candidiasis and herpes zoster, although this is not consistent across the literature field, as 
some studies suggest there is no difference between risk of infection between single 
agent and combination therapy (SONIC trial(12)). The risk of lymphoma is increased in 
combination therapy and specifically the risk of hepatosplenic T cell lymphoma is 










Although genetics can by no means explain the increasing incidence of Inflammatory 
Bowel Disease, there is a genetic predisposition. In 1987, Monsen et al(14) published an 
observational study of the familial occurrence of inflammatory bowel disease in patient 
with UC. They showed that the prevalence of UC in first-degree relatives was 15 times 
higher than in non-relatives and there was a general prevalence of 7.9% for IBD 
(regardless of the type) among relatives.  
By 1989 the first genetic associations for UC were being identified by candidate gene 
analysis in the major histocompatibility complex; HLA genes (15), as well as T cell receptor 
and Immunoglobulin heavy chains (16). The HLA region continued to be of significant 
interest, with the HLA-B locus associated with UC susceptibility in Japanese populations 
(17), and HLA-DR2, HLD-DR4 being associated with UC in the context of ANCA antibodies 
(18). The HLA regions continued to have both positive and negative associations with UC 
depending on the size, the clinical heterogeneity and ethnicity of the cohort (19-21). The 
impact of disease heterogeneity, ethnicity and differing methodologies on genetic marker 
studies was highlighted by Satsangi et al (22) in their investigation of the relationship 
between ANCA status, HLA genotype and clinical patterns on IBD where ANCA positive 
status was not associated with HAL-DR2 or DR4 in the UC population.  
Also within the MHC complex lie the tumour necrosis factor genes. In 1996, the 
distribution of 4 polymorphisms in TNF genes were analysed in IBD (20), which began to 
identify some of the complexities associated with susceptibility polymorphisms. The 
authors highlighted that some of the polymorphisms were more present in UC compared 
to controls, some were less present, and there were tendencies as opposed to statistically 
significant associations. The authors concluded that although the TNF genes were not 
susceptibility markers, they may be markers for subsets of patients with UC.  
Cytokines and their role in inflammation provided a good source of genes for candidate 
gene analysis. The IL-1 receptor antagonist was associated with UC susceptibility in 1994 
(23)with allele 2 of interleukin-1 receptor antagonist (IL-1RA) being significantly over-
represented in UC patients (35% vs 24% in controls), the authors also noted that this was 
more prevalent in UC patients with total colitis. Further examination of allele 2 of IL-1RA 
identified that a synergistic effect between IL-1beta/IL-1RA allelic cluster participated in 
the susceptibility to UC (24). This cluster was reanalysed in a different cohort and no 
significant difference in genotype distribution was found, however when the cohort was 
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stratified by disease severity, there was a higher frequency of UC patients who required 
surgery who had the genotype of interest (25).   
In a further candidate gene study, IL-2 microsatellite markers (polymorphic dinucleotide 
repeats) were modestly linked with UC, but due to small numbers the TDT failed to reach 
significance (26). 
ICAM1 (intercellular adhesion molecule-1) was the next candidate gene to be analysed in 
UC  associated with ANCA status (27), which again on a population wide scale identified 
no association with UC or CD, but when stratified for ANCA-status there was a borderline 
statistically significant association with ANCA negative UC patients. How ANCA status and 
ICAM-1 polymorphisms functioned synergistically was not identified.  
The hint of genetic involvement of epithelial barrier dysfunction in UC, came with the Kyo 
et al paper (28) which identified rare polymorphisms of variable number of tandem 
repeats in the intestinal mucin gene MUC3 that was associated with UC in both Japanese 
and Caucasian populations 
With the advent of improving gene mapping technology and GENEHUNTER (a linkage 
analysis program (29), IBD2, a pericentromeric region of chromosome 12 was identified 
as associated with UC. This was confirmed with strong evidence for linkage of both CD 
and UC (30).  
A further IBD locus, IBD1, on chromosome 16 was associated with UC. By typing eight 
microsatellite markers from the IBD1 locus in 70 kindreds Mirza et al (31) identified that 
the locus D16S419 was associated with an estimated relative risk of 1.46. The authors 
concluded that IBD1 may contribute to the susceptibility of UC.  
GENEHUNTER again, with transmission disequilibrium testing (TDT) was used to confirm 
IBD2 as being linked to UC in 122 North American Caucasian families (32). Chromosome 
12 and chromosome 16 continued to provide strong linkages to IBD in sibling genotyped 
cohorts but this technique requires large cohorts of sibling related disease and non-
disease sufferers. 
In a step away from candidate gene analysis, genome wide screening using 377 autosomal 
markers in sibling pairs identified IBD susceptibility loci in 1p, 3q and 4q with potential 
epistasis between 1p and IBD1 (33). Genome wide screening on larger sibling pair cohorts 
using autosomal markers began to link further chromosomal loci to UC, including loci on 
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chromosome 1, 6 (6p particularly – the site of leukocyte antigen and TNF genes), 10 and 
22.  
Genome wide scanning provides the basis for further candidate gene analysis, an example 
of this is the gene for natural resistance associated macrophage protein 2 (NRAMP2).  This 
was examined on the basis of the genome wide scanning and a plausible hypothesis that 
NRAMP2 had a role in innate immunity. Unfortunately, nonparametric linkage analysis 
and TDT did not provide evidence of linkage of NRAMP2 to IBD, nor UC or CD specifically. 
Further sequence analysis, although identified that the signal from the genome wide 
scanning of chromosome 12 was not NRAMP2 and that the signal was due to linkage 
disequilibrium with the disease causative gene (34). Higher density genome wide scans 
aimed to overcome this difficulty, but locus heterogeneity and sample size were limiting 
factors in the fine localisation of disease susceptibility loci (35, 36) in the early 2000s.  
With the completion of the Human Genome Project in 2003(37) which identified 3 billion 
bases of human DNA and the International HapMap Project 2005(38) it was possible to 
catalogue the wealth of single nucleotide genetic variants within humans. The HapMap 
described the SNP position within the DNA and their distribution amongst populations.  
As described above, allelic variations in candidate genes had already been associated with 
UC, however now, scientists had the availability to undertake hypothesis free analysis of 
the genetics of disease cohorts, thereby potentially identifying novel susceptibility genes 
associated with disease susceptibility by genome wide association scanning.  
Genome wide association (GWA) is an approach that involves rapid scanning of markers 
across genomes of specific populations to highlight genetic variations associated with a 
particular disease. GWA involves identifying SNPs that are present in the target 
population e.g. patients with UC, significantly more or less frequently than in the control 
group. The SNPs, however, may not be disease causative, and like the NRAMP2 story, the 
identified SNP may be in linkage disequilibrium with the causative variant.  
Fine mapping for possible causal alleles may alleviate this problem, but again markers that 
are strongly correlated could still be relatively distant, but statistically close. Deep 
sequencing where whole genomes are sequenced multiple times allows for validation of 




Over 163 SNPs(39) have been associated with Inflammatory Bowel Disease, many 
involving the adaptive immune system overlapping between both CD and UC, suggesting 
a common pathway(40). Key pathways(41) that have been identified for CD include 
autophagy pathways, the innate and adaptive immunity and bacterial recognition. For UC, 
the mucosal epithelial barrier has been highlighted as an area of interest (41)(Table 1-3). 
Gene Protein Function 
CDH1 E-cadherin Adherens 
junction protein 

























ITLN1 Intelectin-1 Brush border 
protection 
PTGER4 EP4 Receptor Epithelial 
restitution 
CARD15 NOD2 Recognition of 
PAMPS 
Table 1-3 UC risk associated genes that have roles in the intestinal epithelial barrier 
Whole genome sequencing at low coverage has identified a further missense variant at 
ADCY7 that doubles the risk of UC (42). Further high resolution fine mapping, identified 
18 associations to a single causal variant with >95% certainty and a further 27 associations 
with a single variant with >50% certainty. The variants were enriched for protein coding 
changes, direct disruption of transcription factor binding sites and tissue specific 
epigenetic marks, with gut mucosa associations stronger in UC (43). Translational impacts 
of IBD SNPs have been seen in the IL23/IL17 axis, as well as the JAK/STAT pathway. SNPs 
in the IL23 receptor have been associated with both CD and UC, as well as psoriasis and 
ankylosing spondylitis suggesting a shared inflammatory pathway. The IL23/IL17 axis has 
been heavily implicated in inflammatory bowel disease with risk variants being identified 
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in the IL23R, STAT3, JAK2(signal transduction), IL12b (common subunit of IL12 and IL23) 
and CCR6 (chemokine expressed on IL17 producing cells)(39, 44, 45). In terms of 
translational aspects of this, the JAK pathway has been targeted via Tofacitinib, on oral 
JAK inhibitor, which has been trialled for induction of remission in patients with moderate 
to severe UC(46); Ustekinumab (Stelara), which targets the p40 subunit of IL12/23 is 
another novel therapeutic agent used in  CD(47). 
Many of the loci identified within the GWA share association with other inflammatory 
disorders such as coeliac disease, multiple sclerosis, primary biliary cirrhosis (which is 
clinically associated with UC) highlighting that these susceptibility loci create a 
predisposition to a chronic inflammatory state(41), but the phenotype is determined by 
other factors, such as tissue specific epigenetics (as highlighted by differential genome 
wide transcriptome(48) and methylome analysis of colonic biopsies in UC patients 
compared to healthy controls(49) or environmental factors such as smoking, the role of 
the gut microbiota(50), enteric infections and antibiotic exposure in childhood. To add 
weight to this, twin studies have demonstrated a change in microbiota between patients 
with CD and their healthy twin(50). The relapsing/remitting nature of UC and the onset of 
disease in the 2nd the 3rd decade of life also (51)implicates environmental processes in the 
instigation of the inflammatory response.  These environmental factors and epistasis(52) 
may explain the gap between the explained heritability and the true heritability of UC.  
IBD related genes have been shown to organise into regulatory networks enriched for 
inflammatory and immune networks (53). Using integration of large scale DNA, RNA 
variation data in the context of active IBD using immune networks, a conserved 
inflammatory component was highlighted which was enriched for genes associated with 
known CD and UC susceptibility loci. Key driver genes including CD53, RHOH, DOCK2, FGR, 
NCKAP1L, CXCL10, FCER1G, SLAMF8, NFAM1, P1K3CD, DOK3, GBP5, AIF1, GPSM3 have 
been identified and validated in macrophage cell culture models.  None of the individual 
mutations gave rise to spontaneous colitis in the models, highlighting that none were 
causal, but result in subtle modulations of regulatory states. The networks demonstrated 






The human GI tract is exposed from birth to food, environmental toxins and 
microorganisms.  Colonisation of the human GI tract from birth by microbes is essential 
for normal function of the GI tract and development of the GI associated immune system 
(51). This complex and dynamic ecosystem containing a diverse intestinal microbiota that 
includes Archae, Bacteria and Eukarya have been shown to impact on human health 
parameters including metabolic (55), nutritional (56), physiological (57, 58) and 
immunological processes(59) within the human body.  Disturbance of the microbiota in 
childhood, for example, by multiple exposures to antibiotics has been associated with 
development of allergies (60) and CD (61, 62). Across IBD a reduction in bacterial diversity 
of the microbiota has been observed consistently and in UC a reduction in Bacteriodetes 
has been documented (63). The role of microbiota dysbiosis in the aetiology of intestinal 
inflammation remains unclear (64), but we know there is a fine homeostatic balance 
between the beneficial effect of the commensals and the risk of commensals causing a 
systemic inflammatory response should they cross the gut wall. The human body defends 
against this at the point of contact with the formation of a selectively semi-permeable 
epithelial barrier.  
This intestinal barrier has three major components composed of physical, biochemical 
and immune elements.  
 
1.2.2 The	physical	barrier	of	the	mucosal	epithelium	
The physical barrier consists of a stratified mucous layer and mucosal epithelium 
comprising enterocytes, goblet cells, crypt epithelial cells, and intraepithelial lymphocytes 
which form and are part of a semi-permeable epithelial barrier. Beneath the mucosal 
epithelium is connective tissue and supportive tissue of the lamina propria. Within the 
lamina propria are the immunocompetent cells including dendritic cells, macrophages 




































































The mucous layer is mainly comprised of densely O-glycosylated MUC2 (65) secreted by 
goblet cells. Muc2-/- mice develop colitis and have an increased risk of colorectal cancer 
associated with the presence of bacteria in direct contact with the mucosal 
epithelium(66). Examination of colonic biopsies from UC highlight a reduction in the 
number of goblet cells and corresponding reduction in expression of MUC2 and 3, with 
reduction correlating with severity and extent of disease(67). During inflammation, the 
mucous layer in UC is thinner or absent (68), probably due to an increase in mucolytic gut 
microbiota  in UC patients (69).  
 
Enterocytes, which form the majority of the mucosal epithelium, are columnar cells 
approximately 25um in height and 8um in width. Their apical surface is covered with 
microvilli which is covered in a mucous layer. The enterocytes are connected with 
adjacent cells by junctional complexes; tight junctions, adherens junctions, desmosomes, 
and gap junctions. These junctions help maintain barrier integrity. The basal membrane is 
anchored to the extracellular matrix by hemidesmasomes and focal adhesion complexes 
(Figure 1-7). The extracellular matrix is composed of collagen, laminin, fibronectin and 
glycosaminoglycans.  Defects in the epithelial barrier and increased intestinal 
permeability has been demonstrated in UC and CD as well as non-affected family 
members and spouses (70-72).    
 
Tight junctions regulate epithelial permeability (73). The junctional complexes are 
disordered in UC, with desmoglein-2 (desmosome), occludin, E-cadherin and Beta catenin 
expression reduced in inflamed UC colonic samples compared to non-inflamed UC colonic 
samples and non IBD controls (74). Tight junction structure is known to be altered in CD 
in both inflamed and non-inflamed mucosa leading to an impaired barrier function (75).  
Inflammatory cytokines TNFa and IFN-y trigger intestinal barrier defects acutely by 
cytoskeletal contraction (actin reorganisation) (76) or chronically by modulation of tight 



































































The junctional complexes are also regulated by microRNAs. miRNAs are small, 
endogenous RNA molecules that can negatively regulate target gene expression at the 
post transcriptional level.  Table 1-4 identifies the miRNAs involved in intestinal epithelial 
permeability, several of which have been shown to be overexpressed in UC. MicroRNAs 
are aberrantly expressed in both the mucosa and peripheral blood of UC patients (Table 
1-5)(81), however their functions have yet to be fully elucidated. 
 
















Mir-21 Degradation of 
RhoB mRNA, 
































Mir-212 Repression of 
ZO-1 expression 
unclear 
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Mir-505 Down regulated 





As well as being a physical barrier, enterocytes recognise gut microbiota with pattern 
recognition receptors (PRR) such Toll Like Receptors (TLRs), nucleotide oligomerisation 
domain (NOD) or caspase recruitment domain families (CARD). These receptors recognize 
microbes by essential and highly conserved ‘pathogen-associated molecular patterns’ 
(PAMPs) or ‘microbe-associated molecular patterns’ (MAMPs). When stimulated with a 
ligand, the PRRs induce a rapid first line of defence.  There is, however, tolerance towards 
the presence of commensal microbiota by limiting the expression of PRRs in the human 
colon e.g. TLR3 and TLR5 which recognise viral infections and flagellin are abundantly 
expressed, but TLR2 and TLR4 (which recognise lipoptide agonists and lipopolysaccharide) 
expression is low in a healthy gut but can be induced (82). Toll like receptor signalling 
compounds include MyD88, which, when knocked out in mice leads to reduced levels of 
mucin-2, impaired antimicrobial activity, a greater number of mucus associated bacteria, 
translocation events and colitis susceptibility (83). PRR signalling, therefore plays an 
important role in intestinal homeostasis as well as the mucosal innate immune response. 
 Stimulation of PRR in colonic enterocytes leads to production and secretion of 
antimicrobial peptides called Beta-defensins. Beta-defensins are dependent on PRRs for 
transcription induction or for secretion. Human Beta –defensin 1 (HBD1) is constitutively 
expressed in colonic enterocytes, HBD2 is inducible and upregulation is dependent on 
inflammation or pathogens present (84, 85). Patients with colonic CD (CD) have a 
diminished ability to upregulate HBD2 and secrete it (85). In CD, a single nucleotide 
polymorphism (SNP) in the HBD1 gene promoter was annotated to affect the HBD1 mRNA 
level (86), leading to low HBD1 mRNA levels in colonic CD (87). In active UC defensins are 
upregulated  (88) indicating stimulation of PRRs in the inflammatory process.  
Once the mucosa is injured AMPs from immune cells within the lamina propria are 
released, this includes calprotectin which is now utilised in a clinical setting by physicians 
as a marker of inflammatory in IBD patients (36) (89). Calprotectin is a calcium binding S-
100 protein family member that is released from dead and dying neutrophils. It inhibits 
growth of Staphylococcus aureus, E. coli and Candida albicans.  Lactoferrin, a glycoprotein 
AMP that is found in the secretory granules of neutrophils, was also investigated as a 
biomarker of inflammation in IBD (90), but was found to be less sensitive than faecal 
calprotectin (91) (92). Lactoferrin sequesters iron in the mucous layer, thereby inhibiting 
microbial growth. Immune cells within the lamina propria also release TNFalpha and IFNy 
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which induces epithelia cell apoptosis, leading to increased permeability of the intestinal 
mucosa (93).  
1.2.4 The	colonic	innate	and	adaptive	immunity	cross	over	
The interplay between the rapid, non-specific response of the innate immune system and 
the highly specific, long lasting immunity of the adaptive immune system plays a key role 
in intestinal homeostasis and when dysregulated, the pathogenesis of IBD. The triggers of 
the innate immune system, the PRRs are controlled via expression and localisation. For 
example, intestinal epithelial cells lack expression of TLR4, or MD2/CD14 (required 
proteins for TLR4 recognition and signalling), or TLR4 is located in intracellular 
compartments to avoid responding to LPS from commensal microbiota.  Upregulation of 
MD2 and TLR4 is seen in CD due to high local levels of IFN-y or TNFa (94). Low levels of 
TLR2 protein are found at subapical locations and TLR5 (flagellin recognition) is found on 
the basolateral side, thereby reacting only when microorganisms cross the epithelial 
barrier (95). If TLR9 (intracellular DNA recognition) is activated at the basolateral side of 
intestinal epithelial cells, it causes secretion of cytokines via degradation of the NFKB 
inhibitor IkBa, thereby activating NFKB. If TLR9 is activated at the apical side of IECs, it 
causes IkBa accumulation, thereby preventing NFKB signalling (96).  
Once a TLR response is triggered, as opposed to the oral and airway epithelium which 
secrete predominantly antimicrobial peptides, the intestinal epithelium secretes 
inflammatory mediators. Pro-inflammatory cytokines such as IL-1b, IL-7, IL-8, IL-15, IL-12, 
IL-33 and IL-18 drive recruitment and activation of granulocytes (predominantly 
neutrophils), macrophages, dendritic cells (DC), Natural Killer cells and innate 
lymphocytoid cells (ILC) (97-99). Activation of dendritic cells leads to increased production 
of the cytokines described above, causing proliferation and activation of NK and ILCs. ILCs 
regulate CD4+ T cell responses to commensal bacteria(100), NK cells modulate CD8+T cells 
(101, 102). IL-18 secretion also increases IL-2 and INF-y production, thereby changing 
mucus production and composition.  IECs also secrete anti-inflammatory cytokines IL-10 
and TGF-b, thereby reducing an excessive inflammatory response and aiding the tissue 
repair process (103).  If the intracellular TLRs are triggered, it produces a rapid interferon 
(IFN) response which has two major effects, firstly the expression of viral restriction 
factors is upregulated by IFNs, secondly IFNS can modulate the functions and activation 
of DCs, NK Cells, T cells and B cells (104).  
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Intestinal DCs have functional plasticity in their ability to generate either inflammatory or 
tolerogenic immune responses.  In the homeostatic state, DCs are hyporesponsive 
(105).In IBD, activated DC accumulate at the sites of inflammation (106). They function as 
a hub for multiple multicellular immune cascades, bridging the innate and the adaptive 
immune systems. They contribute to T reg generation (107), imprint their homing 
properties on T cells and B cells in order to localise immune responses to particular tissues 
(108), for example by increasing expression of a4b7 integrin (gut homing) on T cells and 
induce B cell class twitching to IgA producing B cells with tolerogenic properties (109).  
There are multiple different T cell populations that can be present in the intestinal lamina 
propria, but two specific types show distinct intestinal trophism; gdT cells and Th17 cells.  
gdT cells, are unconventional CD3+ T cells which have both innate and adaptive immune 
functions. They have TLR, Notch and NKG2D activating receptors which they use in 
conjunction with the T cell receptor to rapidly respond to stress-induced ligands and 
infection – irrespective of their molecular nature. In the intraepithelial lymphocyte 
compartment, they are CD8aa+, when circulating they are MHC unrestricted.  
gdT cells demonstrate cytotoxic responses in the same manner as conventional T cells 
through perforin/granzyme , Fas/FaL pathways and production of TNF alpha(110) (111). 
gdT cells have also been shown to modulate goblet cell numbers and thereby mucus 
production (112); gdT deficient mice have an increased susceptibility to DSS colitis due, in 
part, to a reduction in the number of goblet cells.  
Th17 cells are CD4+ T cells which are enriched in the lamina propria under homeostatic 
conditions. Although in IBD they have been shown to be microbiota reactive (113), they 
have a dynamic response which can be both pro-inflammatory and anti-inflammatory, as 
evidenced by the lack of response or exacerbation of symptoms in trials of anti-IL-17A or 
anti-IL17RA antibodies in CD patients (114) (115).   
Th17 cells produce signature cytokines in excess in both CD and UC (116); IL17, IL-21 and 
IL22. IL17 stimulates innate immune cells and epithelial cells to produce IL-1, IL-6, G-MSF 
and IL-8 which in turn leads to increase neutrophil production and recruitment leading to 
increased pro-inflammatory signalling (117) (118). IL22 is not only produced by Th17 cells, 
but also by NK cells and ILCs (119). Detection of IL22 by intestinal epithelial cells leads to 
increased epithelial barrier integrity (120) and production of REGIII antimicrobial proteins 
(121, 122).   
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Intestinal B Cells are specialised in IgA production as differentiated plasma cells. Secretory 
IgA in the intestinal lumen acts as a barrier by opsonising pathogens to protect the 
epithelium from invasion. The sIgA system is tightly integrated with both innate and 
adaptive immune mechanisms, influencing adaptive T cell responses (123) and contribute 
to immune homeostasis.  B cells also function as antigen presenting cells, polarising 
effector T cell responses (124). IL10 produced by B cells with the cognate B cell/T cell 
interaction is required for the generation of mucosal Tregs (125) (126).  Regulatory B cells 
have a inflammatory suppressive function, producing IL-10 and TGFb, thereby playing a 
role in suppressing inappropriate responses to intestinal microbiota and innocuous 
antigens. 
Several SNPs correlating to genes encoding proteins involved in the maintenance of the 
epithelial barrier have been demonstrated in association with UC. A selection of the 
candidate genes from Jostins et al(39, 127) and their potential site of protein impact on 
the intestinal barrier are diagrammatically represented in Figure 1-5.  
The genes highlighted by eQTL in Jostins et al as UC risk associated are hypothesised to 
have roles in maintenance of the epithelial cell function via gene regulation or 
downstream signalling of PPR recognition (SLC9A3, CALM3, RNF186, PRKCD, CDH1, 
HVELM, HNF4A, NFKB1, CARD11, IRF5, GNA12) , roles in wound healing in the extracellular 
matrix (MMP24, ECM1, ITIH1, LAMB1) or roles in the innate-adaptive cross talk (IRF5, 
NFKB1, HLAs, CARD11).  The functional annotation of the SNPs to drive the hypothesis, 






















































Autophagy is the regulated self-degradative process by which there is controlled digestion 
of damaged and unnecessary cellular components. Under homeostatic conditions, 
damaged cellular components are targeted by protein adaptors which engage autophagy 
machinery to engulf and deliver the components to the lysosome for degradation.  In 
conditions of nutrient starvation, autophagy is utilised to liberate energy stores, thereby 
promoting cellular survival. Antibacterial autophagy can be triggered by recognition of 
bacterial pathogens, or indicators of pathogen invasion such as membrane damage, 
membrane remnants, amino acid starvation, protein aggregate formation or the presence 
of bacterial DNA (128). Functional autophagy is required in the intestinal epithelium to 
maintain the secretion of mucins as well as maintenance of normal gut microflora (129). 
Autophagy is required in goblet cells that secrete mucins, Fc-gamma binding protein 
(crosslinks MUC2 to provide stabilisation) and trefoil factors (for mucosal defence). Three 
core autophagy proteins ATG5, ATG7 and LC3B have all been demonstrated to regulate 
goblet mucin secretion (130). In enterocytes, autophagy functions as part of the cellular 
innate immune system to restrict bacterial replication and dissemination. Functioning 
autophagy is also required for the maintenance of microvilli, the microscopic membrane 
protrusions that increase the surface area of the apical side of enterocytes.   
CD has well defined autophagy risk susceptibility genes (ATG16L1, IRGM) as well as 
extensive examination of the role of autophagy in macrophages and dendritic cells in CD 
mouse models and AG16L1 models (131, 132).  Conversely UC does not have the genetic 
markers of autophagy involvement, however deficient autophagy processes have been 
identified. Schuster et al (133) showed that patients with active UC have reduced 
chromosome associated protein D3 (CAP-D3) expression. In colonic cell lines, they showed 
the reduced CAP-D3 decreased autophagy and impaired intracellular bacterial clearance 
of intracellular Salmonella. Hao et al  (134) have shown that a potent regulator of 
autophagy, Beclin 1 is expressed at a higher levels in UC patients’ colonic mucosa as 
compared to patents with irritable bowel syndrome. Whether this is due to the 
inflammatory process, or whether this is an instigator of the inflammatory processes seen 
in UC is unclear.  
Human viruses are well documented to subvert and in some cases, regulate the 
autophagy process; Epstein-Barr virus (EBV), hepatitis C viruses, Influenza A, Herpes 
Simplex Viruses and Measles virus all require autophagy to replicate and shed their viral 
particles (135-138). The documented human gut virome (139) is predominated by 
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bacteriophages, but the role of enteropathogenic viruses has been mooted previously as 
an instigating factor in the pathogenesis of mucosal inflammation(140). In the CD 
ATG16L1 mouse model, Paneth cell abnormalities are triggered by infection with a mouse 
norovirus, which alters the transcriptional signature of Paneth cells and the inflammatory 
response when the mice were treated with dextran sodium sulphate (DSS) (141). In both 
small paediatric and adult cohorts, enteropathogenic viruses such as rotavirus, norovirus, 
astrovirus or adenovirus have not been detected during follow up or relapses (140, 142) 
suggesting that the ongoing inflammation of UC is not due to enteropathogenic viruses. 
EBV and to a lesser extent CMV have been implicated in the instigation of IBD, by Lopes 
et al (143). In a study of 95 IBD patients with active disease and 50 healthy controls and 
EBV were more prevalent in the colonic mucosa of patients with IBD compared to the 
controls, with no difference between the inflamed and non-inflamed mucosa. EBV utilises 
both TLR and autophagy dependant pathways in dendritic cells to evade the immune 
system (144) as well as to enhance viral replication (145). EBV has been shown to infect 
the basolateral surface of epithelial cells via integrins and activation of adhesion 
molecules (146), giving credence to the presence of EBV not just in mature B cells and 
dendritic in the lamina propria of UC patients, but in the enterocytes also.  
It is plausible, that even though core autophagy genes do not form a part of the UC risk 
susceptibility cohort, the core autophagy process or autophagy regulation is involved in 
instigation or maintenance of mucosal inflammation that characterises UC. Potential 
pathways for dysregulation of autophagy include downstream effects of a genetic 




Focal adhesion complexes (FACs) are large protein assemblies that physically link and 
transduce signals from the external environment to the intracellular environment via 
integrins (147). The function of the focal adhesion is both mechanical and responsive. It 
functions as a cellular anchor via integrins binding to their extracellular ligands and to the 
actin cytoskeleton to modify the physical features of the cell. Depending on the initiating 
signal, FAC can be involved in regulating inflammatory gene expression via signal 
transduction pathways such as interleukin 1 (IL-1) signalling (148, 149) or regulating 
calcium fluxes via phosphatidyl inositol signalling (150) which impact in inflammatory 
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cascades. Many components of the FAC are involved in downstream signalling cascades 
such as the MAPK/ERK pathway (151), AKT1 (152) and Wnt signalling (153). In this way, 
pathways affected by the FAC range from apoptosis (154), production of cellular 
protrusions (155) to cell cycle progression (156)and cellular proliferation (157).  
A major component of the FAK is the focal adhesion kinase (FAK). Activation of FAK is 
necessary to maintaining and repairing the epithelial barrier in cell culture via tight 
junctions (158).  Lipopolysaccharide induces tight junction permeability via 
FAK/MyD88/IL1 receptor pathways (159, 160). In addition to this, FAC GTPases such as 
RAC1 (161) and tyrosine phosphatase members of the FAC have a role in the regulation 
of the NACHT, LRR and PYD domains-containing protein 3 (NLRP3) inflammasome (162), 
which mediates the release of IL-1 and IL-18 from cells. IL-18 signalling drives the 
breakdown of barrier integrity in murine models of UC. Intestinal cell inflammasome 
activation occurs in pathogen recognition via integrin signalling though the FAC. Impaired 
inflammasome signalling leads to increased sensitivity of murine intestinal mucosa to mild 
chemical disruption in DSS models of colitis (163).  
Although neither the focal adhesion complex, nor the NLRP3 inflammasome have been 
implicated in UC in the GWAS, integrin genes have been (164).  GWAS and meta-analysis 
identified variants at ITGA4, ITGB8 and PLCG2 and SLAMF8 (as identified by Peters et al 
2017). It is plausible that by using a network and systems biology approach, non-trivial 
regulatory pathways affected by UC associated SNPs that may impact on the function of 





This body of work has evolved significantly from the initial PhD project which was to 
evaluate the role of UC associated SNPs in Extracellular Matrix Protein 1 in the 
maintenance of the epithelial barrier via a dysregulation of matrix metalloproteinase 9 
function. The first 12 months of the PhD included work identifying co-localisation of ECM1 
and MMP9 in epithelial cell lines and early work in genome editing to create ECM1 knock 
out cell lines.  At this point, new deep sequencing results were released to myself and Dr 
Mark Tremelling by the UKIBD Genetics Consortium that identified that the ECM1 SNPs I 
was investigating were not UC associated. I made a decision not to pursue the ECM1-
MMP9 interaction any further. The field of SNP epistasis and non-coding SNP function 
annotation was nascent but very interesting, so I approached Dr Tamas Korcsmaros with 
a concept of utilising SNP-SNP interactions to stratify SNPs for experimental validation. 
Under his guidance, I manually created a SNP analysis workflow to identify the function 
of UC associated SNPs and interactions between them, which underwent multiple 
iterations and updates as the databases were updated or changed. This is outlined in 
Chapter 2.  Over the next year, having identified SNPs for experimental validation utilising 
the techniques I outline in Chapter 3 it was clear we could take the bioinformatics pipeline 
further to advance the goal of having personalising medicine based on a patient genotype. 
This final step is outlined in Chapter 4 and would not have been possible without the 
collaboration of Dr Dezso Modos from Professor Andreas Bender’s cheminformatics 
group (Department of Chemistry, Cambridge), Dr Miles Parkes (IBD Research Group, 





UC is a chronic debilitating disease characterised by ulceration of the colonic mucosa 
leading to symptoms of profuse bloody diarrhoea, abdominal pain, and fatigue and weight 
loss. The aetiology of UC is thought to be due to a disordered immune response to a 
microbiota signal in genetically susceptible hosts. Advances in genetics have led to the 
identification of single nucleotide polymorphisms (SNPs) associated with chronic diseases 
such as inflammatory bowel disease (IBD). Further advances in fine mapping and deep 
sequencing have narrowed down these associations; however, the assessment of the 
physiological function of these SNPS is still in its infancy.  
The overall aim of this PhD is to use a multidisciplinary approach to determine the 
function of UC associated SNPs, to help understand the role of SNPs in the pathogenesis 
of UC in general and in a patient-specific context.  
The specific objectives of this project are as follows: 
1. To annotate UC associated SNPs and identify network interactions to create a UC 
interactome (UC-Ome) (Chapter 2);  
2. To experimentally validate a stratified SNP identified as relevant within the UC-
Ome (Chapter 3); 





2. From	Genes	 to	Disease:	A	network	medicine	approach	 to	
UC	
Overarching  Aim :  
To annotate UC associated SNPs and identify network interactions 
to create a UC interactome (UC-Ome) 
2.1 Introduction		
2.1.1 Cellular	connectivity	
The human cell is complex, containing hundreds of thousands of interacting components 
from large complex proteins, DNA, RNA, to small molecules, lipid and carbohydrate 
messengers, and elements such as calcium. One facet of this, the protein-protein 
interactions, is described as the human interactome, which is estimated to contain more 
than 100,000 individual proteins(165), with each of these interacting with each other. The 
human interactome contains experimentally validated protein-protein interactions for 
the open reading frames for 17,500 unique genes (HuRI-CCSB – unpublished). A further 
facet of the complexity of the human cell is the extensive regulatory interactions between 
RNA molecules e.g. miRNAs regulating messenger-RNA, and protein-DNA interactions e.g. 
transcription factor activation and repression of genes. Given this level of complex 
interconnectivity it is no wonder that specific gene abnormalities can cause phenotypic 
perturbations in downstream molecular pathways. There is, however, significant 
redundancy in pathways such as cell cycle and regulatory signalling pathways.  Damaging 
mutations that affect expression of key members of these pathways such as p53 or 
members of the Wnt pathway are seen in colon cancer but the phenotypic impact of 
individual single allele genetic variations in the same pathways are difficult to identify and 
even more difficult to experimentally validate.  
A global view of how multiple single nucleotide polymorphisms (SNPs) associated with 
disease fit within the human interactome is required to identify common pathological 
pathways associated with disease. However, this requires an in-depth analysis of the 




Functional genomics is a term used to describe the use of genome-wide assays such as 
genome sequencing, and transcriptomics to study gene and protein function which 
focuses on the dynamic aspects of transcription, translation, regulation of gene 
expression and protein-protein interactions. The use of bioinformatics allows insight into 
complex dynamic cellular activities enabling stratification of proteins of interest. 
Integrating functional genomics with bioinformatics, and network biology allows 
identification and visualisation of each individual SNP impact within the context of a larger 
cellular interactome. By this mechanism, specific combinations of SNPs can be identified 
that in combination impact on strategic pathways for the disease of interest. This is known 
as network medicine.  
A network at its simplest is defined as elements, or nodes, that are connected by links, or 
edges. We utilise networks in every-day life, from networks of work colleagues, to social 
networks accessed by social media. In these examples we, as individuals, are nodes.  The 
edges are our link with others. The number of edges (links) to a node or individual is called 
a degree, so the more ‘social network friends’ we have, the higher our degree.  The edges 
can be directed or undirected e.g. the network can show that there is an interaction 
present (two people are social media friends) or the direction of the interaction (person 
A sends a message to person B, but not the other way round).  
Biological networks are not random, they will have a large number of nodes with very few 
connected neighbours, and a small number of nodes that have a huge number of 
connecting neighbours. These highly ‘sociable’ nodes are called hubs. An analogy of this 
would be UK airports. The UK has multiple airports with just a few connecting 
destinations, and a few airports e.g. those in London, with a huge number of connecting 
destinations. The London airports would be considered hubs.  
To identify the most important nodes within a network, indicators of centrality (e.g nodes 
that are central to the working of the network) can be used. Degree centrality is an 
indicator of the number of edges or connections a node has; therefore, the highly social 
nodes or hubs will have the highest degree centrality, like the person with the greatest 
number of social media friends described above.  In a biological context, an abundant 
transcriptional regulator such as STAT3 or NFKB1 will have the highest degree centrality 
as they interact with a large number of proteins and genes. Degree centrality only gives 
information regarding the number of edges a particular node has, it will not give 
information regarding the importance of that node to the network. For example, an 
individual node with six connections that sits separately from several connected nodes 
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will have a higher degree centrality than each of the connected nodes which only have 
two or three edges, however from a biological pathways perspective, the connected 
nodes are more important. To use the airport analogy again, if a traveller needs to get 
from Scotland to New York, then the airport in Scotland which connects to 10 other local 
destinations but nothing further afield will have a high degree centrality but is not 
important to the traveller (and therefore not important to the network). The airport with 
1 destination that will connect him to a New York airport is more important to the traveller 
and therefore the network.  
For an indicator of the node with the most amount of information going through it, e.g. 
the node that created cohesiveness within a network by connecting different parts of the 
network together, or joins the network together, a measurement called betweeness 
centrality is used. In graph theory terms betweeness centrality is used to indicate the node 
that has the largest number of shortest paths running through it. The higher the 
betweeness centrality, the more ‘influential’ that node is to the network.  An example of 
this would be a party planner who controls each aspect of a wedding from the flower 
arrangers, to the musicians and the caterers, all of which are different groups, but the 
planner provides the cohesiveness to create the wedding. 
A biological example of this would be an adapter protein that gets phosphorylated by a 
MAPK pathway which then activates the apoptosis pathway and inhibits autophagy. This 
adapter protein links three distinct components of the network and in order to get from 
one part of the network to the next, the information has to go through this node. The 
node described is Stat3, therefore a node can have both high degree centrality and 
betweeness centrality, but they are mutually exclusive and the measurement confers 
import depending on the question asked.  
The building and interpretation of robust biological interaction networks is dependent 
upon three major factors; 
1. High quality multi-omics data 
2. Creation and curation of interaction databases 
3. A multidisciplinary team with experimental and computational skillsets 
With the advent of technologies allowing cost effective and rapid genotyping, 
transcriptomics, proteomics, lipidomics and DNA methylomics there is a wealth of data 
available associated with specific disease states. Cancer is a model for the use of network 
medicine to identify novel biomarkers, underlying molecular mechanisms of disease or 
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genetic ‘fingerprints’ of disease (166) and drug repurposing. However, identification of 
disease pathways of interest in autoimmune diseases such as Diabetes (167) and Juvenile 
Idiopathic Arthritis (168) using multi-omics datasets has also been successful. Using multi-
omics techniques and visualising the results within a network has the potential to identify 
the interaction between SNP affected proteins, and SNP- SNP interaction, or SNP epistasis.  
The limitations of using bioinformatics include the dependence on experimentally 
validated datasets for example the lower the quality of the data, the increasing risk of 
false positive or false negative results and random network generations.  
2.1.2 SNP	epistasis		
Epistasis is defined as the interaction between non-allelic genes such that the phenotypic 
effect of genes can change depending on their combination. SNP epistasis explores the 
phenotypic impact between SNPs. A common approach is to undertake pairwise analyses 
of SNPs but this requires immense statistical power in terms of cohort numbers and 
numbers of SNP pairs (127, 169).  Other approaches have used logic regression to identify 
higher order interactions, which still uses a pairwise approach, but identifies groups or 
trees of SNPs with interactions.  This has been utilised within the UC cohort and identified 
potential epistatic mechanisms between 4 SNP groups: 1. HLA.DQA1.B1/DRA.B1  and 
UBQLN4/RIT1 or IFNG/IL26/IL22; 2. FNG/IL26/IL22 or REXO2; 3. IL23R/IL12RB or REXO2 
or GPR35 and 4. MST1 or near KIF11 and near USP25 (52). The phenotypic effect of the 
epistasis has not been identified. Phenotypic analysis requires a gene by gene approach, 
as undertaken by Diegelmann et al (170) who identified that IL23R variants influence 
DMBT1 expression and that DMBT1 variants have altered transcription factor binding. The 
gene by gene approach requires a stratification strategy for candidate SNPs. 
2.1.3 SNP	functional	annotation:		
Two major questions in SNP research are which are the causative SNPs and what do they 
do? Fahr et al (171)  identified putative causative SNPs in coding and non-coding disease 
variants in 21 autoimmune diseases, using high density genotyping and epigenomic data 
mapping causal variants to create an tissue enriched predictive resource. Immunochip 
was designed to finemap previously identified risk associated SNPs, and meta-analysis has 
been used to further hone potential causative SNPs in IBD (53, 172). This research aims to 
build on the wealth of data accumulated in the two ground-breaking papers from Fahr et 
al(171) and Jostins et al (39) in an attempt to provide evidence for the question of what 
SNPs do.  
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Approximately 10% of IBD associated SNPs (UC/CD and IBD overlap) are within protein 
coding regions (non-synonymous/missense or synonymous SNPs), the majority (90%) are 
within introns, intergenic regions or regulatory regions.   
Tools such as SIFT (173) or SNPEff (174) utilise structural analyses to determine the 
predicted outcome of missense SNPs either tolerated or deleterious and SNP nexus (175), 
which functionally annotates individual SNPs into site and predicted effect on 
transcriptome/proteome based on cancer data. In IBD, there has been a lot of interest in 
exonic SNPs in  ATG16L1 (176-201), MST1 (195, 207), IL23R (176, 178, 181, 208-213), 
IRGM (177, 179, 180, 183, 190, 191, 194, 195, 214-218), NOD2 (184, 185, 189, 196, 201, 
219-229), CARD9 (229-235), RNF186 and PRDM1 (231, 236-240).  
As missense and synonymous disease associated SNPs account for approximately 10% of 
GWAS SNPs, analysis of SNPs in non-coding regions is important. Enrichment of risk SNPs 
in active regulatory elements in  non-coding DNA such as promoters and enhancers have 
been used to create refined hypothesis for the genetic predisposition of disparate 
diseases such as Parkinson’s disease (241), schizophrenia (242), systemic sclerosis (243) 
and prostate cancer (244).    
Non-coding SNPs are potentially within sites of splice sites, microRNA (miRNA), miRNA 
binding sites (miRNA-BS), transcription factor binding sites (TFBS) or long non-coding 
RNAs (lncRNAs).   
 
MiRNAs are small non-coding RNAs, which bind to cis-elements in the 3’untranslated 
region (UTR) of target mRNAs to fine-tune target gene expression. MiRNAS are generated 
by a two-step process: pre-miRNA (hairpin like partially duplexed) from pri-miRNA by the 
drosha/DGCR8 complex in the nucleus and mature miRNA from pre-miRNA by the 
DICER/TRBP complex in the cytoplasm (245).  For translational suppression, base pairing 
between the ‘seed’ sequence of miRNA (nucleotides 2-7 or 2-8 at the miRNA 5’end) is 
required with the target mRNA.  The miRNA/mRNA interaction guides RISC for translation 
inhibition (246). MiRNA signatures in colon, blood and saliva are able to differentiate 
between CD and UC indicating a differing miRNA regulation or genetic impact between 
the two IBDs (Schaefer 2015).  
SNPs could impact on the hairpin structure guided miRNA processing, have 
thermodynamic effects on strand loading as well as causing a change in the seed sequence 
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or shift in the processing sites that could all result in a change in production of mature 
miRNAs, change the mRNA targets that the seed miRNA can bind to, change the affinity 
of the binding or create novel miRNA with different targets (247). 
There is evidence that SNPs within conserved miRNA binding sites are deleterious. This is 
due to the specific Watson and Crick pairing of miRNA to mRNA, a SNP within the 3’UTR 
of mRNA would impact on miRNA binding (248). This has been shown in schizophrenia 
associated SNPs (249) and Coronary Heart Disease associated SNP rs4846049 (250). There 
are 458 papers identifying miRNA binding site changes caused by SNPs, however there is 
only one paper identifying a change in a miRNA binding site for IBD SNPs – a SNP in IRGM 
which alters the binding site to mir-196 in CD (251). 
MiRNAs are involved in intestinal epithelial homeostasis as demonstrated in the 
Dicer1ΔIEC mice where the deletion of Dicer abolishes all miRNA function in intestinal 
epithelial cells. These mice display a phenotype with a reduction in goblet cells, and 
increase in inflammatory immune cells, disorganised intestinal architecture with 
associated increased intestinal permeability, decreased mucus production and decreased 
Th2 cytokines with IBD symptoms and inappropriate Th1 responses during infection. With 
regard to the epithelial barrier the Dicer1ΔIEC mice exhibit a weakened epithelial barrier 
associated with a decrease in claudin expression (252).  
As with colonic cancer, there is differential expression of several miRNAs in IBD as 
compared to controls and this has been assessed both by colonic biopsy and in 
peripherally circulating miRNAs (253).  
Transcription factors are proteins that bind to DNA usually in the promotor region, 
upstream and close to the transcription start site of a target gene. They regulate the 
expression of the gene by activating or inhibiting the transcription machinery. These 
promotor sequences containing TFBS have some conserved structural properties 
including stability, bendability and nucleosome position preference and curvature. 
Changes in TFBS by SNPs have been assessed for ADRBK1, AKT3, ATF3, DIO2, TBXA2R and 
VEGFR genes and hypothesised to be associated with a variety of disease phenotypes such 
as diabetes, high altitude sickness, asthma and hypospadias (254). From a pubmed search 
in 2017, there are 582 papers identifying alterations in TFBSs by SNPs across a wide variety 
of disease and across a variety of species. In terms of IBD; in CD DMBT1 variants have 
been shown to have altered transcription factor binding sites (170). In both CD and UC 
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PTPN2 SNP rs2241879 has been predicted to alter transcription factor binding sites to 
multiple inflammatory transcription factors including NFKB and GATA-3(255). The IBD 
associated NKX2-3 variant rs11190140 has been shown to have altered NFAT binding to 
its promoter compared to the non IBD associated allele (256). In Silico analysis of IBD SNPs 
to undertake functional annotation have identified 18 noncoding regulatory SNPs in 
known transcriptional factor bindings sites which are hypothesised to dysregulate 
expression of nearby genes including PLC1, ANKRD55, BACH2, CCDC26, CREM, FADS1, 
FOSL1, SMAD3, PRKCB, IKZF3, DNMT3B, CD40 and UBE2L3 (257). 
Long non-coding RNAs (lncRNAs) are non-protein coding RNAs >200 nucleotides in length 
which are typically transcribed by RNA polymerase II (258). They participate in the 
regulation of gene expression via transcriptional and post transcriptional mechanisms, 
regulation of proteins post translationally, organisation of protein complexes and cellular 
signalling (259, 260). The GENCODE project (258) collected over 10,000 human LncRNA 
genes. The role of these is still being characterised, however certain conserved lncRNAs 
have been shown to have a role in immune regulation. lncRNA secondary structure 
disruptive SNPs have been identified within or in close proximity of IBD loci associated 
candidate genes with tissue specific expression patterns (261).  
The generation of mature RNA for protein translation requires the removal of non-coding 
intronic regions from precursor mRNAs and the ligation of exons. This removal of intronic 
regions and ligation of exonic regions is called splicing and is an essential step in gene 
expression in eukaryotes.  Splicing is performed by large protein-RNA complexes called 
spliceosomes. Splicing occurs when the splicesomes recognise specific splice sites. The 
splicing process is regulated by proteins within the splicesome, splicing factors and RNA 
sequence elements including the core splicing motifs and splicing enhancer or silencer 
sequences. 
Splice site consensus sequences are located at the ends of introns. The transition of exon 
to intron is known as the splice donor site, and the transition from intron to exon is known 
as the splice acceptor sequences. The highly conserves splice sites are characterised by 
having GT (donor) or AG (acceptor) dinucleotides at the intron ends.  
The splicing process can be disrupted by mutations in trans-acting splicing factors or cis-
acting sequences in introns and exons.  Cis acting mutations include those that disrupt the 
constitutive splice sites or disrupt the regulatory sequences (enhancers or silencers).  
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Splice site destruction can result in deletion of the adjacent exon or retention of the 
adjacent intron. A SNP in BTNL2 donor splice site (rs2076530) has been identified in 
sarcoidosis leading to a frameshift and a premature stop codon truncating the protein, 
however it is not of the same import in other granulomatous diseases(262). In IBD, the 
CARD9 SNP rs4077515 (230) affects a splice site and is protective for IBD.  
There are a variety of tools which offer SNP analysis. Var2GO uses a SNPeff platform and 
applies gene ontology to the genes local to the SNP. FASTSNP analyses SNPs to identify 
protein changes, transcription factor binding sites in promoter sequences or enhancer 
regions and alternative splicing regulation, preferentially identifying phenotypic 
candidates with a low minor allele frequency given the strong selective pressure against 
strong phenotypes. SNP Function Portal analysis includes analysis of genomic elements, 
transcription regulation, protein function, pathway, disease and population genetics.  
However, given that it is over 10 years old, it utilises HapMap Phase II so is now obsolete.   
In recent years, there has been an upsurge in mathematical modelling based and 
experimentally validated tools for identifying changes individually in protein binding 
motifs (Eukaryotic Linear Motifs (263)), miRNA seed sequences (miRBASe, mirDB, 
Tarbase), miRNA binding sites (Tarbase, miRANDA), transcription factor binding sites 
(JASPAR), splice sites (Human Splicing Finder 3.0 (HSF) (264), Max Entropy Scan (MES) 
(265) Alternative Splicer Site Predictor (ASSP) (266)),  and long non-coding RNA sequences 
as well as curated protein-protein interaction databases ((267)) which together allow for 
in-depth analysis of multiple disease associated SNPs.  
At the time of writing there is no single tool which brings all of these modalities together 
with a network visualisation tool such as cytoscape and downstream gene ontology which 
allows the ability to assess the network for novel disease pathways downstream of 





I hypothesised that utilising the wealth and breadth of bioinformatics tools available we 
could functionally annotate the UC associated SNPs and using a systems biology approach 
we could identify disease associated pathways. Given that UC is thought to be a disease 
of the intestinal epithelial barrier, I further hypothesised that the UC associated SNPs 
would be involved in integral epithelial barrier pathways including tight junction 
maintenance, autophagy or the focal adhesion complex.  
The aim of this project, therefore, was to identify UC associated SNPs that had a role in 
tight junction maintenance or regulation, autophagy, and the focal adhesion complex, 
with a view to identifying candidates for experimental validation and shedding light of 
pathogenic processes associated with UC. 
The objectives were: 
1. Identify the predicted and experimentally validated regulatory (splicing, miRNA, 
transcription factor, long non-coding RNA) effects and protein-protein interaction 
effects of UC associated SNPs 
2. Create a UC interactome network  
3. Identify components of the network associated with tight junction maintenance 
and regulation, autophagy and the focal adhesion complex to enable SNP 















A glossary of databases and technical terms can be found before the appendix.  
I identified UC associated index SNPs from either Jostins et al(39)supplementary data 2 
which passed the GWAS threshold for significance (p= 5 x 10-8), or Farh et al 2014 (166) 
dataset pulled directed from the Broad Institute repository, which were enhancing to the 
colonic mucosa.  Using the Fahr et al dataset, I identified finemapped SNPs with the 
highest ‘PICS’ value to index SNPs to all the index SNPs from the Broad and Jostin’s 
datasets. The finemapped SNPs were included if they enhanced to the colonic mucosa. 
This SNP list is called the ‘parent cohort’ (PC). 
I also identified index SNPs and finemapped SNPs not enhancing to any tissue from the 
Fahr et al dataset, as well as IBD associated SNPs from Jostins et al dataset, to be used to 
broaden the network. This SNP list in addition to the parent cohort is called the ‘enhanced 
parent cohort’ (EPC).  
If there was no finemapping available for an index SNP (e.g. the Immunochip finemapped 
SNP had an R2<0.8) then the highest proxy partners (based on tightest linkage 
disequlibirium and distance) were assessed using a SNAP proxy search (268) and were 
included in the analysis. 
Each SNP was annotated using Ensembl (269) from the rsID using GRCh38.p7.  
Risk alleles were taken from the original data source. For the broad institute finemapped 
SNPs, the risk allele was annotated as the non-ancestral allele from dbSNP(263), and the 
non-risk allele as the ancestral allele. 
The SNPs and alleles used as well as their source can be found in Appendix 2a. 
The workflow from SNP data to network can be seen in overview in Figure 2-1. Each 





Figure 2-1 SNP workflow logic flow chart from SNP site identification, through functional 





I extracted SNPs annotated to be missense in Ensembl(269) from the extended parent 
data set. Each rsID was input into PolyPhen2 (270, 271) to ascertain a prediction of how 
deleterious the change was. 
Using linkouts (NP or XP identifier) from Ensembl (269) and dbSNP (263) I extracted the 
FASTA amino acid sequence for both the risk allele and the non-risk allele. The full amino 
acid sequences for the proteins were input manually into the stand alone web-based 
service ELM (263). The motif cutoff was 100. The output for risk and non-risk allele was 
compared by eye in excel and any differences identified at the amino acid site. Changes 
to binding sites or enzymatic functions were highlighted and the corresponding protein 
target was identified. Each change was annotated as a loss or gain with reference to the 
non-risk allele. For effects associated with autophagy ‘LIR’ motifs, these were further 
analysed in iLIR (272), a web based service for identifying and scoring LIR motifs. 
Data mining to confirm literature evidence of identified protein-protein interactions was 
undertaking using STRING v10 (273), with interaction score set to high confidence (0.7) 
and no more than 50 interactors in the first shell. I looked for text mining, experiments, 
databases, co-expression and co-occurrence. I excluded neighbourhood and gene fusion 
functions.  
Deleteriously affected protein names and their binding partners were converted to 
Uniprot (274) identifiers and input into the UC Network in Cytoscape (275) v 3.3.0. The 
first neighbour proteins (downstream binding partners) were not identified as this was 






The nucleotide sequence containing the SNP risk or non-risk allele +/- five nucleotides 
from intronic, synonymous and missense SNPs were compared against 606 curated 
hexamer exonic splice enhancing (ESE) motifs (annotated as CHESEL) collated and 
provided by Dr Wilfried Haerty, Earlham Institute (Appendix 1). This initial run identified 
there were sites of interest therefore this avenue was examined further.  
It is best practice for splice site analysis to use at least three different programmes, 
therefore I used a combination of Human Splicing Finder 3.0 (HSF) (264), Max Entropy 
Scan (MES) (265) – based on the HSF web based server 
(http://www.umd.be/HSF3/HSF.html) with Alternative Splicer Site Predictor (ASSP) (266), 
another web based server (http://wangcomputing.com/assp/index.html). The 
combination of HSF/MES/ASSP has been shown to have the highest performance based 
on receiver operative curve analysis (276). For exonic splice enhancers, exonic splice 
silencers and branch points; HSF was used.  
The HSF analysis was done using the corresponding  Ensembl  transcript ID for the rsID. If 
there was more than one transcript available, the transcript corresponding to the parent 
gene was used first. If multiple transcripts from different genes were present 
corresponding to one SNP site – all transcripts were run if available.  
There can be a difference between the ensemble ancestral allele and minor allele, and 
the UC denoted risk and non-risk alleles. If there was a difference, each allele was run 
against the ancestral allele in HSF. If the risk /non risk alleles were concordant with the 
Ensembl alleles then just these alleles were run. Default parameters were used for the 
HSF server utilising the mutation analysis function.  
Transcripts that were identified as having an alternative splice site were analysed using 
ASSP. The same Fasta sequence for transcripts used in HSF were used in ASSP with the 
‘wild type’(ancestral), the risk or non-risk alleles being present and analysed.  The results 
were analysed with regard to concordance or discordance with the HSF and MES results.  
The translated transcript (e.g. protein) was included into the downstream network as 
‘splice site affected’ if there was 2/3 concordance between the three programmes, even 
if the confidence value or variation value differed.   
Transcripts were converted to their protein name Uniprot ID.  
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lncRNAs were excluded from the analysis as were any transcripts which were unavailable 
in cDNA format (e.g. were in n. format).  Statistics were undertaken in GraphPad Prism.  
OmniPath (267) interactions were downloaded on 25/01/2017 and imported into 
Cytoscape v3.3.0. The transcripts affected by splicing sites or splicing regulation were 
converted to uniprot identifiers and were used as search terms in the OmniPath 
Cytoscape Network to identify downstream directed protein-protein interactions. By 
using a directed network upstream interactions such as transcription factors for SNP 
affected genes were specifically excluded, as these would not be biologically relevant to 
the SNP function and impact.  
2.3.4 Identification	of	mature	miRNAs	affected	by	SNPs	
For all the intronic, intergenic, downstream gene variants (DGV), upstream gene variants 
(UGV), 5’untranslated region(UTR) and 3’UTR SNPs, flanking sequences of 10 nucleotides 
either side of the SNP risk allele or non-risk allele (or ancestral allele if no non-risk allele 
was identified) were retrieved from dbSNP. These were then manually input into miRBase 
(277) standalone web browser. Using the BLASTN facility (E cut off of 10) and SSEARCH 
facility (E cut off 10), the 21 bp sequences were analysed for sequence homology with 
known human mature miRNAs. Only homology sequences where the presence of the risk 
allele caused a loss of sequence homology, as compared to the non-risk allele sequence 
were considered biologically relevant.  A literature review of the identified miRNA was 
undertaken in 2014 and repeated in 2017 using PubMed and searching for the mir term 
e.g. mir-1266 filtered to human species.   
miRNAs would only be included if 2 out of 3 of the methods used were concordant or 
suggestive. When further stringency was required 3/3 concordance was utilised. 
The human mature miRNAs identified were then input into miRDB(278) to identify 
predicted miRNA target genes, initially only those with a target score of >80 were put 
forward for inclusion into the UC network.  On creation of the network, further stringency 
was required, therefore a higher cut off point of target score >95 was chosen.  
A miRNA homology network was created in Cytoscape 3.3.0 using, for ease of reading, the 
gene in which the SNP resides (or intergenic or lncRNA) as the source node and the miRNA 
predicted targets from miRDB as the interaction nodes. The first layout was perfuse force 
directed to give an overview of any networks that were formed. On identifying two 
separate networks, these were separated and  gene ontology (biological function in homo 
sapiens) analysed via BinGO (279) (gene ontology app in Cytoscape) and Genome scale 
64 
 
Integrated Analysis of Gene Networks in Tissues (GIANT) (280). The larger network was 
further analysed identifying nodes which had 2 or more source or interacting nodes 
interacting with them. This network was then visualised in an attributable circle format. 
Network statistics were performed within Cytoscape on the larger network.  
The SNP sites were then compared against the known genomic site in Ensembl for the 
identified mature miRNA.  
2.3.5 Identification	of	miRNA	binding	sites	affected	by	SNPs	
The 22bp sequences of mature miRNAs were retrieved from miRBase(277). The 10 base 
pair flanking sequences of all the risk alleles and non-risk alleles were assessed for the 
presence of miRNA binding sites using the web based tool miRanda (281-283). Hits 
predicted to occur in the seed region (2’-8’) of the miRNAs and with pairing scores >= 150 
and energy threshold <= -7 kcal/mol were considered as significant. Further stringency 
was required therefore the threshold of >155 pairing score and energy threshold of<-20 
kcal/mol were used. Other parameters were set to default settings. The outcomes were 
denoted as a loss , a gain of a putative binding site or a neutral results relative to the non-
risk allele e.g. the risk allele caused a loss of binding site that was present with the non-
risk allele sequence. A neutral result was found when the binding site remained regardless 
of risk or non-risk allele.  
Analysis of conserved miRNA binding sites in target mRNA was undertaken in miRanda, 
using the target mRNA search function identifying conserved miRNAs with good mirSVR 
scores, then non conserved miRNA with mirSVR scores.  
Genes affected by changes in miRNA binding sites were converted to their protein Uniprot 
identifiers and used as search terms in the OmniPath Cytoscape programme as described 
above. Direct outgoing first neighbours of the affected genes were input into the UC 





Each risk or non-risk allele plus 50 base pair flanking sequences were compared 
individually against binding profiles represented by Position Specific Scoring Matrices 
(PSSMs) corresponding to 140 human transcription factors from the JASPAR database 
(284) using the nucleotide ambiguity code to identify transcription factor binding motifs 
which covered the SNP site individually. Coverage of the Jaspar Database increased from 
140 to 396 human transcription factors in 2016 (283), so one by one analysis was 
unfeasible. With the assistance of Dr P Sudhakar the PSSMs downloaded in JASPAR format 
were converted to the TRANSFAC format to enable easier handling of results.  The 
Regulatory Sequence Analysis Tool (RSAT) called matrix-scan (285) was used to search for 
potential transcription factor binding sites in both the risk and non-risk allele sequences 
The background model estimation was determined by using residue probabilities from 
the input sequences with a Markov order of 1. Both forward and reverse strands of the 
sequences were searched. Hits with a P-value <= 1e-05 were considered as putative 
binding sites. Other parameters were set at default values.  
The SNP sites were visualised in UCSC genome browser on Human Dec 2013 
(GRCh38/hg38) Assembly to identify regulatory elements for the associated genes (from 
ORegAnno) and to identify if the SNP occurs within an enhancer area. If the SNP occurred 
within an enhancer, the enhancer score was identified from GeneCards and the known 






The data was imported into Cytoscape, using ID of effecting gene as source node and ID 
of SNP effected gene as the target node, with the type of interaction being the interaction 
edge. The name of effecting gene and effected gene as well as loss/gain data was 
imported as edge attributes. Each subtype of interaction e.g. miRNA BS, TFBS was 
demarcated by a change in shape, colour or border colour as per the legend. The UC 
network was demarcated as UC in node table column to separate it easily from the UC 
interactome, the ‘affected genes’ were demarcated as affecting genes in a separate 
column to ensure we only identified first neighbours of the affected proteins, not any 
effecting  proteins in the network.  
Omnipath was imported into a new network (with direction as edge attribute) and this 
network was merged in union format with the UC SNP network, keeping the same style.  
First nodes from UC column and their first neighbours were selected from the network, 
then effected proteins and their first neighbours were selected from the network, then 
effected proteins and directed outgoing nodes were selected from the network. Nodes 
that were not downstream first neighbours of the effected gene (not effecting gene) were 
removed to create the UC interactome. First neighbours were demarcated by a change in 
label colour. 
2.3.8 Subnetwork	identification	
The nodes for the Autophagy Regulatory Network(ARN) were obtained from 
http://autophagy-regulation.org. These were compared against the UC Interactome 
network and the Autophagy_UC subnetwork was created. Nodes were only included if 
they were a UC node or first neighbour of a UC node.  
The nodes for the focal adhesion complex were downloaded from the Adhesome (286) in 
November 2015.  
Tight junction proteins, their regulators and maintenance nodes were obtained directly 










In the Parent Cohort (PC) analysis of 60 SNPs associated with UC (UC), 52 (88%) had fine 
mapping within the Broad Institute dataset and were enhancing to the colonic mucosa. 7 
were finemapped on immunochip only and therefore we did not have tissue enhancing 
information for them. 1 SNP had no finemapping and no proxy (rs6927022). For the 
extended analysis, a further 66 finemapped SNPs which had no tissue enhancement but 
were UC associated and 36 IBD associated SNPs were included, this added a further 103 












(number of index 
SNPs) 
Numbers added 
by  Extended 
Parent Cohort 
(number of index 
SNPs) 
% Total in PC 
/%Total in EPC 
Overall Totals 
PC/EPC 









2 (2) 5(4) 3.33%/4% 
Upstream Gene 
Variant 
16 (7) 5(4) 26.66%/12% 
Intergenic 4 (4) 15 (10) 6.66%/12% 
3’untranslated region 2(2) 3(3) 3.33%/3% 
5’untranslated region 1(1) 1(1) 1.66%/1.2% 
Regulatory region 
variant 
5(2) 2(2) 8.33%/4% 
Non-coding transcript 
variant 
2(2) 0 3.33%/1.8% 
Synonymous 3(3) 3(3) 5%/3.6% 10% coding 
/8.4% coding Missense 3(3) 5(5) 5%/4.8% 
Within lincRNA 21 (8) 8(6)  35%/17% 




There were three missense SNPs in the Parent Cohort (Table 2-2);  
• Thr139Met in G-protein Coupled Receptor 35 (GPR35) 
• Leu333Pro in Interleukin17 Receptor E Like (IL17REL) 
• Gln1042His in Regulator of Telomere Elongation Helicase 1 (RTEL1) 
Only Thr139Met in GPR35 was possibly damaging in polyphen2. In ELM, there were no 
ligand changes, but amino acid 139 resides within a transmembrane domain.  Methionine 
is a very hydrophobic amino acid which is fairly non reactive, but may play a role in 
binding/recognition of hydrophobic ligands such as lipids. Threonine is less hydrophobic 
than methionine but is polar and usually found at the surface of proteins(287). There is 
no specific protein identified so no datamining was undertaken. 
Leu333Pro in IL17REL was identified as a benign change in PolyPhen2. Leucine and proline 
are both very hydrophic amino acids. Proline is a unique amino acid, being an imino acid 
as it contains an NH2+, not an NH3+. This means that it is unable to conform to main chain 
structures adopted by other amino acids. It is used to form tight turns in protein 
structures, or introduce kinks into alpha helices. Due to this it is usually found at the 
protein surface and forms part of WW and SH3 motifs that are key to intracellular 
signalling cascades (287).  This is represented in the ELM results, with a gain in WW2 motif, 
but losing MYND1 and SUMO motifs at the same site. MYND1 is a domain that binds 
proline rich motifs and has been shown to be mainly involved in protein-protein 
interactors in the context of transcriptional regulation (288). The SUMO ligand binds small 
ubiquitin related modifiers which regulate extensive protein-protein and protein-DNA 
interactions (289). Of interest is that there are no other MYND ligand sites on IL17REL. 
There is one other SUMO ligand site which remains intact in both the SNP affected and 
‘wild type’ protein. There are no other WW2 motifs on the wildtype protein. There is no 
specific protein identified so no datamining was undertaken. 
Gln1042His in RTEL1 was also predicted as benign by PolyPhen2. Glutamine is a polar 
amino acid, found on the surface of proteins. Histidine is also a polar amino acid, but it 
has a pKa near physiological pH , thereby is able to switch from a neutral to a positive 
charge, altering its preference for being in the protein core or exposed at the surface 
(287).  RTEL1 regulates homologous recombination (290, 291), limits excessive crossing 
over during meiotic recombination (292) and maintains integrity of telomeres (293). Only 
1 ligand change was identified by ELM, with a loss of motif which is phosphorylated by 
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phosphoinositide-3-OH-kinase related kinases (PIKK) family members. PIKK members,; 
mTOR, ATM, ATR, PRKDC, SMG1 and TRRAP are proteins with serine/threonine kinase 
activity with roles in DNA repair and DNA damage checkpoints (294). There are seven PIKK 
domains in the wild type protein, with the loss of only one it is likely to be a mild 
phenotype at best.  None of the PIKK members were identified during data mining as 
associated with RTEL1.  
In the extended cohort there were a further five missense SNPS (Table 2-2); 
• Arg381Gln in Interleukin 23 receptor (IL-23R) 
• His167Arg in the Fc Fragment of IgG Receptor IIa (FCGR2A) 
• Arg689Cys in Macrophage Stimulating 1 (MST1) 
• Arg225Trp in Cluster of Differentiation 6 (CD6) 
• Gly353Arg in Neurexophilin and PC-esterase domain family member 1 (NXPE1) 
Polyphen2 was unable to compute results on multiple occasions for rs3197999 Arg689Cys 
in MST1, and there was no difference seen in ELM. Arginine is a very positively charge 
polar amino acid, whereas cysteine can be either charged or hydrophobic, suggesting the 
substitution would have an impact on protein function. Hauser et al (207) have seen a 
gain of function in MST1 Cys689 cell systems, leading to an increased stimulatory effect 
of MSP on chemotaxis and proliferation by THP-1 cells. There is no specific protein-protein 
interaction identified so no datamining was undertaken. 
Arg381Gln in the IL-23 Receptor was identified as probably damaging by PolyPhen2, with 
a loss of a pro-protein convertase 7 cleavage (PCSK7) site identified by ELM. Both arginine 
and glutamine are polar amino acids; arginine has a predominately positive charge.  PCSK7 
is a membrane bound calcium dependent endoprotease in the trans-Golgi network (295), 
therefore hypothetically it could be involved in post translational modification of the IL-
23 Receptor. There are no other PCSK7 binding domains on the wild type protein, however 
there are 3 other PCSK family domains that remain intact in both the wild type and SNP 
affected protein. Due to the large IL-23R datamining result, PCSK7 was used as a search 
term instead and only 7 interactors were returned, none were IL-23R, reflecting a global 
paucity of data on PCSK7.  
His167Arg in FCGR2A was identified as benign by PolyPhen2. Both histidine and arginine 
are positively charged polar amino acids. In ELM there was a loss of FHA domain and SH3 
binding domain which was not contiguous with the amino acid site (both motifs 202-208). 
There was a gain of BRCA1, and GSK3 just adjacent to the amino acid site (161-165 and 
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159-166, respectively).  Neither BRCA1 nor GSK3 were found on datamining. At the amino 
acid site was a gain of a LIR motif that binds ATG8 protein family members (QKFSRL 163-
168). There are already four other independent LIR motifs in the wild type protein 
(EPPWINV 46-52, SEWLVL 121-126, DPTFSIP 169-175, DGGYMTL 285-291).  iLIR(272) 
identified the motifs in the wild type (position 121-126) in a disordered region and with a 
high position specific scoring matrix (PSSM) making it a functional candidate. QKFSRL 163-
168 was not in a disordered region and has a low PSSM, therefore has a low prediction to 
be functional. None of the ATG8 family was found associated with FCGR2A on datamining. 
Arg225Trp in Cluster of Differentiation 6 (CD6) was predicted to be benign in PolyPhen2.  
Whilst arginine is positively charged, tryptophan is an aromatic hydrophobic amino acid. 
As it is aromatic amino acid it can interact with other aromatic groups that are not protein 
ligands. There were no ligand differences seen in ELM, but the amino acid occurs within a 
scavenger receptor domain.  This contains the activated leucocyte adhesion molecular 
binding site. Scavenger receptor areas also function to recognise and remove unwanted 
entities e.g non-self molecules such as lipopolysaccharide (296). There is no specific 
protein-protein interaction identified so no datamining was undertaken. 
Gly353Arg in Neurexophilin and PC-esterase domain family member 1 (NXPE1) is 
predicted to be probably damaging by PolyPhen2. Glycine is a very flexible small, 
hydrophobic  amino acid, and can often be found in tight turns in structures that can give 
it a functional role, therefore a change in a conserved glycine could have an impact. Given 
that arginine is a large positively charged amino acid, one can see why PolyPhen2 
identified this substitution as probably damaging.  ELM identified a single gain of the WH2 
motif which binds to the hydrophobic cleft in actin subdomains 1 and 3. Upon actin 
binding , the area forms an alpha helix, followed by a flexible loop with is stabilised by 
actin binding (297). STRING identified that at the high stringency cut offs for datamining, 
no associations were found for NXPE1, and even at the lowest stringency cut offs no 













Functional site Loss/Gain  Site function Probability 
IL-23R Rs11209026 Arg381gln Probably 
damaging 
Score 1 














LIG FHA 1 
202-208 
loss FHA domain is a signal 
transduction module, 





gain Phosphopeptide motif directly 
interacts with the carboxy 
terminal of BRCA1 
1.91e-03 





Canonical LIR motif that binds 
to atg8 protein family 
members to mediate 
autophagy 
5.20E-03 
LIG SH3 3 
202-208 
loss Motif recognized by SH3 
domains with a non canonical 
class 1 recognition specificity 
1.32E-02 
MOD GSK3 1 
159-166 
gain GSK3 phosphorylation 
recognition site 
2.68e-03 
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Rs3197999 Arg689cys Unable to 
compute 
None NA NA NA 








   




Loss PxLxP motif is recognized by a 
subset of MYND domain 
containing proteins. 
6.50E-04 
Lig SUMO Sim Par 
1 
330-336 
Loss Motif for the parallel beta 
augmentation mode of non-





gain PPLP is the motif recognized 






Loss Endocytic vesicle (Nb 1 or 4 
ligands) 
2.75E-03 




Loss (ST)Q motif which is 
phosphorylated by PIKK family 
members. 
9.23E-03 





gain The WH2 motif is of variable 
length (16-19 amino acids) 
binding to the hydrophobic 
cleft formed by actin’s 
subdomains 1 and 3. At the N-
terminus it forms an alpha-
helix followed by a flexible 







All intronic, missense and synonymous SNPs from the extended parent cohort were 
analysed in the splicing workflow(n=96). 65 SNPs were intronic, 17 were in long non 
coding RNAs, 8 were missense SNPs, 6 were synonymous SNPs. One of the synonymous 
SNPs (rs3742130 GPR18) also encoded an intronic SNP (UBAC2).  
31 SNPs were excluded for having no cDNA HGVS transcript to be able to run in HSF/MES. 
A further 11 SNPs had HGVS annotation that brought up permanent error messages in 
HSF/MES (c.- numbers or c.* numbers); these were also excluded. 
A total of 65 SNPs were therefore analysed in this component, 21 from the parent cohort 
and 44 additional in the extended parent cohort.  
Within the parent cohort,  three cryptic  splice sites were identified by Human Splice 
Finder (HSF). 
These were in CARD9 (Rs10781499 - synonymous SNP), IL17REL (rs5771069 - missense 
SNP) and MST1 (rs13085791 - synonymous SNP). CARD9 rs10781499 risk allele A is 
predicted to activate a cryptic acceptor site which would mean cleaving the exon at the 
3’ site, reducing this exon by 161 nucleotides. Identification of this site as a splice site was 
also found by MES and ASSP. Although of note – compared to the wild type allele C the 
non-risk allele in ASSP was also potentially a splice site, but with a lower confidence; 0.55 
compared to 0.62 with the risk allele. The non-risk allele was identified as altering a exonic 
splice enhancer, however the ‘wild type’/ancestral allele did not form part of an ESE from 
the curated hexamer ESE list that could then be altered by other alleles. All three non-
wild type alleles at this site were predicted to either alter ESE sites (G,A) or create an 
exonic splicing silencer (ESS) indicative that this site is a hotspot for splicing or splicing 
regulation. CARD9 is predominantly expressed in peripheral blood mononuclear cells and 
B lymphocytes(232, 235) as an integral part of innate immune signalling by intracellular 
and extracellular pathogens(229).  
IL17REL rs5771069 risk allele G is predicted to activate a cryptic splice donor site, cleaving 
32 nucleotides from the exon. There was agreement from both ASSP and MES, but with 
low confidence values (0.3). Alleles A and C are both predicted to have no effect on 
splicing in HSF (splice sites, ESE, ESS or branch points). In CHESEL, I found two hexamers 
ESEs for the wild type sequence and three hexamer ESEs for the non-risk allele. There 
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were no hexamers for the risk allele sequence. By RNAseq data, IL17REL is predominantly 
expressed in the terminal ileum and upper GI tract(298).  
MST1 rs13085791 risk allele A is predicted to activate an exonic cryptic acceptor splice 
site, cleaving 90 nucleotides from the exon in HSF. However, there is no concurrence 
between HSF, MES or ASSP, therefore this result been discounted.   The non-risk allele is 
predicted to alter an exonic ESE site, however neither the wild type allele (G), nor the non-
risk allele (C) or the risk allele (A) encode an ESE motif in CHESEL.  
With the extended parent cohort 3 further cryptic splice sites from missense SNPs were 
identified in HSF; FCGR2A c.500G<A (G allele  - non-risk, A allele  -  risk), however there 
was no concordance with MES or ASSP; MST1 c.515C<A (C allele – wild type, A allele – 
non-risk), again with no concordance with MES or ASSP. These two results were therefore 
discounted. The final cryptic splice site was via a missense SNP in NXPE1 c.631G<T (G allele 
wild type, T allele – risk). HSF predicted a cryptic donor site with 46.6% variability. MES 
was unable to identify the wildtype, therefore no results from that matrix, but ASSP was 
in concordance with 0.8 confidence value, leading to a cleavage of 169 base pairs from 






Table 2-3 Parent Cohort Cryptic splicing site analysis in Human Splice Finder (HSF), Maximal Entropy Scan (Max Ent) and Alternative Splice Site Predictor (ASSP). ESE = Exonic Splice Enhancer. 
Confidence values calculated from ASSP 0= unsure 1 = full confidence.











G A c.126C>A Activation of an exonic cryptic 
acceptor site, with presence of one or 
more cryptic branch point(s). 
Potential alteration of splicing. 
3’ 51% 
new site 





c.126C>G Alteration of an exonic ESE site. 






A G c.998T>G Activation of an exonic cryptic donor 
site. Potential alteration of splicing. 
3’ 68.28% 






c.998T>A No significant splicing motif alteration 
detected. This mutation has probably 












A c.373G>A Activation of exonic cryptic acceptor 
site, with presence of one or more 
cryptic branch points. Potential 
alteration of splicing. Alteration of 














type, risk  or 
non-risk allele 
-90 
c.373G>C Alteration of exonic ESE site. Potential 
alteration of splicing 
NA NA     
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Of the 606 hexamer motifs in CHESEL, 30% (n= 184) were found to be affected by SNPs.  
82%  (n= 79) of the SNP sequences contained hexamer motifs. In order to understand this 
further, they need to be broken down into the individual sites/effects e.g. intronic, 
synonymous and missense SNPs. By considering the UC associated SNPs as biallelic 
(risk/non-risk), there can be one of three outcomes for the SNPs: Type 0 – neither of the 
SNP sequences encode an ESE; Type 1 – either SNP sequences encode an ESE but not both; 
or Type 2 – both sequences encode an ESE. Currently there is no in silico mechanism to 
determine the strength of the ESE motif in comparison to another out of the context of 
the site of the ESE e.g. adjacent to a branch point, at an exon terminus. Therefore, with 
the current tools available, only Type 1 outcomes are considered deleterious.   
The literature is mixed with regard to synonymous SNPs (sSNPs) and ESEs. There is 
evidence for both positive selection of sSNPs in ESEs (300), but also that ESEs have the 
lowest frequency of SNP affected ESEs due to removal of deleterious variants by purifying 
and/or natural selection (301, 302).  In this cohort; of the 6 sSNPs; two were Type 0 (MST1, 
CPSF3L), three were type 1 and one was type 2 (Figure 2-2).  For the Type 1 SNPs, sSNPs 
in APEH is predicted to cause a loss of ESE motif, whereas sSNPs in CARD9 and RTEL1 are 
predicted to cause a gain of ESE.  
Of note, the Type 2 SNP was rs3742130 which is both a synonymous SNP for GPR18 and 
an intronic SNP for UBAC2. UBAC2 is primarily overexpressed in neutrophils and 
peripheral blood mononuclear cells, although is also expressed in the colon(298), whereas 
GPR18 is overexpressed in B lymphocytes and is predominately expressed in immune cells 
as opposed to the colon(298). This is indicative of cell specificity of gene expression, for 
which a Type 2 SNP may have a differential effect depending on the strength of the ESE in 
different cell types.  
By comparison to the sSNPs, the missense SNPs analysis (mSNPs) painted a very different 
picture; none of the eight missense SNPs were type 0, four were type 1 and four were 
type 2 (Figure 2-2)The mSNPs in GPR35, FCGR2A and IL17REL are predicted to cause a loss 
of ESE motif with the risk allele. The mSNP in CD6 is predicted to cause a gain of ESE motif. 
mSNPS in NXPE1, MST1, RTEL1 and IL23R all have ESE hexamer motifs in both the risk and 








Table 2-4 Predicted exonic splicing enhancer (ESE) motifs corresponding to changes in ESE or Exonic Splicing 
Silencer (ESS) motifs identified in HSF . Allele of interest in bold for CHESEL results. Nil= no corresponding motif 
found within the sequence. WT = wild type allele. NR = non-risk allele. R = risk allele. Grey shading indicates 
source from extended parent cohort. 
  





C G A c.126C>G Alteration of an exonic ESE .  Nil nil 




C C T c.673C>T Creation of an exonic ESS, 




G A G c.1142G>A Creation of an exonic ESS 




G C T c.631G>C Alteration of an exonic ESE.  CCCAGG 
CCAGGA 
nil 
c.631G>T  Creation of an exonic ESS. TCAGGA 
RTEL1 
ENST00000369996 
C C T c.147C>T Creation of an exonic ESS.   






A A G c.1347A>G Alteration of exonic ESE .  Nil nil 
MST1  
ENST00000448220 
G C A c.373G>C Alteration of exonic ESE . Nil nil 
c.373G>A  Alteration of exonic ESE .   Nil 
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As previously noted in the literature(302-304) functioning ESE motifs are also found in the 
intronic sequences. Of the fifty-four intronic (non lncRNA) SNPs, twenty-two had type 1 
outcomes, twenty-two had type 2. Eight intronic SNP sequences had type 0 outcome 
(Figure 2-2).   
To analyse whether there was a significant difference between the numbers of ESEs in 
intronic sequences and the exonic sequences, I used a Two-way ANOVA and Tukey’s 
multiple comparison’s test, there was no significant difference between the 95% 
confidence intervals (CI) of the difference of means between the numbers of sequences 
found without any ESE hexamers in any of the SNP sites (e.g. intronic, synonymous etc). 
There was a significant difference as described above between the hexamers identified 
in either risk or non-risk allele sequences between intronic sites and the rest of the 
potential sites (p = 0.033, p=0.03, p=0.045 for synonymous, missense and lncRNAs 
respectively). There was carried over to a significant difference between the 95% CI of 
the difference of means between the numbers of intronic sequences and the numbers 
of synonymous sequences that had a type 2 outcome. The rest of the comparisons were 
non-significant ( 
Table 2-6).  
The intronic ESE results from CHESEL (Table 2-5) indicate that where there is more than 
one fine mapped SNP in an intronic area within a gene e.g PUS10, C1orf106, CCNY, 
C5orf66, NFKB1, GNA12, IL17R, SFMBT1, each of those SNPs encode an (different) ESE 
hexamer motif, suggesting co-localisation of those motifs with enrichment of disease 
associated SNPs within them. There are two exceptions, APEH has a finemapped intronic 
SNP with no ESE hexamer motif and IL23R has two finemapped SNPs with no ESE hexamer 
motifs, where both have one SNP sequence each which does contain a motif. Although 
co-localisation of exonic splice enhancers has been seen in exonic regions in oncogenes 
such as BRCA2, with polymorphisms localising to these sites associated with splice 
variants (305), this has not been documented in intronic regions. A common feature of 
intronic splice enhancer motifs is C triplets or G triplets. These are not commonly found 
at exonic splice sites, and mutations in exonic C tripletswhen they do occue does not 
change their function.  Co-occurrence of C and G triplets within an intron is thought to 
create a functional synergy to create a larger ribonuclearprotein complex through 
transacting sites(306).  
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NR5A2 rs2816958 and C5orf66 have C triplets in their hexamer motif, APEH has a G triplet 
in its hexamer motif. Looking at the wider sequences for the putative co-localising intronic 
ESE motifs; neither PUS10 SNPs, CCNY nor NFKB1 have C or G triplets within their 11 bp 
sequences, C1orf106 had a G triplet in one SNP sequence (rs59655222), C5orf 66 had a 
triplet C in one SNP sequence (rs254562), GNA12 had a C triplet in rs1182188 and a G 
triplet in rs798502, IL17R (rs11567701) had a G triplet and SFMBT1 (rs2564956) had a G 
triplet. There was no co-occurrence of C and G triplets within one sequence, further 
analysis is required to assess if the disease associated intronic SNPs that cluster with 
putative enhancing motifs, be it CHESEL motifs or triplet motifs, are close enough to 
function synergistically to cause a splicing variation or aberration. The presence or 
absence of the triplets within the SNP sequences does not indicate that these are 
definitely are or are not enhancing sites, but it does add weight to the CHESEL intronic 
results. In terms of the downstream effect, the heterogenous ribonucleoprotein (hnRNP) 
family bind intronic sequences to have an enhancer effect. Thus, a gain of an intronic ESE 
motif with the risk allele was denoted as a gain of splicing enhancement, whereas a loss 




Non risk Risk SNP/ID Site Gene Name 
TATGGCAGTGA TATGGTAGTGA rs6911490 intronic ATG5 
AATCAGAACTA AATCATAACTA rs11229555 intronic GLYAT 
TCTCCTTCCAC TCTCCCTCCAC rs1182188 intronic GNA12 
GCTAATGTACA GCTAACGTACA rs8005161 intronic GPR65 
TGTGTGTAGGA TGTGTATAGGA rs11041476 intronic LSP1 
TACCTGTGTCC TACCTATGTCC rs1893217 intronic PTPN2 
ATTTTTGTACT ATTTTCGTACT rs7596362 intronic PUS10 
TTGATATTTGA TTGATCTTTGA rs7608697 intronic PUS10 
CTCTTGTAGAC CTCTTATAGAC rs7608910 intronic PUS10 
TGTGGAACTTG TGTGGGACTTG rs2564956 intronic SFMBT1 
TTTAAATTTAA TTTAAGTTTAA rs12942547 intronic STAT3 
TCACATTGGGA TCACACTGGGA rs59655222 intronic C1orf106 
ACAGTACTGTC ACAGTGCTGTC rs254560 intronic C5orf66 
ATTCCGTCTCA ATTCCATCTCA rs28671712 intronic CHP1 
CTGTTCGCTCT CTGTTTGCTCT rs7495132 intronic CRTC3 
gtcagTtgtca gtcagAtgtca rs267984 intronic DAP 
CTCTTTCAGTT CTCTTCCAGTT rs10896794 intronic LPXN 
GTTTAGATAAC GTTTAAATAAC rs543104 intronic MAML2 
ATGCCGTGTAT ATGCCATGTAT rs2425019 intronic MMP24 
GATACAATGTT GATACGATGTT rs3774937 intronic NFKB1 
AGCAGGTCAAC AGCAGTTCAAC rs3766606 intronic PARK7 
GTGAGTAACAC GTGAGGAACAC rs2266959 intronic UBE2L3 
actgcGttcca actgcAttcca rs6062504 intronic ZGPAT 
TCAAACCTGGG TCAAATCTGGG rs11130213 intronic APEH 
CAAGTGGTTTT CAAGTAGTTTT rs12131796 intronic C1orf106 
ctttgTtgaat ctttgCtgaat rs12132298 intronic C1orf106 
GATAACTGCAG GATAAATGCAG rs7554511 intronic C1orf106 
TTTACTCCTGC TTTACGCCTGC rs41299637 intronic C1orf106 
CTTCCTTACCC CTTCCCTACCC rs254562 intronic C5orf66 
TTGCTCTGCAC TTGCTGTGCAC rs12254167 intronic CCNY 
GATGATAGCAA GATGAGAGCAA rs12261843 intronic CCNY 
gtcacCgtact gtcacTgtact rs6481950 intronic CCNY 
TAGCAGGAGGT TAGCAAGAGGT rs11879191 intronic CDC37 
TGCAAGTGCTA TGCAACTGCTA rs267939 intronic DAP 
tctgaAgggtc tctgaCgggtc rs798502 intronic GNA12 
GTGGCCTTGAT GTGGCTTTGAT rs11168249 intronic HDAC7 
ACGCACATCTG ACGCAGATCTG rs11567699 intronic IL17R 
CAACTGGGATT CAACTTGGATT rs11567701 intronic IL17R 
TATGATGTTAG TATGACGTTAG rs113935720 intronic IL23R 
GAGAGAGACTT GAGAGGGACTT rs7657746 intronic KIAA1109 
ATAGCAAGAAA ATAGCGAGAAA rs3774959 intronic NFKB1 
TCCCAGGCAGT TCCCAAGCAGT rs2816958 intronic NR5A2 
CAGGCTCTGCT CAGGCGCTGCT rs4560096 intronic PUS10 
TCCAACCTGGT TCCAAGCTGGT rs2581817 intronic SFMBT1 
GGAAACACCAT GGAAAAACCAT rs1517352 intronic STAT4 
Table 2-5 CHESEL Intronic sequences with hexamer motif matches, type 1 and type 2 outcomes in grey. EPC. 
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Comparing the ESE hexamers found in CHESEL with the HSF results for the intronic 
samples, although may be of interest to compare the two modalities is an untenable 
comparison given the large number of exclusions in HSF due to inabilities to run a number 
of intronic transcripts, therefore the intronic SNPs found in CHESEL were put forward to 
the network, with the caveat that we are unable to assess the false positive nature of 
these results.  
HSF also identified multiple exonic splicing silencer motifs in the synonymous and 
missense SNP sequences identified in Table 2-4. 
Attempts to confirm these with other ESS prediction tools was unsuccessful as published 
or validated prediction tools such as FAS-ESS (http://genes.mit.edu/fas-ess/) or MutDB 
(www.mutdb.org) are either no longer working or do not have the rsIDs we are interested 
in within their databases. The ESS motifs (genes affected) were put forward to the 
network, again, with the caveat that we are currently unable to assess the false positive 


















Figure 2-2Comparison of number of SNP sequences for each ESE outcome. Type 0 outcome = no ESE hexamer 
in either risk or non-risk allele sequence. Type 1 =ESE hexamer found in either risk or non-risk SNP allele 
sequence. Type 2 outcome = ESE hexamer found in both risk and non-risk allele sequences.  * = p=<0.05, actual 











  Type 0     
    Synonymous vs. Missense 2 -22.46 to 26.46 ns 0.9913 
    Synonymous vs. LncRNA -3 -27.46 to 21.46 ns 0.9721 
    Synonymous vs. Intronic -8 -32.46 to 16.46 ns 0.6854 
    Missense vs. LncRNA -5 -29.46 to 19.46 ns 0.8906 
    Missense vs. Intronic -10 -34.46 to 14.46 ns 0.5347 
    LncRNA vs. Intronic -5 -29.46 to 19.46 ns 0.8906 
     
  Type 1     
    Synonymous vs. Missense -1 -25.46 to 23.46 ns 0.9989 
    Synonymous vs. LncRNA -2 -26.46 to 22.46 ns 0.9913 
    Synonymous vs. Intronic -27 -51.46 to -2.536 * 0.0333 
    Missense vs. LncRNA -1 -25.46 to 23.46 ns 0.9989 
    Missense vs. Intronic -26 -50.46 to -1.536 * 0.039 
    LncRNA vs. Intronic -25 
-49.46 to -
0.5356 * 0.0458 
     
  Type 2     
    Synonymous vs. Missense -3 -27.46 to 21.46 ns 0.9721 
    Synonymous vs. LncRNA -5 -29.46 to 19.46 ns 0.8906 
    Synonymous vs. Intronic -25 
-49.46 to -
0.5356 * 0.0458 
    Missense vs. LncRNA -2 -26.46 to 22.46 ns 0.9913 
    Missense vs. Intronic -22 -46.46 to 2.464 ns 0.0752 
    LncRNA vs. Intronic -20 -44.46 to 4.464 ns 0.1055 
 






Using a BLASTN search, sixteen human mature microRNA homologous sequences were 
suggested to be ‘lost’ with the presence of a SNP risk allele as compared to the non-risk 
allele (Table 2-7). The scores for homology are based on the statistics for local alignments 
lacking gaps, where the ideal is to find two segment pairs which cannot be improved by 
extension or trimming called high scoring pairs – the higher the score the better the 
alignment. To ensure this is not by random alignment, the E value tells you how likely the 
alignment is to have occurred by chance.  As shown by in Table 2-7, the BLASTN scores 
are only moderately high (which could be a function of the short sequence analysed) and 
the E values are less than ten, but an E value of 10 gives a probability of random chance 
of 0.999. Given these ‘grey’ results, we searched the MiRBase database miRNA for miRNA 
motifs using SSEARCH to add confidence to the findings. The SSEARCH facility is better 
placed to search short sequences, hence the higher scores but the payoff is higher E values 
in some cases, such as mir-6755-3p, to the extent of not finding the previously identified 
















miR-1266-3p   
rs4380874 intergenic 
62 5.7 110.9 8.1 
miR-6775-3p   60 8.4 not found 
miR-548at-3p NXPE2P1 rs561722 UGV 61 6.9 109.7 9.9 
miR-6777-3p TMBIM1 rs2382817 5’UTR 67 2.2 not found 
miR-5692a IKZF3 rs12946510 DGV 61 6.9 not found 
miR-519c-3p lncRNA rs6920220 intronic 61 5.3 116.3 4.1 
miR-526b-5p 
KIAA110
9 rs7657746 intronic 63 4.3 not found 
miR-552-5p 
CDC37 rs11879191 intronic 
61 6.9 116.6 4.1 
miR-6835-5p not found 112.6 6.5 
miR-5701  lncRNA rs11742570 UGV 63 4.7 116 4.9 
miR-365a-3p 
ITLN1 rs4656958 UGV 
61 6.9 114.5 5.1 
miR-365b-3p  61 6.9 114.5 5.1 
miR-4699-3p 
CCNY rs12254167 intronic 
63 4.7 116 4.9 
miR-5010-5p 62 5.7 110.9 8.1 
miR-511-5p 66 2.6 not found 
miR-6082 CHP1 rs28374715 intronic 68 1.8 121 3.2 
miR-6875-5p lncRNA rs941823 intronic 65 3.2 118 4.1 
Table 2-7 Human Mature miRNA homology sequences lost with the presence of the risk allele in the 21bp 
flanking sequence, when compared to the non-risk allele 21bp sequence. Data summarised from MirBase. 




Analysis of the miRNA targets in Cytoscape 3.3.0 identified two subnetworks, a smaller 
subnetwork consisting of two star clusters around a lncRNA SNP site and an intergenic 
SNP site. This suggested that there were interlinking (or first neighbour) interaction nodes 
between the source nodes. First neighbour nodes are of interest as these can link our 
SNPs of interest to a downstream impact not otherwise identified from looking directly at 
the SNP affected site. Unfortunately, despite visually looking connected, the clustering 
coefficient was zero, BinGO did not identify any biological process enrichment, and 
confirmation of no biological enrichment in all tissues analysed (intestine, colon, B 
lymphocyte, T lymphocyte, Whole blood) in Genome-scale Integrated Analysis of Gene 
Networks in Tissues (GIANT) all suggested that the network created was not a indictor of 
a biological process, but by random chance. 
Genome analysis of the annotated sites for the miRNA in Ensembl identified no 
correlation between the SNP sites and the true miRNA annotated sites.  The homology 





449 putative miRNA binding sites (MBS) were identified in 117 SNP sites using the initial 
cut-off threshold of total score >150, energy score<-7. Given the high rate of false positive 
motifs we had identified in previous sections, and the literature quoting false positive 
rates between 20-40% (Baek 2008, Krek 2005, Selbach 2008, Cloonan 2008) for algorithm 
based predictive miRNA binding site prediction tools; a more stringent threshold of total 
score >155, energy score <-20 was applied.  
This resulted in 104 putative MBS in 56 SNP sites. A further 6 MBS in 3 SNP sites were 
excluded from network creation for being neutral (loss and gain of the same miRNA 
binding site), 18 were excluded as being within intergenic regions, 1 was excluded for 
being within a non-coding transcript variant, 5 were excluded for being in antisense RNAs, 
2 were excluded in uncharacterised RNA (RP11-415K). After exclusions, there were 71 
putative MBS in 36 SNP sites (Table 2-8).  
2.4.4.3 miRNA-mRNA	sites	affected	by	SNPs	
Seed sequences of miRNAs are at positions 2’-8’of the miRNA, however there can be 
mismatch or wobble at positions 5,6 and 7 (Loeb 2012) which can create variation in 
binding. Perfect complementarity of 11 nucleotides starting at position 3, 4 or 5 can 
repress mRNA translation (Shin 2010). Unfortunately, these only accounts for <10% of 
miRNA/mRNA interactions found in the human transcriptome (Bartel 2009).  
The miRanda algorithm used creates an optimal local alignment of the miRNA with the 
mRNA using a weighted dynamic programme algorithm – this gives preferential weight to 
the ‘2-8’ pairing, and is a sum of match/mismatch scores with gap penalties. The level of 
perfect complementarity is given as a percentage alignment score, which takes into 
account the miRNA-mRNA alignment length and the gaps within that alignment. The 
alignment lengths for the SNP sequences were set to >11, the longest alignments were 
20nt long. The best alignment was 100%, in 11 nt in rs72703058 which is an intergenic 
SNP. The lowest alignment score was 57.89% in a 20nt alignment sequence for 
rs41299637 (C1orf106). The intergenic and lncRNAs miRNA binding sites were 
interspersed equally across the range of percentage alignments.  
Each SNP site could have multiple miRNA binding sites within in it (mean = 2.2, median = 
2, mode = 1, minimum-maximum =1-6). The Pearson correlation was significant with r = -
0.85 (-0.98-0.1 95%CI); r2=0.73, p=0.036 which was not unsurprising given the low 
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probability of 1 SNP site having 6 miRNA binding sites associated with it as opposed to 
1SNP site having 1 miRNA binding site associated with it.  
There was no overlap in the specific miRNAs that would bind, within the included set. Two 
genes (KIR3DL2-rs1654644 and ITGAL-rs12716977 ) shared miRNA (hsa-miR-4716-3p, hsa-
miR-1268b respectively) with lncRNA sites (rs200073939  and rs11757201)(see below). 
These SNPs are not finemapped or in linkage disequilibrium with their shared miRNA 
partner. From the intergenic sites (excluded) 1 miRNA (hsa-miR-6812-5p) was shared 
between two intergenic sites (rs72703050, rs2413583). Again, these SNPs are in different 
sites and are not in linkage disequilibrium with each other or fine mapped together.  
The main role of miRNAs is to negatively regulate gene expression. Binding of the miRNA 
to mRNA leads to splitting and deadenylation of the mRNA, thereby causing translation 
repression. A loss of a miRNA binding site would suggest that negative regulation could 
not occur by that particular miRNA and vice versa; a gain of a miRNA binding site may 
indicate gene silencing. 54% of the putative MBS were lost with the risk allele, 46% were 
gained, loss affecting 17 genes; gain affecting 18 genes, with an overlap of 8 genes 
between loss and gain (MST1, NXPE1, CD6,ITGAL, CCNY, C1orf106,KIAA1109, NR52A) via 
different miRNAs. The overlap gene SNP sites were synonymous (MST1), missense 
(NXPE1, CD6), upstream gene variants (ITGA) and intronic (C1orf106, CCNY,KIAA1109, 
NR52A). Although 3’UTRs are the primary site of miRNA binding to mRNAs, miRNA binding 
sites have been shown to be active in open reading frames (exonic and intronic regions), 
and 5’UTRs (307-310).  53% (n=29)of the MBS (regardless of loss or gain) were intronic, 
16% were missense (n=9), 13% were synonymous (n=7), 11% were upstream gene 
variants (n=6), 4% were down stream gene variant (n=2), 2% were 3’UTR and 5’UTR (n= 1 
each). 
Similarly to the splice site motifs, there are six finemapped genes that have MBS motifs in 
multiple SNP sequences; TNFRSF14, C1orf106, CCNY, RTEL, MST1 and ITGAL. Although 
there is evidence that multiple binding sites for one miRNA within a target gene optimises 
the repression of said target gene (281, 311, 312), this is not represented as a SNP effect 
in this dataset but there is increasing evidence that combinations of different miRNAs 
work in conjunction to repress target genes(313-315). 
Analysis of the conserved miRNAs in miRanda with good mirSVR scores(316) for each of 
the gene mRNAs did not identify any other binding sites for any of the miRNAs we have 
identified (no redundancy of conserved sites).  Analysis of non-conserved sites in miRanda 
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did confirm two SNP predictions; mir-661 in RTEL1 (rs2257440) and in FCGR2A miR-204-
5p (rs1801274) as being where we expected it to be in the mRNA (it is lost with the risk 
allele). The RTEL MBS also had redundancy – another binding site approximately 100 base 
pairs part. For the broad institute finemapped SNP rs59655222 (that used the alleles 
denoted in Ensembl), miRanda identified the miRNA binding site (which should have been 
a gain in binding site with the risk allele). This emphasises the importance of having the 
right allele for understanding the disease process. In ITGAL mRNA there were eight miR-










miR-2392 rs727088 3’UTR CD226 155 -25.3 loss 
miR-1291 rs2382817 5’UTR TMBIM1 164 -22.59 gain 
miR-8073 rs10797432 DGV TNFRSF14 155 -25.01 loss 
miR-7157-3p rs10910092 DGV TNFRSF14 157 -20.19 loss 
miR-3941 rs11041476 Intronic LSP1 156 -20.61 loss 
miR-6511b-5p rs41299637 Intronic C1orf 106 156 -24.63 gain 
miR-7159-5p rs12132298 Intronic C1orf106 162 -21.55 loss 
miR-199a-5p rs59655222 Intronic C1orf106 171 -30.61 gain 
miR-199b-5p rs59655222 Intronic C1orf106 167 -28.54 gain 
miR-4733-5p rs59655222 Intronic C1orf106 169 -22.79 loss 
miR-1229-5p rs254562 Intronic C5orf66 162 -31.66 gain 
miR-433-5p rs6481950 Intronic CCNY 161 -24.35 loss 
miR-4430 rs6481950 Intronic CCNY 155 -23.82 gain 
miR-6870-3p rs12261843 Intronic CCNY 165 -27.05 gain 
miR-5589-5p rs28374715 Intronic CHP1 162 -25.64 gain 
miR-204-5p rs1801274 Intronic FCGR2A 158 -21.98 loss 
miR-6867-3p rs1801274 Intronic FCGR2A 157 -21.06 loss 
miR-4433a-3p rs1182188 Intronic GNA12 161 -28.4 loss 
miR-6880-5p rs1182188 Intronic GNA12 163 -21.27 loss 
miR-4510 rs1182188 Intronic GNA12 159 -21.06 loss 
miR-6760-5p rs1182188 Intronic GNA12 156 -20.62 loss 
miR-7847-3p rs1182188 Intronic GNA12 158 -20.44 loss 
miR-4647 rs3024495 Intronic IL10 159 -21.88 gain 
miR-3183 rs7657746 Intronic KIAA1109 161 -23.84 loss 
miR-2114-5p rs7657746 Intronic KIAA1109 160 -22.53 loss 
miR-642a-5p rs7657746 Intronic KIAA1109 158 -21.4 loss 
miR-3184-3p rs7657746 Intronic KIAA1109 164 -20.91 gain 
miR-625-5p rs1654644 Intronic KIR3DL2 165 -23.44 loss 
miR-4716-3p rs1654644 Intronic KIR3DL2 155 -20.19 loss 
miR-6839-5p rs483905 Intronic MAML2 162 -20.79 Loss 
miR-619-5p rs2816958 Intronic NR5A2 164 -27.61 gain 
miR-6513-5p rs2816958 Intronic NR5A2 156 -21.29 loss 
miR-4538 rs2581817 Intronic SFMBT1 165 -22.06 gain 
miR-3653-5p rs10891692 Miss NXPE1 156 -23.87 gain 
miR-1200 rs10891692 Miss NXPE1 159 -23.24 gain 
miR-3192-5p rs10891692 Miss NXPE1 158 -23.11 loss 
miR-6761-5p rs10891692 Miss NXPE1 155 -20.67 gain 
miR-4281 rs11230563 Miss CD6 159 -29.88 gain 
miR-6849-5p rs11230563 Miss CD6 157 -25.48 loss 
miR-6759-5p rs3208008 Miss RTEL1 159 -26.71 loss 










miR-6747-3p rs5771069 Miss IL17REL 157 -25.13 gain 
miR-7113-3p rs12103 Syn CPSF3L 162 -28 gain 
miR-4502 rs10781499 Syn CARD9 165 -22.14 gain 
miR-369-3p rs1131095 Syn APEH 179 -21.76 loss 
miR-6746-5p rs13085791 Syn MST1 162 -32.94 loss 
miR-8085 rs13085791 Syn MST1 157 -23.59 loss 
miR-661 rs2257440 Syn RTEL1 155 -31.88 loss 
miR-6769a-3p rs9822268 Syn MST1 156 -22.9 gain 
miR-548aa rs11150589 UGV ITGAL 169 -24.04 gain 
miR-548t-3p rs11150589 UGV ITGAL 169 -24.04 gain 
miR-548ay-3p rs11150589 UGV ITGAL 158 -23.32 loss 
miR-548at-3p rs11150589 UGV ITGAL 162 -21.13 loss 
miR-1268b rs12716977 UGV ITGAL 166 -35.99 loss 
miR-1268a rs12716977 UGV ITGAL 166 -35.49 loss 
Table2-8  continued Summary of miRNA binding site affinities to SNP sequence. Highlighted genes are SNPs in 





Long non-coding RNA with miRNA binding sites within them have been shown to affect 
post-transcriptional regulation by miRNAs by competing with the mRNA targets of 
miRNAs, thereby reducing the availability of the miRNA, reducing repression of the target 
mRNA(317).   Of the 71 putative binding sites, 17 (24%) were predicted to occur due to a 
combination of 8  SNPs in 6 long non coding RNAs and 2 SNPs in upstream gene variants 
of long non coding RNA RP11-386E5.1(Table 2-9). In order for this competition to occur, 
the lncRNA and mRNA pair that is targeted by a common miRNA must be expressed in the 
same tissues. Using lnCeDB, the miRNA identified were not found within the only 2 long 
non-coding RNA the database held data for, from within our dataset; RP11-95M15.1 and 
LINC00484. Predictions for the mRNA pairs that share the miRNA with the lncRNA have 
not been undertaken, as this would make the network fraught with false positive results 
from non-validated ‘predictions on predictions’. Accordingly, the SNPs have not been 
separated into parent and extended parent cohorts but visualised as a whole cohort in 











miR-1268b rs11757201 intronic RP11-95M15.1 159 -27.46 17 81.25% gain 
miR-499a-3p rs11757201 intronic RP11-95M15.1 157 -21.53 19 71.43% loss 
miR-557 rs13277237 intronic CCDC26-001 158 -20.41 19 72.22% loss 
miR-608 rs2396087 intronic RP11-344J7.3 166 -32.43 21 71.43% loss 
miR-6782-5p rs2396087 intronic RP11-344J7.3 156 -28.38 21 75.00% loss 
miR-3936 rs2396087 intronic RP11-344J7.3 155 -25.19 20 73.68% loss 
miR-1913 rs2396088 intronic RP11-344J7.3 168 -28.04 20 78.95% loss 
miR-3137 rs2396088 intronic RP11-344J7.3 157 -26.52 22 66.67% gain 
miR-1301-3p rs2396088 intronic RP11-344J7.3 165 -24.59 17 81.25% loss 
miR-1254 rs4743820 intronic LINC00484 160 -33.17 22 71.43% loss 
miR-323b-3p rs6584283 intronic LINC01475 162 -27.27 20 73.91% gain 
miR-8089 rs6940798 intronic RP11-344J7.3 155 -24.31 22 65.22% gain 
miR-2110 rs6940798 intronic RP11-344J7.3 163 -22.27 19 72.22% gain 
miR-6799-3p rs9770544 intronic RP1-170O19.14 156 -21.17 16 73.33% loss 
miR-6809-3p rs6883964 UGV RP11-386E5.1 168 -23.68 18 88.24% gain 
miR-6830-3p rs6883964 UGV RP11-386E5.1 163 -20.02 19 72.22% loss 
miR-3934-5p rs6888952 UGV RP11-386E5.1 163 -22.36 16 87.50% loss 





Thirteen SNPs were predicted by JASPAR to occur within transcription factor binding sites.  
RTEL1 encodes a DNA helicase crucial for telomere maintenance and DNA repair. It is 
known to be regulated by NRSF1, NRSF2, AP1, NFKB1, ARP1, E47, Ik1. Rs2297441 is 
predicted to gain the homologous sequence for transcription factors HOXB13 and 
HOXD13.  HOXB13 and HOXD13 are sequence specific transcription factors which form 
part of the developmental regulatory system which provides cells with specific positional 
identities on the anterior- posterior axis. There was no ORegAnno annotation for this site, 
the SNP does occur within an enhancer region which is an elite enhancer, however the 
enhancer region does not regulate RTEL1.  
TNFRSF14 encodes a member of the tumour necrosis factor superfamily. It functions in 
signal transduction pathways to activate inflammation and inhibit T cell immune respose. 
It also binds herpes simplex virus envelope proteins to mediate the viral entry into the 
cell. It is regulated by GATA1, NKx2-5, Nkx5-1, RP58, STAT3, ARE6, E2F. rs10797432 is 
predicted to encode a loss of binding to INSM1 is a transcriptional repressor involved in 
beta cell development. There was no ORegAnno annotation, nor does the SNP occur 
within an enhancer region.  
HDAC7 encodes a histone deacytylase which plays a critical role in transcriptional 
regulation by altering chromosomal structure to prevent transcription factor binding, 
thereby repressing transcription. It has transcription factor binding sites to PAX4A, E47, 
C-ETS-1, SEF1, NKX2-5, ZIC3, FAC1, PPAR-GAMMA 1 and 2.  Rs11168249 is predicted to 
cause a loss of transcription factor binding to LEF1 and TC7L2. The SNP occurs both within 
an ORegAnno annotation site for SMARCA4, as well as an enhancer region. This elite 
enhancer region does contain a binding site to TC7L2 but not LEF1.  
IL17R encodes a membrane bound glycoprotein which binds with low affinity to 
interleukin 17A. It is regulated by AP1, c-JUN, ATF-2, GATA3, NF-AT1,2,3,4, NF-AT, 
C/EBPalpha.  Rs11567699 is predicted to cause of loss of binding by ZBTB18. There is no 
ORegAnno annotation, but it does occur within an elite enhancer region which does 
regulate IL17R, but a ZBTB18 binding site is not found within this enhancer. 
FCGR2A encodes a protein that is found on the cell surface of phagocytic immune cells, 
including macrophages and neutrophils and is directly involved in the phagocytic process 
and initiates cellular responses against pathogens and soluble antigens. It is regulated by 
STAT3, AML1a, P53, FOXD1, STAT1, HLF, HAND1, E47 and EVI-1. rs4657041 is predicted to 
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cause the loss of binding sites for DUXA and RARA transcription factors. There was no 
ORegAnno nor enhancer annotation for this site. 
CRTC3 is a member of the CREB regulated transcription coactivator family. It is regulated 
by deltaCREB, CREB, NKX6-1, MSX-1, AML1a, CRE-BP1, ATF-2, CP2 and ZIC3.  Rs7495132 
is predicted to cause a loss of binding site for FOXA1 and a gain of TBX19. There was no 
ORegAnno nor Enhancer annotation for this site. 
LPXN is a member of the focal adhesion associated adapter protein family. It is involved 
in the regulation of cell adhesion, cell migration and is a negative regulator in integrin 
mediated cell adhesion events. It is regulated by C/EBPalpha, c-ETS1, HOAX3 and FOXC1. 
Rs10896794 is predicted to cause a gain of binding site for IRF1, STAT1 and STAT2. IRF1 
transcriptional regulation occurs with IRF1 as a homodimer, or as a heterodimer with 
unphosphorylated STAT1 which bind partially overlapping interferon consensus 
sequences or as part of an interferon enhancesome with NFKB, ATF-2/c-jun, and IRF3, 
IRF7. There are no other cis or trans acting transcription factor binding sites to create an 
interferon enhancesome 2kB upstream or downstream of LPXN.  The SNP does not occur 
within an enhancer region, however, it is immediately downstream of two ORegAnno 
annotations for CEBPA which raises the possibility of transcription factor cooperativity 
which is a previously documented phenomena between STATs and C/EBPs(318-320). The 
SNP is also immediately upstream of a microsatellite region. 
CHP1 encodes a calcium binding phosphoprotein that binds to the Na/H exchanger NHE1. 
It mediates the association between microtubules and membrane bound organelles of 
the endoplasmic reticulum and Golgi apparatus. It is also an endogenous inhibitor of 
calcineurin activity.  rs28671712 is predicted to cause a gain of transcription factor binding 
site to IRF1, however the p value is significantly smaller than the rest of the predictions. 
There was no ORegAnno nor enhancer annotations for this site. 
IL10 encodes Interleukin 10, which is primarily produced by monocytes. It is a cytokine 
that has pleiotropic effects on inflammation and immunoregulation. It downregulates the 
expression TH1 cytokines, MHC class II antigens, and costimulatory molecules on 
macrophages. Conversely it enhances B cell survival, proliferation and antibody 
production. It is considered to be an essential immunoregulator in the intestinal tract. It 
is regulated by STAT3, SP1, deltaCREB, CREB, GR-beta, GR-alpha, GR and PBX1a. 
rs3024495 occurs within an elite enhancer region that does regulate IL10. It is predicted 
to cause a gain in binding site to ZNF263. ZNF263 is a KRAB domain containing zinc finger 
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protein which has both transcription activation and repression properties. IL10 is not 
known to be regulated by ZNF263.  
ITGAL encodes integrin subunit alpha L which combines with the beta2 subunit (ITGB2) to 
form the lymphocyte function associated antigen 1 (LFA1). LFA1 has a role in leucocyte 
intercellular adhesion and as a lymphocyte costimulatory molecule. It is known to be 
regulated by AML1a. rs11150589 is within an elite enhancer site which is known to 
regulate ITGAL, and is predicted to cause a gain of binding site to IRF1.  




SNP Site Gene 
Transcription 
Factor strand sequence P Value Loss/Gain 
rs2297441 3’UTR RTEL1 HOXB13 D CTAATAAAAC 9.10E-06 Gain 
rs2297441 3’UTR RTEL1 HOXD13 D CTAATAAAAC 6.20E-06 Gain 
rs10797432 DGV TNFRSF14 INSM1 D TGCCAGGGGGAG 5.20E-06 Loss 
rs12946510 DGV IKZF3 MEF2C D GAGTTAAAAATAAAA 7.10E-06 Gain 
rs11168249 intronic HDAC7 LEF1 R CAAGATCAAAGCCAC 6.40E-06 Loss 
rs11168249 intronic HDAC7 TCF7L2 R CAAGATCAAAGCCA 3.90E-06 loss 
rs11567699 intronic IL17R ZBTB18 R TGGACAGATGTGC 8.20E-06 loss 
rs1654644 intronic KIR3DL2 ZNF263 R GGGGGATTTGGGTGAGGGGGA 7.30E-06 loss 
rs4657041 intronic FCGR2A DUXA R ATGACCTAATCAC 9.00E-06 loss 
rs4657041 intronic FCGR2A RARA D TAGGTGATTAGGTCATGA 5.30E-06 loss 
rs7495132 intronic CRTC3 FOXA1 D AGTCTGTTTGCTCTT 6.50E-06 Loss 
rs10896794 intronic LPXN IRF1 D GATTTGTTACTCTTTCAGTTT 6.60E-06 gain 
rs10896794 intronic LPXN STAT1::STAT2 D ACTCTTTCAGTTTTT 5.10E-06 gain 
rs28671712 intronic CHP1 IRF1 R TTTTTTTTTTTTTTTTGAGAT 1.00E-05 gain 
rs3024495 intronic IL10 ZNF263 R GATGGTGAGAGGAGAGGAGGG 3.70E-06 gain 
rs7495132 intronic CRTC3 TBX19 D GTTCGCTCTTATATGTGAAA 8.80E-06 gain 
rs11150589 UGV ITGAL IRF1 D CTGTGGTTTTGATTTGCATTT 9.50E-06 gain 





A total of 43 SNP affected proteins identified from the previous tables were input into 
Cytoscape with their annotation, totalling 117 nodes and 79 edges (Figure 2-3). Although 
the UC nodes had 30 connected components, with 13 isolated nodes,  as can be seen in 
the demonstrative figure 2-3, the UC nodes do not form a network.   
The commonest modality (e.g type of effect) was a splice effect (not separating the 
splicing effect types). 65% of the affected proteins/genes were affected by splicing 
changes; 56% were affected by miRNA binding site changes; 25% were affected by 
transcription factor binding site changes, and 14% were affected by changes in the protein 
linear motif structure.  
51% of SNP genes/proteins were affected by 1 modality alone (not taking into account 
the frequency that the modality was identified), 37% were affected by 2 modalities, and 
12% were affected by 3 or more modalities. Interestingly, only one had all 4 modalities 
(RTEL1). We noted a trend between the number of modalities/frequency of hits and the 
minor allele frequency (Figure 2-4) but not with PIC values (Figure 2-5). We saw disease 
associated SNPs with a potentially significant phenotype e.g. multiple predicted effects, 
had higher minor allele frequencies. There was a natural break at a minor allele frequency 
(MAF) of 0.5, with 12 SNPs having a MAF <0.5 (group A) and 11 SNPs having a MAF >0.5 
(group B). The groups were significantly different for both modality and frequency of 
modalities using a Mann-Whitney two tailed T-test (Figure 2-6) (p = 0.0071 and P=0.0029 
respectively), covariance (using Two-way ANOVA) was significant p=0.0013. Minor allele 
frequency in combination with the number and frequency of modalities predicted at a 







Figure 2-3 UC SNP Nodes denoted by their Uniprot IDs with the miRNA whose binding site is affected (diamond) 
or transcription factor whose binding site is affected (oval) by SNPs. Some proteins are affected by protein 
linear motifs (ELM) (green blocks), SNPs affecting slice sites in mRNA have a coloured outline to the node. 
mRNA with splice enhancer sites affected by SNPs have a turquoise border, mRNA with splice silencing sites 
affected by SNPs have a pink border and mRNA with splice motifs affected by SNPs have an olive border. mRNA 

























































































































Figure 2-4 The relationship between single nucleotide polymorphism minor allele frequency and number of 
modalities predicted to affect the SNP site and the frequency of the modality at that site. Kolmogorov-Smirnov 
Test significant; not a normal distribution. 
  
Figure 2-5 The relationship between single nucleotide polymorphism PIC value and number of modalities 
predicted to affect the SNP site and frequency of the modality at that site. Kolmogorov Smirnov Test not 
significant; normal distribution 
 
Figure 2-6. Comparing number of modalities or frequency of hits affecting SNP sites with a minor allele 
frequency < or >0.5, with standard error bars and significance levels **P<0.01 
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The 5 genes that were affected by 3 modalities or more were RTEL1, IL17REL, NXPE1, CHP1 
and FCGR2A. All are UC specific except FCGR2A, which is IBD specific (NXPE1 and CHP1 
have no tissue localisation in the Broad dataset). These 5 proteins, when analysed in 
GIANT are found predominantly in mononuclear phagocytes and neutrophils, with the 
gene enrichment from mononuclear phagocytes highlighting intracellular pathogen 
pathways (Leishmaniasis pathways (p = 2.25 e-5), human tuberculosis pathways (p=9.6 e 
-4)), and immune function pathways (Phagosome pathways (p=5.61 e-4), regulation of 
monocyte chemotaxis (p=8.28 e-4), regulation of smooth muscle cell migration (p=9.07 e-
4), muscle cell migration (p=1.01 e-3), monocyte chemotaxis (p=1.20 e-3), myeloid 
leukocyte migration (p=1.23 e-3), smooth muscle cell migration (p=1.35 e-3), leukocyte 
chemotaxis (p=1.54 e-3), and regulation of cell adhesion mediated by integrin (p=1.58 e-
3)). The gene enrichment for neutrophils was equally interesting highlighting intracellular 
pathogens again (human tuberculosis p=9.88 e-4), Staphylococcus aureus infection 
(p=1.16 e-2)) and immune function (phagocyte bactericidal dysfunction (p=2.27 e-3), 
phagosome pathway (p=3.26 e-3), leucocyte cell-cell adhesion (p=3.28 e-3), granulocyte 
migration and chemotaxis (p=3.62 e-3), Natural killer cell mediated cytotoxicity (p=1.18 
e-2), cytokine-cytokine receptor interaction (p=1.19 e-2 and myeloid leukocyte migration 
(p=1.26 e-2)).  
There are 15 SNP affected genes with 2 or more modalities (11 UC specific genes; IL23R, 
ITGAL, IL10, KIR3DL2, CARD9, C5orf66, MAML2, LSP1, GNA12, C1orf106, SFMBT1 and  4 
IBD specific genes; LPXN, TNFRSF14, CRTC3, CD6).  The GIANT analysis of these 15 genes 
identified tissue specificity to dendritic cells, natural killer cells, the caecum and the 
appendix. In the caecum, the only gene enrichment present was for Staphylococcus 
aureus infection (p=4.85 e-2).  
For dendritic cells, infection pathways formed a major part of the gene enrichment 
(Tuberculosis p=8.81 e-3, Trypanosomiasis p=3.06 e-2, Epstein-Barr Virus infection p=3.29 
e-2, Toxoplasmosis p=4.01 e-2, Staphylocuccus aureus infection p=4.27 e-2, Measles virus 
infection p=4.45 e-2, HTLV-1 infection p=4.92 e-2), as well as JAK-STAT pathways p=2.88 
e-2, cytokine to cytokine receptor interaction p=2.81 e-2, Inflammatory Bowel Disease 
from 2 different sources (OMIM and KEGG) p=3.53 e-2 and p=4.82 e-2  and intestinal 
disease p=4.87 e-2. The NK cells all enriched for immune functions.  
Infectious agents have been proposed as triggers for inflammatory bowel disease, 
including Cytomegalovirus (321),  alpha hemolysin secreting Escherichia coli(322), 
Salmonella(323), Mycobacterium avium ssp paratuberculosis(324), Epstein-Barr Virus 
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(325), Helicobacter pylori (326) , enterohepatic helicobacter species (327), Varicella zoster 
virus (328), enteropathogenic viruses (140) and intestinal parasites (329). Pathobiont 
accumulation in the gut microbiota has also been proposed as an aetiological agent 
including expansion of Prevotellaceae, Escherichia coli, Enterococcus faecalis, Bilophila 
wadsworthia, Desulfovibrio spp. A reduction in abundance of Firmicutes, and 
Faecalibacterium prausnitzii have been identified as associated with IBD and IBD 
outcomes. What is not clear with all these proposed agents is whether these are triggers 





The results from the gene enrichment indicate that the UC associated SNPs affect 
infection handling pathways, not necessarily indicating causative infectious agents, but 
could point towards a commonality and a synchronicity of the SNPs to particular 
pathogenic pathways. To examine this further and clarify phenotypic effect we created 
the UC interactome, identifying the first neighbours of the UC nodes e.g binding targets, 
enzymatic targets, signalling proteins and pathways downstream of the UC nodes 
themselves. Omnipath is the largest, curated protein-protein interaction and 
transcription factor-protein database available, combining a large number of smaller 
databases. The merged Omnipath-UC_SNP network contained 8058 nodes and 49149 
edges. Once the non-first neighbour nodes were removed the UC interactome contained 
338 nodes with 2023 edges (Figure2-7). It had 143 connected components, with a 
clustering co-efficient of 0.113 (highly clustered = 1.0, un-clustered =0.0). There were 5 
isolated nodes, which were removed. There were no self-loops. As is normal with a large 
network, the gene ontology (using BiNGO in Cytoscape) identified large number (n=1344) 
of biological processes which were enriched within the network. Most of these were non-
specific e.g biological, cellular or metabolic processes, however several themes were over 
represented in the enrichment, particularly in the first 500 enrichments (adjusted p 
ranged from p=6.6526E-47 to p=6.1878E-5). The themes were signalling (12%; 4.7% 
kinases, 0.1% kinases involved in NF kappa B regulation), immune response (8.9%), 
induction and regulation of apoptosis/programmed cell death (4%), handling of infectious 
agents (3.8%), response to wounding (2.2%), the WNT pathway (0.74%), and autophagy 
(0.2%). 
Honing the network to just the genes/proteins with >2 modalities predicted at the SNP 
site and their first neighbour (82 nodes, 289 edges); there were 768 gene ontology 
enrichments (correct p=2.8561E-26 to p=4.9178E-2).  The most prevalent theme was 
immune response (19.5%) which, unlike the larger network, included gamma delta T cell 
differentiation and regulation, alpha beta T cell differentiation and regulation, production 
and response to interleukins 1,2,3,6,8,10,12,17 and 18 as well as mucosal immunity. 
Signalling themes accounted for 10.5%, including small GTPase pathways, RHO and RAS 
pathways, as well as Toll Like Receptor 2 and 4 signalling pathways, which could equally 
be counted in the response to an infective agent which accounted for 7.6% of the 
ontology. 1% of the 7.6% was the production or regulation of antimicrobial peptides. 
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Apoptosis or cell death accounted for 3% of the Gene Ontology. The last cohesive group 
was the cell matrix, adhesion or integrin (not signalling) themed group accounting for 
1.5%. Autophagy did not feature in this subgroup.  
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Figure2-7 The UC Interactome – identified from the merged Omnipath-UC network, by identifying the 
downstream first neighbours of the UC network in a perfuse force directed layout. Although not readily 
readable, the complexity of the network can be readily appreciated. UC SNP Nodes and Omnipath first 
neighbours, are denoted by their Uniprot IDs.  The node shape denotes either a protein (rectangle), a miRNA 
whose binding site is affected (diamond) or transcription factor whose binding site is affected (oval) by SNPs. 
Some proteins are affected by protein linear motifs (ELM) (green blocks), SNPs affecting slice sites in mRNA 
have a coloured outline to the node. mRNA with splice enhancer sites affected by SNPs have a turquoise border, 
mRNA with splice silencing sites affected by SNPs have a pink border and mRNA with splice motifs affected by 
SNPs have an olive border. mRNA with both a splice motif and a splice silencing site affected by a SNP have a 
light brown border.  
Transcription Factor 
         Exonic splice enhancer 
     Exonic splice silencing 
Splice site 
ESS/Splice site 





TLR4 expression is low in colonic intestinal epithelial cells, the receptors are found in the 
basolateral surface of the enterocytes, however in active CD they are found apically. TLR2 
expression in the colon is also low – it is found mainly in colonic crypts. The role of TLR2 
in the colonic epithelium is preservation of tight junction structure. The tight junction did 
not feature as a gene ontology theme, however regulation of wound healing and signalling 
cascade associated with regulation of actin filaments did feature. The tight junction 
subgroup network (figure 7) identified 2 UC associated nodes which were tight junction 
nodes: GNA12, MST1. These are both signalling proteins involved in tight junction 
regulation, GNA12 had 8 binding partners (high degree centrality, low betweenness 
centrality). Interestingly MST1 was a stand alone node, this could be explained by the 
directionality of the network as we were attempting to identify downstream binding 
partners only. There were ten additional UC associated nodes which were first neighbours 
to tight junction nodes (table 11). There were 33 nodes based around 8 components.  
More importantly there were four tight junction nodes which are putatively affected by 2 
different SNP affected proteins, 3 kinases (protein kinase C alpha, -SRC and FYN) and one 
transcriptional regulator, Jun. The c-SRC kinase node is affected by both protein tyrosine 
phosphatase N2 (PTPN2) node and Stat3 node, which are both predicted to have higher 
expression compared to the non-risk allele via loss of splice enhancers. The Fyn kinase 
node is affected by both the PTPN2 node and the CD226 node, both of which are predicted 
to have higher expression secondary to the loss of a splice enhancer and the loss of a 
miRNA binding site, respectively. The protein kinase C node is affected by the CD226 node 
as described above and the GNA12 node which is also predicted to be over expressed due 
to a loss of a miRNA binding site.  The Jun node is affected by STAT3 and NFKB1 in opposite 
directions (NFKB1 is predicted to be under expressed due to the gain of an ESE and STAT3 
is due to be overexpressed due to the loss of an ESE). STAT3 and JUN, and NFKB1 and Jun 
are known to be transcriptionally co-operative in different pathways; the JAK/STAT 
pathway and the Activated TLR4 pathway respectively and together in the response to 
IL6.    
Two proteins were identified as UC associated binding partners which were a scaffolding 
protein Actin, an integral protein of cell cytoskeletons, and an adaptor Par1 or Coagulation 
factor II receptor (F2R) which is involved in the maintenance and disruption of the 
endothelial barrier.  
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In terms of numbers of modalities affecting the UC nodes in the tight junction subnetwork, 
half of the UC nodes had >2 modalities. The four tight junction nodes with 2 UC binding 
partners were from predominantly singleton modalities (splicing or miRNA binding sites), 
except for GNA12 which has 2 modalities. The majority of findings are very non-specific 
as the kinases, transcriptional regulators and signalling proteins are ubiquitous. When 
analysed for UC specificity, only half of the nodes are UC specific; GNA12, NFKB1, MST1, 
ITGAL, NXPE1 and CHP1. The other half were IBD specific; CD226, IKZF3, CD6, PTPN2, LPXN 
and STAT3. The network is, therefore, made up of a small number of UC specific 
associated proteins, and as suggested by the prior gene ontology work, it is not clear from 
this methodology how much of the pathological driving force behind UC specific disease 
is dysregulation of tight junctions.  
Stratification using minor allele frequency (where available), number of modalities 
effecting the SNP site and UC specificity of the most important nodes, identifies that 
GNA12 (over expressed) would be a potential candidate for experimental validation, as 
would LPXN (over expressed) from the IBD side.   
GNA12 is a membrane bound GTPase, which binds to the tight junction protein ZO-1 and 
activates SRC to increase paracellular permeability. Tight junction integrity is disrupted by 
GNA12 stimulated SRC phosphorylation of ZO-1 and ZO-2, which leads to dissociation of 
two important tight junction proteins claudin 1 and occluding from the ZO-1 complex 
(330). GNA12 also has a role in the adaptive immune system in mouse models of T cell 
mediated pathology where inactivation of GNA12 leads to an increased activity of integrin 
leukocyte function antigen 1 in murine CD4+ T Cells and lymphadenopathy sue to 
increased lymph node entry and enhance T cell proliferation (331). GNA12 also has a role 
in LPXN translocation to focal adhesions (332).  
LPXN is a member of the paxillin protein family, is a thrysoine phosphoprotein which 
forms a part of the focal adhesion complex, serving as a scaffold to focus and regulate 
specific effector molecules (kinases) to a subcellular location. Via this mechanism it 
mediates the phosphorylation of the actin binding protein CaD via the extracellular signal 
regulated kinase(ERK) 1 and 2 pathway (333). When phosphorylated by  Lyn, LPXN also 
activates the JNK pathway which leads to phosphorylation of ZO-1 and dissociation of the 






 Figure 2-8 UC interactome-Tight Junction associations. The blue ovals are the nodes from the UC interactome. The orange ovals are the first neighbours of UC affected  






UC Gene Name Uniprot ID Modality Effect TJ Uniprot Name TJ function 
CD226 Q15762  Loss_up P17252 PKCA Kinase 
P06241 FYN Kinase 
IKZF3 Q9UKT9 TFBS Gain_up P01112 GTPase H-RAS Signalling 




CHP1 Q99653 TFBS gain_up Q13153 Pak1 Kinase 
CD6 P30203 ESS gain_up P68400 CK2 Kinase 
PTPN2 P17706 ESE Loss_up 
P06241 FYN Kinase 
Q03135 CAV1 Signalling 
P12931 c-SRC Kinase 
LPXN O60711 TFBS Gain_up P07948 Lyn Kinase 
STAT3 P40763 ESE Loss_up 
P09769 Fgr Kinase 
P51451 Blk Kinase 
P08631 Hck Kinase 
P45983 Jnk1 Kinase 
P12931 c-SRC Kinase 
    P63000 Rac1 Signalling 
    P05129 PKCgamma Kinase 
    Q05655 PKCD Kinase 
    P05412 Jun Transcriptional regulator 
NXPE1 Q8N323 multiple up and down P68133 Actinin Scaffolding/Adaptor 
ITGAL P20701 multiple down and up P25116 Par1 Adaptor 





Programmed cell death/apoptosis featured highly within the gene ontology with the 
network pathways including positive regulation of caspase activity, positive and negative 
regulation of the Jun N-terminal Kinase (JNK) pathway, RAS and GTPase pathways, positive 
and negative regulation of apoptosis, cell death and regulation of programmed cell death. 
Autophagy and apoptosis often occur in the same cell, with multiple common upstream 
signals including JNK which phosphorylates BCL-2, promotes apoptosis, as well as 
decreasing BCL-2 inhibition of Beclin 1, leading to an active Beclin 1-VPS34 complex and 
autophagy.  There is also shared downstream proteins in both networks e.g ATG5 is an 
autophagy protein, which also generates an amino-terminal fragment that can sensitise 
cells to apoptosis (via mitochondria) and precursors of proteins that, with caspase 
activation can accelerate the apoptotic process.  
The UC Interactome-Autophagy subnetwork (Figure 2-9), when visualised as a directed 
network identified 12 UC associated genes which interact with major regulators of 
autophagy e.g. BCL-2 and BCL-3 (Table 2-12), only ATG5 was the only autophagy and UC 
overlapping node. The modalities are all represented in the network Figure 2-8, with 
splicing changes forming the majority. The nodes highest betweeness centrality (the most 
important nodes for the network) are two UC nodes STAT3 and STAT1, as shown by figure 
2-10. The larger the circle, the greater the betweeness centrality and the more important 
that node is to the network. Both Stat1 and Stat3 activation are regulated by PTPN2. Stat3 
has been implicated in multiple steps in autophagy depending on the cellular site of stat3. 
It is the main transcriptional enhancer of several autophagy related genes including BCL2, 
BECN1, and PIK3C3, all of which are anti autophagy. STAT3 within the UC interactome is 
predicted to have increased expression. STAT3 is known to be overexpression in UC 
colonic biopsies, as compared to normal colons and even more so in inflamed UC colonic 
specimens. It is a significant transcriptional regulator interleukins IL6, IL22 and IL23, and 
is the signal transductor from the IL10, IL27 and IL6 receptors. The STAT3 SNP has a minor 
allele frequency of 57.8% (0.578), indicating that a significant percentage of UC patients 
tested had this allele, whereas the regulator PTPN2 (which is predicted to be over 
expressed) has a MAF of 16%, therefore globally would not be having such a large impact 
on the UC population, and indeed the regulation of stat3 will not be the only effect.  Stat3 
is also significantly implicated in the apoptosis pathway.  
The apoptosis_UC interactome subnetwork (Figure 2-11) is made up of 2 groups; the 
NKFB1/MAML2/LPXN/CRTC3 group and a GNA12/CARD9/STAT3/IL23R group. There is 
111 
 
significant overlap in the regulators of autophagy and apoptosis from within the UC 
interactomes ( 
Figure 2-12).  Once again, to get an overarching view of the pathogenesis of UC, looking 
at the nodes with the highest minor allele frequency e.g STAT3 57.8% (increased), IL23R 
93% (increased), GNA12 70% (increased), CRTC3 89% (increased) , these overlap as 
regulators in both autophagy and apoptosis, therefore depending on the incoming signal 
the SNP may affect the cellular decision to undergo autophagy or apoptosis and 
dysregulation of either has been shown to have a negative impact on intestinal barrier 






























































































































































































   































































































Name Uniprot ID Effect 
Autophagy  
Uniprot Name Function 
STAT3 P40763 loss_up 
Q13263 TRIM28 Transcriptional regulation of post transcriptional regulator 
P18146 EGR1 Transcriptional regulation of post transcriptional regulator 
P17676 CEBPB Transcriptional regulation of post transcriptional regulator 
Q14765 STAT4 Transcriptional regulation of post transcriptional regulator 
P24385 CCND1 Autophagy protein 
P10415 BCL2 Post transcriptional regulation 
Q16665 HIF1A Transcriptional regulation of post transcriptional regulator 
   P05412 Jun Autophagy protein 
IL23R Q5VWK5 GAIN_UP Q14765 STAT4 Transcriptional regulation of post transcriptional regulator 
PTPN2 P17706 LOSS_UP Q02790 FKBP4 Post transcriptional regulation 
ATG5 Q9H1Y0 LOSS_UP 
Q7Z434 MAVS Post transcriptional regulation 
Q7Z6Z7 HUWE1 Post transcriptional regulation 
MST1 P26927 LOSS_UP Q13043 STK4 Post transcriptional regulation 
IL17R Q96F46 GAIN_ DOWN Q9Y4K3 TRAF6 Post transcriptional regulation 
UBE2L3 P68035 GAIN_ DOWN 
O75592 CLCN1 Post transcriptional regulation 
P62987 UBA52 Post transcriptional regulation 
Q7Z6Z7 HUWE1 Post transcriptional regulation 
CARD9 Q9H257 GAIN_ DOWN P31946 PRDX2 Post transcriptional regulation 
GNA12 Q03113 LOSS_UP Q12802 AKAP13 Post transcriptional regulation 
CRTC3 Q6UUV7 GAIN_UP 
Q13153 Pak1 Autophagy protein 
P20749 BCL3 Transcriptional regulation of post transcriptional regulator 
   P20749 BCL3 Transcriptional regulation of post transcriptional regulator 
NFKB1 P19838 GAIN_ DOWN 
P17676 CEBPB Transcriptional regulation of post transcriptional regulator 
P05412 Jun Autophagy protein 




Figure 2-10 Betweenness centrality of the major autophagy UC cluster in a directed network. UC 
nodes are yellow. The larger the circle, the higher the between-ness centrality, therefore the more 







Figure 2-11  UC-interactome-apoptosis undirected network. The nodes are from the UC interactome 
overlapping with apoptosis network. The UC nodes with their miRNA or transcription factor which has a 
binding site altered by a SNP, and the first neighbours from Omnipath which are also apoptosis proteins.  
 
 
Figure 2-12 Venn diagram identifying the overlap of UC proteins with first neighbours in both autophagy and 





ELM affected protein 












Integrin receptor based adhesion and adhesion to the cell matrix have been identified 
consistently within the UC SNP gene ontology analysis.  The focal adhesion complex (FAC) 
is a potential signalling and scaffolding link between tight junctions, apoptosis and 
autophagy. Unlike all the other networks, which had isolated nodes, or multiple separate 
smaller networks, the FAC_UC network (Figure 2-13) is a small but cohesive network. Four 
nodes are both UC and FAC nodes: LPXN, Stat3, NFKB1 and PTPN2. Like the other 
networks, signalling regulation forms the backbone of the network as seen with the kinase 
and phosphatase nodes been predominant within the network. We can see a direct 
impact on protein-protein interaction with integrins and important cytoskeletal proteins 
via PTPN2 which phosphorylates integrin alpha 5, and caveolin1. Caveolin 1 is major 
protein component of caveolae, which are small invaginations in cell plasma membranes 
which are a type of lipid raft. Caveolae undertake clathrin independent-raft dependant 
endocytosis which is exploited by Echovirus, Coronovirus, Rotavirus and by some strains 
of E.coli. Another structural protein affected by protein-protein interactions with UC risk 
protein is vinculin. LPXN binds vinculin, an integral cystoskeletal protein of the focal 
adhesion, via it’s LIM domain. Vinculin links the talin-integrin complex with F-actin 
thereby controlling the transmission of extracellular mechanical cues to the actin 
cytoskeleton, which includes cues to polarise and response to mechanical shear force 





Figure 2-13 UC-interactome-focal adhesion complex undirected network. The nodes are from the UC 
interactome overlapping with the adhesome network.  The UC nodes with their miRNA or transcription factor 
which has a binding site altered by a SNP, and the first neighbours from Omnipath which appear in the 



















UC is a heterogenous disease in terms of clinical phenotype, response to medication and 
outcome as described in Chapter 1. Despite the heterogeneity, there are a handful of SNPs 
that re-occur across multiple networks, have more than two predicted modalities for their 
SNP effect and have a high minor allele frequency. This is almost counter-intuitive, as 
genetic selection would suggest that a SNP that has a strong phenotype would be selected 
against and therefore within the population would have a lower minor allele frequency.  I 
would argue that the modalities we have identified produce weaker phenotypes via 
transcriptional, post transcriptional and translational regulation and that the cumulative 
effect is key, not the individual SNP affect.  A case in point are the rare variants in CARD9, 
and IL23R. Using different techniques, we confirmed the splice site alteration in CARD9 
which has been shown to produce a truncated protein, however it is in a very small 
number of UC patients. Accepting the significant bias of the hypothesis driven networks, 
neither CARD9 nor IL23R were the most key components of any of the networks we 
analysed. Taken out of context the SNP in PTPN2 would be an antithesis to this argument, 
it is a relatively rare variant, has a low modality yet it is a component of each of the 
subnetworks we have analysed. It also has roles in haematopoiesis, T cell receptor 
signalling, cytokine mediated signalling among multiple other signalling cascades.  As such 
there is redundancy as other phosphatases can ‘cross cover’ PTPN2. Unfortunately, like 
STAT3, it would appear to be so ubiquitous it would feature in the networks regardless of 
the hypothesis. Interestingly PTPN2 knock out mice display severe impairment of T cell 
development and exhibit severe inflammation and survive only 5-6 weeks after birth 
associated with a loss of the epithelial barrier. Our results indicated that the UC associated 
SNP leads to the loss of an exonic splice enhancer (consequence could be a retained intron 
at worst) which is difficult to equate with a loss of PTPN2 function.  
The results from the network analysis confirm in broad strokes what has been postulated 
previously in terms of the host-microbe interactions, interestingly highlighting viral-host 
interactions as a potential avenue of exploration, and the role of immune regulation in 
UC. It has also suggested further evidence for the role of the UC associated SNPs in the 3 
components of the maintenance of the epithelial barrier; tight junctions, autophagy, and 
potentially joining it all together, the focal adhesion complex.  
In terms of stratification for experimental validation, we need to apply three key concepts:  
1. They have to be a significant component of the network  
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2. The hypothesis has to be clear and therefore they have to produce a clear downstream 
validateable phenotype  
3. The modality has to be experimentally testable.  
There were 4 SNP affected proteins which were in all the subnetworks; NFKB1, STAT3, 
PTPN2 and LPXN. NFBK1, STAT3 and PTPN2 are all regulatory with multiple complicated 
downstream signalling effects as well as being difficult to test modalities (splicing 
enhancement). LPXN, although an IBD node, had both a putative splicing enhancement as 
well as strong evidence for transcription factor binding sites for IRF1, STAT1 and STAT2 
and there are clear documented roles of LPXN within the focal adhesion complex.  
There are limitations of this workflow. The workflow is dependent on high quality GWAS, 
finemap or deep sequenced SNPs. The workflow itself is not biased and cannot 
differentiate between poorly associated and causal SNPs, therefore care must be taken 
as to the data input into the workflow. Consideration was applied to this when separating 
the data from the parent cohort and the extended parent cohort, however given the 
broad overview of the interactome utilising the IBD SNPs as well as the UC associated 
SNPs not just localised to the colonic mucosa gave more cohesion to the networks.  
For each modality, we used more than one in silico technique to functionally annotate the 
SNPs. Each technique has its own stringency and statistical validation and where possible 
we used a maximal concordance rule e.g. the two techniques had to agree and if more 
than two techniques were used, then the majority result went forward. Where there was 
not a comparable technique available, then the stringency of the network was based upon 
the fallibility of one technique e.g. the splicing silencing motifs. This can lead to a high 
false positive hit rate. Within each of the techniques, where available we used the most 
stringent settings, so it is possible that novel, weaker binding sites for miRNA and 
transcription factors have been missed, but the pay-off was lower false positive rates. 
Each technique has its own limitation for example ELM did not identify a specific ligand 
binding site change in GPR65, despite Polyphen identifying thr139met as possibly 
damaging, but the transmembrane domain was impacted. Emtage et al (337)have shown 
that standard computational docking tools for ligands in GPCRs are limited as ligand 
binding pockets are dynamic and using a pressurisation modelling method they identified 
that minor changes in amino acid side chain orientations can open a fissure between 
transmembrane helices, which can then accommodate ligands.  
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The mature mirNA seed sites were a significant limitation as multiple mature miRNA 
sequences were identified but could not be used as we were unable to confirm that the 
full stem-loop sequence was present, or that the mature miRNA was at a documented 
locus for that miRNA, therefore given the significant number of targets each miRNA has, 
these were removed from network analysis. This produces a potential gap within the 
network, as we’ve already seen that regulation is a key component of the UC interactome 
function.  
We were also unable to incorporate lncRNAs within the network due to the lack of 
experimentally validated datasets or accessible sequence databases which would allow 
us to identify impact of SNPs on the lncRNA sequence.  
There is clearly a bias to the subnetwork analysis, we were using a network to create 
hypotheses within the broad hypothesis that UC associated SNPs have an impact on the 
intestinal epithelial barrier. This bias was necessary to create focus for the research, as 
the interactome is broad enough to create multiple avenues of research.  
Peters (54) et al 2017 created an integrative approach for constructing a predictive 
network model of IBD. They utilised a paediatric cohort of CD patients (n=322), as well as 
an TNF refractory CD cohort (n=118), and an advanced IBD population (n=134), and 
utilising transcriptomics and probabilistic causal gene networks (Bayesian networks) to 
identify co-expression networks and enriched risk genes within those networks. They then 
utilised those networks to stratify a key driver genes list to validate in macrophages, as a 
hypothesis driven approach. Our approach globally takes a similar route of hypothesis 
free network creation, then hypothesis driving to stratify a list of genes to validate, 
however we differ significantly in our methodology. We utilised a hypothesis free 
approach to create the UC interactome, integrating proteomic data post functional 
annotation of SNPs as opposed to transcriptomic data with gene enrichment. Unlike 
Peters et al, who looked specifically at macrophage specific signatures in a specific subset 
of CD patients with severe disease, we looked for enrichments and pathways involved in 
maintenance of the colonic mucosa across the whole UC disease severity spectrum. 
Utilising transcriptomics from colonic mucosa from quiescent UC patients and integrating 
it with the UC interactome would provide a significant wealth of data and although for 
further stratification and hypothesis driving from the UC interactome and will be done in 




UC appears to be a disease predominantly of regulation, and such may be difficult to 
identify phenotypic effects of the SNPs. By utilising a network medicine technique, we 
have added further evidence to the current literature on SNP effects and created a tool 
by which pathological hypotheses can be obtained and stratification of SNPs to 
experimentally validate can be undertaken. Further work to tease apart the SNP effects 






Overarching aim:  
To experimentally validate a stratified SNP identified as relevant 




Leupaxin (LPXN) SNP rs10896794 was identified as a candidate for evaluation from the 
bioinformatics workflow described in chapter 2, where the hypothesis was that SNPs had 
an impact on the intestinal epithelial barrier function. To validate the LPXN SNP as playing 
a role in the pathogenesis of UC and thereby show that the global UC-ome technique 
produced relevant results we had to evaluate whether LPXN has a role in epithelial cell 
function. The commonest techniques to do this in isolation are utilising intestinal 
epithelial cell models such as Caco2, HT29 and T84. Immortalised cell lines have been used 
to characterise animal models of colitis such as using DSS on caco2 cells (338)Specific cells 
such as dendritic cells and cell lines such as THP1 have been used to investigate 
pathogenesis pathways of colitis such as enteric cell education of dendritic cells (339) and 
identifying how carrageenan works on THP1 cells to cause the phenotype seen in 
carrageenan induced colitis mouse models(340).  
The hypothesis is that the LPXN SNP affects LPXN expression. Techniques to assess the 
impact of changes in gene expression include strategies such as siRNA knock downs vs 
transient ectopic overexpression plasmids or using Clustered Regularly Interspaced Short 
Palindromic Repeats (CRISPR) technology to create over expression and knock out (as 
opposed to knock down) cell lines. The more complex strategy utilises CRISPR to create 
‘SNP’ cell lines that contain the risk allele of interest.  
CRISPR and CRISPR associated nucleases (Cas) in bacteria provide adaptive immunity 
against viruses and plasmids with their RNAs are used to guide the Cas cleavage of foreign 
nucleic acids (ref). The Cas nuclease Cas 9 (originally found in Streptococcus pyogenes) can 
cleave a strand of double stranded target when directed by single guide RNAs that consists 
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of the CRISPR RNA and a transactivating RNA (Figure 3-1). The double stranded DNA 
breaks can be repaired by cellular repair machinery either by non-homologous end joining 
(NHEJ) or homology directed repair(HDR), which depends on the presence of a repair 
template. NHEJ requires less energy expenditure (taking less than 30 mins as opposed to 
approximately 7 hours like HDR), and can introduce unpredictable insertions or deletions 
creating knock out cell lines. HDR uses a template with desired changes to make 
mutations, such as changing alleles to SNP risk alleles in the genomic loci. HDR occurs less 
frequently than NHEJ as it occurs only in S and G2 phases, but can be encouraged by the 
use of exogenous HDR promoters such as brefeldin (341). To encourage HDR further 
CRISPR Cas9 nickases can be used with sense specific sgRNAs to cause single DNA strand 
nicks in opposing DNA strands thereby “dropping out” a segment of DNA which have to 





Figure 3-1 The CRISPR-Cas9 system with non-homologous end joining. Adapted from addgene.org this diagram 
shows how the basic CRISPR Cas-9 gene editing system works using a fully active Cas9 to cause double stranded 












































































































































































































































































































































































































































































































The CRISPR system has been further engineered for activation of endogenous gene 
expression. It has been engineered in two ways, firstly, the Cas9 nuclease has been 
deactivated(dCas9), and is fused to a transcription activation domain (VP64). Using 
sgRNAs to direct the dCas9-VP64 complex to a -200bp region from the transcriptional start 
site of the desired gene to upregulate gene expression. Secondly, the sgRNA hairpin has 
had an aptamer added to it which binds MS2 bacteriophage coat proteins. On the 
‘activation plasmid’ is a MS2-P65-HSF1 fusion protein. P65 and HSF1 bound to the sgRNA 
via the MS2 protein enhance recruitment of transcription factors, thereby causing further 
gene activation. 
  
Figure 3-2 Diagram of the CRISPR-Cas9 activation mechanism, whereby a transactivation domain is fused to a 
deactivated (dead) Cas9. The guide RNA directs the Cas9 to 200bp upstream from the transcriptional start site 
of the gene of interest. The guide RNA has been altered to contain an aptamer that binds to MS2 proteins. On 
the commercial plasmid is a MS2-p65-HSF fusion protein which forms a large transcription factor complex and 
when the MS2 binds to the aptamer on the guide RNA, the enhanced recruitment of transcription factors leads 
to increased transcription of the gene of interest. (Image adapted from Kaczmarczyk et al PLos ONE 2016).  
 
3.1.2 Ex	vivo	techniques	
SNP analyses have been undertaken extensively in peripheral blood cells taken from both 
healthy human subject and those with diseases of interest. In CD, genotyped peripheral 
blood mononuclear cells have been studied for the role of a non-coding SNP within 
FOXOP3 in T cells(343), but analysis of SNP effect on intestinal mucosa remains 
challenging. For analysis the effect of SNPs on the function of the colonic mucosa, it 
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requires more than the analysis of intestinal epithelial cells as these cells work in concert 
with goblet cells, immune cells and the extracellular matrix as well as the milieu of 
cytokines and chemokines produced in response to microbial stress.  In vitro organ culture 
utilises colonic biopsies from human patients as a model of the functioning human 
mucosa which can be kept alive for up to 8 hours. This provides a snapshot of the function 
of the intestinal epithelial cells and any immune cells present in the mucosa at the time 
of biopsy. Cytokine analysis of the mucosal biopsy has been shown to be a useful tool for 
identifying pathogenic responses when analysing lamina propria lymphocyte cytokine 
responses in IBD (344), polarised organ culture of mucosal biopsies has been used to 
create a secretory cytokine readout for treatment efficacy analysis(345). We plan to use 
polarised in vitro organ culture to characterise the role of the UC associated LPXN risk 
allele on cytokine production.  
3.1.3 The	role	of	LPXN	within	the	cell	
LPXN is a 43kDa phosphotyrosine protein member of the focal adhesion complex 
functioning as an adapter molecule. It has multiple different roles depending on the cell 
type it is expressed in. In T cells it binds to PYK2 (a focal adhesion kinase) which modulates 
integrin dependent adhesion in response to integrin engagement, T cell receptor 
engagement or chemokine stimulation (346).In B cells LPXN inhibits B cell receptor 
signalling and IL2 secretion (334).  In osteoblasts LPXN is a critical component of the 
podosomal signalling complex by binding to Pyk2 and pp125FAK and protein tyrosine 
phosphorylation-PEST (PTP-PEST)(347, 348). Overexpression of LPXN in prostate cancer 
cells resulted in an increased associated with Pyk2 with increased cellular migration(347). 
In macrophages Pyk2 has roles in migration, F-actin localisation an Rho and PI-3 kinase 
activation in response to integrin mediated cell adhesion (349) TNF-alpha stimulated 
phosphorylation of LPXN leads to the production of cytoplasmic projections at the leading 
edge of the cell (350). LPXN has also been shown to modulate migration of cancer cells by 
phosphorylation of actin associated proteins, including caldesmon (333). In prostate cells, 
LPXN has also been shown to be a transcriptional regulator of the androgen receptor 
(351). 
LPXN is expressed in multiple cell types and in multiple cancer cell lines, including 
colorectal cancer cell lines. siRNA knock down of LPXN in MDA-MB-231 cell lines inhibited 
adhesion to both collagen I and fibronectin, but only inhibited spreading of cells on 
collagen I not fibronectin (332) However, in other cell lines LPXN expression reduced 
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spreading of NIH3T3 on fibronectin and in K562 cells LPXN supressed a5b1 mediated cell 
adhesion to fibronectin (352). 
LPXN is known to share structural characteristics with paxillin, including LIM domains, and 
functional modules including leucine and aspartate (LD) motifs and like paxillin is known 
to localise to focal adhesions upon cell adhesion to fibronectin. The molecular motifs that 
LPXN and paxillin have in common form functional modules which bind to Pyk2, FAK, SRC, 
LYN, and PTP-PEST; all of which have roles in integrin signalling. Integrin engagement with 
its receptor triggers tyrosine phosphorylation of paxillin which generates SH2-binding 
sites for other SH2 domain containing focal adhesion proteins and Rac1 signalling, 
potentiating the integrin signal mediated by mitogen-activated protein kinases (MAPKs). 
LPXN lacks the homologous tyrosine residues that are phosphorylated in paxillin and its 
expression reduces tyrosine phosphorylation of paxillin thereby supressing the integrin 
signalling. Specifically LPXN has been shown to suppress integrin a5b1 function including 
cell adhesion to fibronectin and cell spreading (352).  
3.1.4 The	focal	adhesion	complex	and	the	NLRP3	inflammasome	
Although there is a paucity of information regarding LPXN function in multiple cells types, 
the role of the focal adhesion complex (FAC) that LPXN functions within is better 
understood. FACs are large dynamic protein assemblies and scaffolds that mechanically 
link and transduce signals from the extracellular matrix to the internal cell via receptor 
modules. The complex participants are most easily characterised by their function; 
structural proteins such as paxillin, talin, actinin, vinculin, or dynamic signalling protein 
including protein kinases such as PYK2, phosphatases, small guanosine triphosphatases 
(GTPases) as regulatory molecules, or adapter molecules that mediate core protein-
protein interactions.  
Within intestinal epithelial cells (IECs), the FAC anchors the intestinal epithelial cell via 
integrins to extracellular matrix ligands(154). Integrins are heterodimers containing an 
alpha and a beta subunits. A wide variety of integrins are expressed on epithelia including 
a such as a1b1, a2b1, a3b1 and a6b4 which are collagen/laminin receptors. Fibronectin 
receptors on epithelia include a5b1, a8b1 and aV containing integrins (353). Signalling 
through the integrins in response to mechanical signals such sheer forces or compression 
allows for transduction of the signal to the actin cytoskeleton (354). This has direct 
implications on wound healing, as well as the invasive and metastatic nature of cancer 
cells, in which this function is best described. FACs have also been implicated in the 
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activation of the NLRP3 inflammasome (355). The inflammasome is another multiprotein 
complex composed of pattern recognition receptors (PRRs) including NOD-like receptors 
and RIG receptors, with the adaptor proteins, apoptosis-associated speck-like protein 
containing CARD (ASC) and pro-caspase-1. To form an inflammasome, ASC oligomerises, 
recruits and activates caspase 1. Caspase 1 cleaves pro-IL-1b, and pro-IL-18 to 
proinflammatory cytokines IL-1b and IL-18. The NLRP3 inflammasome contains the NLRP3 
protein which is held in an inactive state by a heart shock protein (HSP90) and a ubiquitin 
ligase (SGT1). NLRP3 is activated by microbe associated molecular patterns(MAMPs), 
microbial toxins and damage-associated molecular patterns (DAMPs). On activation 
NLRP3 binds to and activates ASC. Both FAK and Pyk2 regulate this inflammasome 
activation; Pyk2 activates ASC directly by phosphorylation and in clinical trials a dual 
inhibitor of Pyk2/FAK significantly reduced monosodium urate-mediated peritonitis, a 
disease model used to study NLRP3 activation (355, 356).  
Integrin-mediated signalling via b1 subunits activates the NLRP3 inflammasome in 
intestinal epithelial cells, with production of IL-18 (355) and in macrophages via  integrin 
heterodimer (fibronectin receptor) a5b1 (357) with IL-1b secretion, and caspase 1 
activation. In UC there is evidence for both protection (in an oxazolone-induced colitis 
model) (358) and involvement in chronic UC (in peripheral blood mononuclear cells) (359). 
There is evidence that adaptor members of the FAC, such as integrin-linked kinase(ILK), 
when mutated in mice, or knocked down in cell lines then there is a reduction in 
chemokine production, specifically MCP-1 and that ILK mutant mice are protected from 
DSS colitis (360). 
In summary; LPXN abrogates integrin signalling in prostate cancer cells, BCR signalling in 
B cells and modulates migration in macrophages and cancer cells. There is no data on the 
normal role of LPXN in IECs, therefore it is difficult to predict the effect any changes in 





The bioinformatics workflow in Chapter 1 indicates that cells containing UC susceptibility 
SNP rs10896794 have increased transcriptional regulation from IRF1/STAT1:STAT2 
binding. As these transcription factors are predominantly activators we hypothesise that 
LPXN will be over expressed in cells containing this SNP.  
Given the hypothesis that a significant part of the UC pathogenesis is disruption of the 
intestinal epithelial barrier, we hypothesise that IECs containing the SNP rs10896794 will 
have suppressed integrin-mediated functions of adhesion and spreading, thereby 
impaired epithelial wound healing, and decreased NLRP3 activation in response to 
MAMPS. In colonic mucosa, it is difficult to hypothesise the role of SNP rs10896794 given 
the multiple different cell types present, however if integrin signalling is supressed we 
hypothesise that the NLRP3 inflammasome will be affected with a reduction in IL-1B and 
IL-18 production in response to MAMPS.  
 
3.3 Aims	and	Objectives	
To identify the phenotypic effect of LPXN overexpression in epithelial cell lines and the 
LPXN SNP within colonic biopsies.  
The objectives are: 
1. To create an LPXN overexpressing epithelial cell line using immortalised cell lines 
HT29, Caco2 or T84 if possible, or other epithelial cells lines such as Hela if 
unsuccessful in IECs; 
2. To assess the response to inflammatory stimuli in LPXN overexpressing cell lines 
on a) wound healing and b) cytokine production; 
3. To investigate the effect of LPXN risk allele rs10896794 homozygosity in 









The investigating genetics of UC (iGUC) study obtained ethical approval from both the 
University of East Anglia Faculty of Medicine and Health Sciences Ethics Committee and 
Human Tissue act subcommittee (ref 20152016-39HT) and the Norfolk and Norwich 
University Hospital Research and Development Committee (ref 02-01-16) 
Patients with known UC undergoing colonoscopy for surveillance or disease assessment 
and those undergoing colonoscopy for polyp surveillance were identified from the 
colonoscopy lists by a member of the medical team. On the day of the procedure the 
patients were fully briefed and asked for written informed consent via the Norwich 





Complete cell media for HT29 and Hela cells was Dulbeccos Modified Eagle’s Media- 
DMEM (Lonza BE12-604F) 500ml, Foetal Bovine Serum, FBS (LabTech FCS-SA) 50ml and 
L-glutamine (Lonza BE17-161E) 5ml.  
HT29 (ATCC HTB38) and Hela (ATCC CCL2) adherent cell lines were maintained in either 
T25 or T75 flasks and passaged following trypsinisation and incubating at 370C for 5-10 
minutes until the cells are rounded, detached single cells. Complete media was then 
added at the required volume for seeding or for cell counting (10mls total for T25, 30mls 
total for T75). If directly seeding to T25 or T75 then a 1:10 passage rate was used. Cell 
media was changed every 3-4 days. HT29 were used from passage 10- 25. Hela were used 
from passage 7-20. Cells are counted using a haemocytometer and standard protocols. 
Hela (ATCC CCL2) adherent cell lines were a gift from Dr I Hautefort, Carding Laboratory, 
Institute of Food Research.  
3.5.2 Cell	transfection	toxicity	assessments	
3.5.2.1 Plasmid	and	transfection	reagent	toxicity	
The cells were grown to 60% confluency in a 24 well plate. 50ul Jet Prime buffer (Polyplus 
#114-01) was mixed with the required amount of trial plasmid DNA by vortexing. The 
required amount of jet prime (see figure 3.1) was added to appropriate DNA/buffer mix 
on a 1:2w/v basis or just buffer and incubated at room temperature for 10 mins. 50ul of 
transfection mix was added per well and the plate was rocked from side to side gently to 
get maximal coverage then incubated at 370C for 24 hours. It was trypsinised, and trypan 
blue stained for alive/dead counts at 24 hours. The toxicity assay extended from 0.25ug 










Table 3-1 identifies the plasmids assessed during the process of optimisation, their source 
and the amount of DNA required for transfection based on the toxicity assays in each cell 
type for each plasmid.  
DNA Source DNA for 
transfection in 
6 wells (Hela) 
DNA for 
transfection  
in 6 wells (HT29)  
LPXN Double Nickase 
Plasmid and Control 
Santa Cruz sc-405101-
NIC  




Plasmid and Control 
Santa Cruz – Sc 
405101-ACT 











Addgene: Gift from the 
Zhang Lab 
3ug 1.5ug 





Table 3-1 Plasmids used to modify the expression of LPXN in Hela and HT29 cells.  The source of the plasmid 
and amount of DNA required for the transfection reaction for HT29 and Hela cells is given. 
3.5.1.1 Antibiotic	Toxicity	
Puromycin was used for positive selection of plasmid transfected cells. This causes 
premature chain termination during translation at the ribosome and was toxic to 
eukaryotic cells. Geneticin (G148) toxicity was also assessed as it was used to selected for 
cells which incorporated a floxed Neo Resistence gene by homologous recombination. 
Hela and HT29 cells were plated onto 24 well plates and grown to 80 % confluence. 
Duplicate wells were then subjected to puromycin from 0.25ug/ml to 10ug/ml. Unlike 
normal kill curves where the optimal concentration was reached at which all cells are dead 
at 7 days, because the transfection protocol required selection pressure for 3 days 
maximum the concentration of puromycin used was that that caused total cell death at 3 





Cells are seeded at a density of 2 x 105 per 2ml into 6 well plates and grown to 60% 
confluency.  200ul of JetPrime (Polyplus, Cat no 114-15) buffer was mixed by vortexing 
with the optimised amount of plasmid DNA determined by plasmid toxicity assay. 
JetPrime transfection reagent was added to the appropriate DNA/buffer mix on a 1:2w/v 
basis and incubated for 10 minutes. 200ul was removed from the 6 well media and 
replaced by 200ul of JetPrime/DNA mix. The 6 well plates were rocked gently from side 
to side to ensure good coverage and incubated at 37°C, 5% CO2.   
For single cell colonies: 
After 48 -72 hours (48 for Hela, 72 for HT29) the cells were trypsinised using 500ul of 
trypsin and incubated at 37°C for 10 minutes. The trypsin was deactivated by the addition 
of complete media.  The detached cells were processed through a limiting dilution in a 96 
well plate using 50% fresh culture medium and 50% conditioned cell media from a T25 
pre-confluent respective cell line with puromycin (2ug/ml for HT29, 3ug/ml for Hela).  The 
96 well plate was incubated at 37°C, 5% CO2. After three days, the media was changed to 
a 1:1 conditioned cell media/fresh media mix. This was changed every three days. During 
the second week, once the surviving cells form colonies covering >50% of the 96 well base, 
they were trypsinised and passaged into a 24 well, then 6 well, then T25 flask. The whole 
passaging process took 6-8 weeks. Once the cells are in a T25 they no longer need 
conditioned cell media, so fresh complete media was used instead.  
A divergence from protocol was required for CRISPR activation plasmids, as these required 
a continuous selection pressure, puromycin 2 or 3ug/ml was added to all media used 
depending on the cell type.  
For mixed colonies:After 48 -72 hours (48 for Hela, 72 for HT29) the cells were trypsinised 
as above using 500ul of trypsin and incubated at 37°C for 10 minutes. The trypsin was 
deactivated by the addition of complete media.  The detached cells were seeded in a 1:2 
dilution to 24 well plates with puromycin/conditioned/fresh media. After three days the 
media was changed to conditioned/fresh media. After two weeks, conditioned media did 
not need to be added. 
3.5.3 Immunocytochemistry		
The cells were seeded at a density of 5 x 104 into single wells of an IBIDI u-slide 12 well 
chamber with a removable gasket (Thistle Scientific IB-81201). Once confluent (usually 
within 36 hours depending on phenotype), 250ul apical media was removed and flash 
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frozen for cytokine analysis. The cells were gently washed in 200ul sterile 1 x Dulbecco’s 
phosphate buffer solution (DPBS)(Sigma D837)  three times and fixed in 4% 
paraformaldehyde (PFA)(made in house) for 15 minutes.  The PFA was removed and 
discarded and the cells washed in 200ul DPBS three times. The DPBS wash was discarded 
and 200ul permeabilisation buffer (0.5% Triton x-100 in DPBS) applied for 15 minutes.  The 
permeabilisation buffer was then discarded and the cells washed in 200ul DPBS three 
times, before blocking buffer was applied for 1 hour (0.2% Triton X-100, 3% Bovine Serum 
Albumin in DPBS). This was then discarded. The cells were incubated with primary 
antibodies or isotype at the optimised concentration (1:100) in blocking buffer at  37°C 
for an hour. The antibodies used were a mouse anti-LPXN monoclonal antibody (Sigma 
SAB4200301) with mouse IgG1 isotype control (BD Biosciences BUV661) or a mouse anti-
LPXN F12 (IgG3 K) (Santa Cruz)sc-376903 with mouse IgG3 K isotype control (Crown 
Bio#C0009). After an hour, the solution was discarded and the cells washed gently in 200ul 
DBPS three times.  The cells were incubated with optimised secondary antibody (1:1000) 
goat anti mouse IgG Texas Red (Abcam ab6787) in blocking buffer at 37°C for thirty 
minutes.  The gasket was then removed and the slides washed in DPBS baths three times. 
Vectashield Hardset AntifadeMounting Medium with DAPI (Vector Laboratories, Cat No: 
H-1500) was then applied with the. The slides were cured 15 mins in the dark, then placed 
at 4°C. 
3.5.4 	Fibronectin	coating	of	glass	slides	
12 well IBIDI glass slides with a growth surface area of 0.56cm2 per well were coated with 
5mg/cm2 human fibronectin (Merck Millipore FC010-100mg) as per manufacturers 
instructions and stored at 4°C until used (life span 1 month).  
3.5.5 Wound	Healing	Assay	
Cells were seeded into either a fibronectin coated 12 well glass slide (F+) or non fibronectin 
coated 12 well glass slide (F-) grown to confluency. Once confluent the cells were 
scratched in a diagonal using a 20ul pipette tip. Half of the slides (F+, F-) were exposed for 
24 hours or 12 hours to a bacterial ligand cocktail of 1ug/ml Lipopolysaccharide from E.coli 
(Sigma L2880), Muramyl dipeptide (Bachem G-1060.0005) , and  Micrococcus lutues  
Peptidoglycan (Sigma 53243). After the allotted time period the slides were fixed in 4% 
PFA and stained as per the immunocytochemistry protocol. The samples were imaged on 
a Zeiss Imager M2 microscope. Wound distance at 5 points along the wound using 10x 
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magnification and phase contrast was determined and then calculated using imageJ (Fiji) 
using the closest distance edge to edge averaged across the 5 points.  
3.5.6 Immunoblotting		
3.5.6.1 Whole	cell	lysate	
Cell culture bottles were placed on ice and the cells washed with ice-cold sterile PBS. 400ul 
Ice-cold NP-40 lysis buffer (Thermofisher FNN0021), 2ul PMSF (Sigma PMSF-RO) and 
protease/phosphatase inhibitor cocktail 4ul (Sigma 11836170001 ROCHE) was added to 
the cells and incubated on ice for 5 minutes before being scraped into a cooled 
microcentrifuge tube. The mixture was then sonicated for 3 x 30 seconds in ice cold water 
and centrifugation at 10,000 RCF for 10 mins at 4°C. The supernatant was carefully 
removed and the pellet discarded. The supernatant was either kept on ice if it was going 
to be used immediately or flash frozen in liquid nitrogen and stored at -80°C.  
3.5.6.2 Biopsy	protein	lysate	
Biopsies were thawed on ice in screwtop eppendorfs to which 122ul CelLytic MT (Sigma, 
C3228) and 3ul protease inhibitor cocktail (Sigma P2714-1BTL) were added with 5 acid 
washed glass beads (3mm diameter). Samples were bead beaten on MP FastPrep at 4m/s 
for 30 seconds, before centrifugation at 10,000RCF at 4°C for 2 mins. The lysate was 
transferred to 1.5ml pre-cooled eppendorfs for centrifugation at 10,000 rom for 10 mins 
at 4°C. The supernatant was carefully removed and stored at -80°C The pellet was 
discarded.  
3.5.6.3 Protein	quantification	
Protein content from whole cell or biopsy lysate were quantified using a Pierce 660nm 
Colorimetric Assay, with fresh BSA as a reference, following the manufacturers protocol. 
In short, a standard curve of BSA was created by serial dilution, in lysis buffer. The test 
samples were assayed neat, and at 1:2 and 1:10 dilutions. All samples were run in 
duplicate adding 1ul sample to 15ul of Pierce Assay Reagent in flat bottomed 96 well plate 
for 5 mins before being read on a spectrophotometer (Bioscreen C plate reader) at 
660nm. The result was averaged across the duplicate samples. In the event of significant 
discrepancy between duplicates, the samples were vortexed and re-analysed. The protein 
content was quantified against the standard curve.  
3.5.7 Western	Blotting	
Samples normalised to protein content in 13ul volume were mixed with 5ul 4X NuPage 
buffer and 2ul 10X NuPage Reducing Agent in Eppendorf tubes and heated to 70°C for 10 
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mins.  20ul reduced sample was added to NuPage Novex Bis-Tris gels 4-12% 1.0mm 12 
well gels with 5ul Page Rule Prestained Protein Ladder (Fermentas) also run on the gel for 
size determination. Gels were run in NuPage mini tank in NuPage MOPS SDS Running 
Buffer at 200V for 50 minutes. 
Blotting pads were soaked in transfer buffer (NuPage Transfer Buffer plus 10% methanol) 
and PVDF membrane was soaked in 10ml methanol. The precast electrophoresed gels 
were levered open using a gel knife and the wells and foot were removed. Soaked blotting 
paper was placed on the gel and air bubbles removed. The gel was turned over and pre-
soaked PVDF membrane was placed on top of the gel then blotting paper on top of the 
PVDF. The blotting paper/PVDF/Gel sandwich was placed in the transfer block (PVDF side 
uppermost) and clamped shut. This was then soaked in transfer buffer and 
electrophoresed for 1 hour at 30V. The PVDF membrane was washed in NATT buffer 
(0.24% Tris Base, 0.8% NaCl, 0.05% Tween20 in 1000ml MilliQ), then blocked in 5% BSA 
for 1 hour (shaking). The PVDF membrane was incubated with the primary antibody 
mouse anti-LPXN F12 (IgG3 K) (Santa Cruz sc-376903) 1:200 in antibody solution (1% BSA 
in NATT buffer), and anti-mouse GAPD loading control primary antibody for 16 hours at 
4°C.  The membrane was then washed extensively (in NATT buffer) then probed with 
donkey anti mouse HRP conjugate 1:5000 dilution for 30 mins at 37°C. The PVDF 
membrane was then washed copiously again before incubation with 1:1 dilution of 
enhancer and buffer PicoRabbit IgG detection Kit (Supersignal West) for 5 mins.  After this 
the PVDF was imaged using a Protein Imagine machine (Protein Simple).  
3.5.7.1 Creation	of	the	LPXN	sgRNA	plasmids		
CHOPCHOP(https://chopchop.rc.fas.harvard.edu/), an online single guide RNA(sgRNAs) 
design tool, was used to design and assess the LPXN sgRNAs using FASTA sequences 
corresponding to the rsID from dbSNP (http://www.ncbi.nlm.nih.gov/SNP/).  
The potential sgRNAs were analysed and stratified depending on their proximity to the 
SNP site, their predicted off target effects and primer off target binding.  
The two target sequences were based on their proximity to the SNP, efficiency, and 
minimising off target effects which was essential for the insertion of the homologous 
recombination template. The two sgRNA sequences were (forward) 
gatgttgcaatttaaatagttgg and (reverse) tggtcctgaacttagacccgataga. The underlined 
sequences did not form part of the sgRNA insert as these are the protospacer adjacent 
motifs (PAMs).    
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Each target sequence with complimentary reverse strand was designed with BbSl1 
complimentary overhangs and manufactured by IDT. The DNA oligos were duplexed in 
DNAse free water with 50nM NaCl, by heating to 95°C for five minutes in a thermocycler, 
then allowing to cool on the benchtop. Duplexes were confirmed by agarose gel 
electrophoresis. The duplex was ligated into the Cas9 plasmid backbone pX334-U6-DR-
BB-DR-Cbh-NLS-hSpCas9n(D10a)-NLS-H1-shottracr-PGK-puro following the protocol in 
the New England Biolab Quick Ligation Kit (Cat M2200S). The ligated plasmid was 
transduced into One ShotTM Top10 Chemically competent E.coli (Thermofisher  C404010) 
using a heatshock protocol and plated onto 100ug/ml ampicillin-LB plates and grown 
overnight at 37°C.  Colonies were picked and underwent colony PCR using the sgRNA oligo 
(forward) as an internal primer and a Cas9 (rev) primer as the plasmid primer. The colonies 
were also grown in a 1ml deep well block containing terrific broth/phosphate buffer/LB 
/Ampicillin mix. Cultures grown from corresponding positive colony PCRs had the plasmid 
extracted using Qiagen Mini-Prep Kit as per the manufacturer’s instructions and 
sequenced by Eurofins using the Mix2Seq kit.  Once positive identification of the sgRNA 
sequence in the correct orientation in the plasmid by sequencing had been confirmed in 
SnapGene, the culture was grown for 12 hours in 100ml LB media supplemented with 
ampicillin. The plasmid was extracted as per the manufacturers protocol with QiaPrep 
Spin Mini Prep Kit (Qiagen 27104) The extracted plasmid was then analysed using 
NanoDrop to ascertain the quality and quantity of the DNA.  
3.5.8 DNA	extraction		
DNA was extracted from cell cultures and colonic biopsies using a Sigma GenElute Mini 
Prep Kit (G1N10) according to manufacturer’s instructions. In short, cells in culture were 
trypsinised, resuspended, RNase treated and incubated with proteinase K before the lysis 
solution was added. The samples were then vortexed and heated to 70 °C for 10 minutes. 
The DNA was extracted from the lysate via ethanol extraction and the use of spin columns. 
The extracted DNA was washed and eluted into 200ul of Tris-EDTA. The DNA quantity was 
confirmed using NanoDrop. DNA samples were stored at -20°C. The protocol for DNA 
extraction from colonic biopsies varied from cell culture in the lysis/digestion step. 
Biopsies were individually resuspended in 180ul Lysis T solution and 20ul proteinase K was 
added. The biopsies were then incubated at 55°C in a water bath for 4 hours until the 
tissue was completely lysed. The mixture then underwent RNase treatment and protocol 




Total RNA extraction from the cell lines was undertaken using the ISOLATE II RNA mini 
kit (Bioline BIO-52072), according to the manufacturer instructions.  
3.5.10 SNP	sequencing	
Human genomic DNA in TRIS-EDTA solution underwent custom sequencing at Eurofins 
Medigenomix GmbH to identify the alleles at SNP sites rs1598859, rs 2227551, 
rs37774937, rs10896794 and rs12254167.  
3.5.11 PCR		
The primers to detect the LPXN SNP site (Chr 11 Position 58571651) in both parental cells 
(Hela, HT29, Cac02, T84) and in transfected cells were: 
Forward: CCTGTCTTTTAGGGTGTGGAGA (pos 58571546) TM 59°C 
Reverse: GCCCAGATTCAAGTCCTGGT (pos58571901) TM 59°C 
HotStarTaq Master mix kit (Qiagen 203443) was used according to manufacturer’s 
instructions (changing annealing temp to 54°C) to produce a 356bp amplicon visualised 
on 1.5% agarose gels. The PCR amplicon was purified using QIAquick PCR purification kit 
(Qiagen 28104) following the manufacturer’s instructions before sequencing at Eurofins 
using the forward primer with the Mix2Seq service.  
3.5.12 qPCR	for	LPXN	gene	expression	
After RNA extraction, each sample was tested for quality and quantity using a Nanodrop. 
cDNA reverse transcription was undertaken using a HighCapacity cDNA Reverse 
Transcription Kit (Applied Biosystems 4374966), as per the manufacturers instruction, 
with the RNAse inhibitor. For each reaction 0.5ug of RNA was used. After cDNA reverse 
transcription, the samples were diluted 1:5 in PCR grade water. Each of the samples were 
qPCR in triplicate for LPXN expression and beta actin expression, used as the internal 
control. ‘No cDNA’ controls were also used to assess for pipetting error and contamination 
of reagents. TaqMan Gene Expression Master Mix (ThermoFisher Scientific 439016) was 
used. The reactions were prepared in a 384-well plate with a reaction volume of 10ul 
(2.5ul template, 7.5ul mastermix). The qPCR was run on a Roche LC48011 Light Cycler.  
3.5.13 Polarised	in	vitro	organ	culture	of	colonic	biopsies	
6 colonic biopsies taken from the rectosigmoid junction (approx. 18cm from rectum) via 
5mm pinch biopsy forceps were taken from consented patients. Only those that were 
macroscopically normal at the time of endoscopy were used for the ‘normal’ colon 
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patients. 1 sample per patient was flash frozen on dry ice immediately (for cytokine 
analysis or DNA extraction), 5 x samples were placed in IVOC media for the 10min 
transport to the laboratory. As per the protocol of Schuller et al 2009 (361) IVOC media 
consisted of (per 100ml): NCTC-135 (Sigma-aldritch) 0.47g,  sodium bicarbonate (Sigma-
aldritch) 0.11g, Dulbeccos modified Eagle’s Medium (Sigma-Aldritch) 45ml, and newborn 
calf serum (NCS)(Sigma-Aldritch) 10ml, distilled water 45ml. Each media aliquot was 
filtered (0.22um) and stored at 4°C, but warmed to 37°C prior to sample collection. 
Each sample was orientated with the mucosal side uppermost and halved across the 
shortest access and prepared for polarised IVOC (pIVOC) (Figure 3-4) and mounted on a 6 
well plate containing 3ml of IVOC media in each well base.  
 
Figure 3-4 Polarised in vitro organ culture (pIVOC). The biopsy orientated with the mucosal side uppermost 
and sealed in between two ’O’ shaped perspex discs, held in place using a snapwell. The apical and basal media 
are kept separate by the biopsy. 
Once mounted, 200ul of media was added apically and for those undergoing bacterial 
stimulation, 1ul/ml or 10ul/ml lipopolysaccharide, peptidoglycan and muryldipeptide 
were added and the plate was incubated on a rotor (12 RPM) at 37°C for 2 hours. The 
apical media was then removed and 2 drops of fresh media placed onto the apical surface 
of the biopsy to prevent the sample drying out. The plate was then re-incubated for a 
further 6 hours after which the biopsy was removed intact from each snapwell, flash-
frozen in liquid nitrogen and stored at -80°C for later RNA or protein extraction.  The basal 






The LEGENDplex Human Inflammation Panel (BioLegend 740118) was used to 
simultaneously quantify 13 human inflammatory cytokines/chemokines (IL-1B, IFN-a, IFN-
y, TNF-a, MCP-1, IL-6, IL-8, IL-10, IL-12p70, IL-17A, IL-18, IL-23, and IL-33) according to  the 






Using western blot the presence of Leupaxin protein was confirmed in HT29, Caco2 and 
Hela cell lines (Figure 3-5) compared against a positive control, Ramos whole cell lysate 
(Santa-cruz sc-2216) 
 
Figure 3-5 Western blot images of HT29, Hela and Caco2 whole cell lysate probed for LPXN expression. Blots 
were incubated with primary Mouse anti-LPXN F12 (IgG3 K) sc-376903 1:200 and anti-mouse GAPD (as loading 
control and donkey anti-mouse-HRP conjugated secondary antibody. The Ramos cell line whole cell lysate was 
used as a positive control LPXN is a 43kDa protein, GAPD is 37kDA.  
HT29, T84, Caco2 and Hela cell lines were sequenced across the LPXN SNP allele site to 
ensure they did not already contain the risk allele using the PCR primers as described 
above, cleaning the PCR product and sequencing using the forward PCR primer with a 
Mix2Seq kit (Eurofins). Caco2 was not used after this stage as the amplicons from the 
primers which should have been specific to the LPXN site reproducibly produced multiple 
different products when sequenced, indicating genetic instability and potentially 
polyploidy of chromosome 11. 
We experienced poor transfection rates in HT29s (<0.01 %), using multiple transfection 
and selection techniques, therefore genetic manipulation using CRISPR plasmids was 
therefore undertaken in Hela cells as a surrogate epithelial cell line, notwithstanding the 




























Transfection rates of each of the plasmids into Hela cells were assessed by cell comparing 
alive/dead cell counts from parental HeLa cells at day 3 of growth in 6 well plates vs cells 
growing under positive antibiotic selection at day 3 (Table 3.2).  
Plasmid Average Transfection Rate  
(n= 6 transfections) 
D10A-puro with forward sgRNA 
D10A-puro with reverse sgRNA 
62% cells alive under puromycin selection 
LPXN Activation Plasmids 60% cells alive under puromycin selection 
LPXN Activation plasmids control 59% cells alive under puromycin selection 
Double nickase LPXN knock out plasmids 38% cells alive under puromycin selection  
Double nickase LPXN knock out control 
plasmids 
46% cells alive under puromycin selection 
Homologous recombination template 
gBlock with Neo resistence (1:3 w/v ratio) 
0.1% cells alive under dual puromycin and 
G148 selection 
Table 3-2 Plasmid transfection rates in Hela cells using JetPrime transfection reagent. Cells were trypsinised 
at day 3 of puromycin selection, stained with trypan blue and counted using a haemocytometer. Cells were 
considered to have been successfully transfected if they were still alive under puromycin selection at 3 days.  
Both the knock out plasmids and knock out plasmid controls had lower transfection rates 
than the D10A and activation plasmids, despite this 5 hela cell lines were created. 1. Hela 
cells with a customised LPXN knock out using a cloned double nickase system with the 
CHOPCHOP designed sgRNAs ligated onto the cassette (D10A-puro) 2. LPXN over 
expressing Hela cell line (puromycin selection) 3. Control hela cells with the activation 
plasmid control transfected (puromycin selection) 4. LPXN knock out via a commercial 
double nickase system (puromycin selection) and 5. LPXN knock out control (using sham 
sgRNAs on the knock out plasmids with the same selection cassette).  
3.6.1.1.1 Creation	of	the	LPXN	SNP	risk	allele	cell	line	
The customised 3119bp homologous recombination (HR) template with the SNP risk 
allele, a floxed EF1A promoter sequence- Neo resistence selection cassette with 430bp 
homology arms either side was designed using SnapGene and manufactured as a gBlock 
by Integrated DNA technologies (IDT).  The gBlock was transfected with the D10A-puro 
plasmids and optimisation steps were undertaken. Optimisation of the plasmid: gblock 
ratio from 1:1w/v to 1:3 w/v, increasing the number of cells transfected from 6 wells to 
10cm plates, using brefeldin to force the cells to undergo a higher rate of homologous 
recombination (209), using of conditioned media to keep single cells alive, and reducing 
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the dose of antibiotic for selection did not work. After 72 hrs of dual antibiotic selection 
the cells would not survive due to low transfection rates and presumed low HR rates, 
therefore it was not possible to progress further to undertake the final steps of 
confirmatory sequencing and floxing the EF1A promoter- Neo resistance cassette out of 
the genome. 
3.6.1.2 Characterisation	of	the	modified	LPXN	expression	cell	lines	
The comparative growth between the cell lines was documented in fibronectin coated 6 
wells at 4 days and 7 days post puromycin selection. On visual inspection (with 
representative areas shown in Figure 3-6), the LPXN (Santa Cruz) knock out cell lines 
produced long elongated spindle shaped cells by day 7 with an average confluency of 18% 
(n= 6, analysed with image J) which was significantly lower than the parental hela cells 
(p=0.0077).  The double nickase (D10A) knockout (SNP specific) produced circular colonies 
of cells by day 7, with an average confluency of 19.5% (n=6) which was also significantly 
lower than the parental HeLa cells (p=0.0039). The circular colonies had large areas of no 
growth between each colony hub suggesting that the colonies had arisen from individual 
surviving cells, but had not yet grown to confluency with other hubs. This pattern was 
unlike the other cell lines which had an even spread of cells growing across the plate. The 
HeLa cell line transfected with the sham control knock out plasmid (n=6) showed normal 
HeLa morphology, but slightly delayed growth (80% confluency by day 7, NS) compared 
to the parental HeLa cell line.  This is expected with puromycin selection as the number 
of transfected cells would be less than the total number seeded, and would therefore take 
longer to grow. The control cell lines were confluent by 10 days (data not shown), whilst 
the commercial knock out cell line never achieved confluency (cell death at <50% 
confluency). The D10A cell line reached confluency by day 21 via convergence of multiple 
single colony hubs.  
The LPXN over expression cell lines grew rapidly and formed clumps as opposed to the 
flat layer of the normal HeLa cell (Figure 3.5, B). The LPXN overexpression cell line was at 
100% confluency in <4 days under puromycin selection, significantly faster than the 
parental HeLa cells under no puromycin selection (p=0.0058).  The control plasmids for 
the overexpression containing the sham sgRNA responded in the same way as the knock 
out sham plasmids; with 80% confluency at 7 days (NS).   
qPCR to confirm LPXN gene expression of the 6 cell lines was undertaken in duplicate on 
two separate occasions with freshly transfected and cultured cell lines at day 10 (Figure 
145 
 
3.6,Figure 3-9).  This confirmed overexpressing cell lines had (on average) 78 fold higher 
levels of LPXN expression than the parental HeLa cells. It was also confirmed the 
commercial LPXN knock out cell line had 1.98-fold less expression of LPXN than the 
parental cell lines (with Ct values of 34-35). The assay indicated that the D10A system was 
only a ‘partial’ knock out with 0.9-fold less expression of LPXN than the parental cell line 
(1.08-fold more expression than the commercial knockout). One explanation for this is 
D10A knock out required 2 large plasmids to be transfected simultaneously. This reduces 
the probability of successful transfection and increases the probability of a mixed genetic 
population. If only one plasmid was transfected and worked at maximal efficacy it would 
cause a single stranded nick which could have deleterious effects, but is more likely to be 
accurately repaired by the cellular DNA repair mechanisms, but the puromycin resistance 
containing plasmid would still be retained, allowing the cell to survive. A further 
explanation is that the sgRNAs cloned into the D10A plasmids were less efficient than the 
sgRNAs in the commercial knock out plasmids. The sgRNAs used for the D10A plasmids 
had the highest efficacy as designed by CHOPCHOP, but we were limited by the number 





Figure 3-6 Characterisation of growth of Hela cells and Leupaxin knock out Hela cell lines over 7 days. A: 
Parental Hela cells images at x 40(day 4) and x 10 (day 7) magnification showing normal growth and 100% 
confluency at day 7. B: Leupaxin double nickase knock out hela cell lines post puromycin selection both at x 40 
magnifications showing at day 4 a mix of scattered individual cells (yellow arrow), dead cells (red arrow) and 
expanding colony growth (outlined in red); at day 7 single colony growth expansion only was present (blue 
circle) with <20% confluency. C Leupaxin (Santa Cruz) knock out cell lines post puromycin selection both at x 
40 magnification showing individual cells with elongated morphology at day 4 (yellow arrow) and cellular 
expansion at day 7, <20% confluency. D Leupaxin (Santa Cruz) knock out control with sham plasmids post 
puromycin selection images at x 40 (day 4) and x 10 (day 7) showing delayed growth compared to the parental 




















Figure 3-7 Characterisation of growth of Hela cells and Leupaxin overexpression Hela cell lines over 7 days. A: 
Parental Hela cells images at x 40(day 4) and x 10 (day 7) magnification showing normal growth and 100% 
confluency at day 7. B: Leupaxin (Santa Cruz) overexpression hela cell lines post puromycin selection both at x 
10 magnifications, showing at day 4 100% confluency. C Leupaxin (Santa Cruz) overexpression control with 
sham plasmids post puromycin selection images at x 40 (day 4) and x 10 (day 7) showing the same growth 


















Figure 3-8 Fold changes (^^CT) of leupaxin expression in Hela cells. Each of the cell lines are controlled with 
beta actin with two biological replicates and two technical replicates for each biological replicate with 
standard deviations. Hela = Parental Hela cells, Knock out =commercial double nickase LPXN knock out, knock 
out control = double nickase sham plasmids, Overexpression = HeLa cell line overexpressing LPXN via LPXN 
activation plasmids, Over expression control =activation sham plasmids, SNP= D10A double nickase cell line. 
 
 
Figure 3-9 Log10 fold changes of leupaxin expression in Hela cells indicating down and up regulation of 
leupaxin expression. Results confirming knock out and overexpression of LPXN compared to the parental hela 
cells. Hela = Parental Hela cells, Knock out =commercial double nickase LPXN knock out, knock out control = 
double nickase sham plasmids, Overexpression = HeLa cell line overexpressing LPXN via LPXN activation 



















































The cellular location of LPXN in the epithelial cell lines, and confirmation of mRNA 
translation in the cells over expressing LPXN was visualised by immunocytochemistry. 
(Figure 3-10). The two antibodies used show slightly different localisations but the isotype 
control antibody produced no staining. At 24 hours, the LPXN staining in the 
overexpression cell line was visualised as granular cytoplasmic staining, with significantly 
less visible staining in the Parental Hela cell line. A composite image was required to 
ascertain the localisation. At 12 hours, the overexpressing cell line displayed clearly 
identified intense fluorescent signal at the plasma membrane (white arrows), indicative 
of focal adhesions, in addition to patchy staining across the cytoplasm (yellow arrow) and 
potentially in the nucleus. Focal adhesion sites were also seen in the parental Hela cells 




   
 
Figure 3-10 Immunocytochemistry staining for LPXN (texas red). A-B: Composite image of transmitted light 
image and fluorescence imaging x 20 at 24 hours Sigma Mouse anti LPXN Monoclonal  antibody (1:100) and 
goat anti-mouse-Texas red (1:1000), and DAPI (blue).  A. LPXN over expression hela cell line B Hela cell line C: 
Composite image of transmitted light image and fluorescence imaging x 20 Mouse IgG1 isotype control (1:100) 
with goat anti mouse texas red (1:1000, and DAPI (blue). D-F immunofluorescence imaging at 12 hours x 20. 
D-E Santa Cruz Mouse LPXN antibody (F12) (1:100) and goat antiimouse texas-red (1:1000), and DAPI (blue). 
F: Mouse IgG3 isotype control(1:100) withgoat anti-mouse texas red secondary antibody (1:1000) and DDAPI 










The wound healing assay was undertaken on cell lines grown on fibronectin of which only 
the parental HeLa and LPXN over expressing cell lines grew to confluency on the glass 
coverslips and therefore could be used for the wound healing assay.  The wound healing 
assay was done in the presence and absence of bacterial ligands (1ug/ml LPS, 
peptidoglycan and MDP).   
The experiment was undertaken twice, with freshly transfected cell lines grown under 
puromycin control for 72 hours and then rested for 24 hours prior to causing the wound.  
The distance between the opposing epithelial edges was measured at the same 5 points 
for each replicate using a template in ImageJ (Figure 3-11) 
 
Figure 3-11 Wound healing assay. The wound defect was measured at 12 hours and 24 hours in parental HeLa 
cells (red solid columns) and LPXN over expressing(LPXN_OE) HeLa cells (blue solid columns) in the absence or 
presence (+/dotted columns) of bacterial ligands. There were two biological replicates for each cell line, with 
two technical replicates for each time point. Cells were fixed and stained and images viewed with an ImageJ 




































Figure 3-12 Comparison of wound defect at 12 hours and 24 hours time points between parental hela cells 
(red solid columns) and LPXN over expressing(LPXN_OE) hela cells (blue solid columns) in the absence or 
presence (+/dotted columns) of bacterial ligands. Statistical significance assessed with a two tailed T test. * 
p=0.0198, **p=0.0001 
 
The LPXN over expression cells lines were able to heal significantly faster in the first 12 
hours than the HeLa controls (p=0.0198) even in the presence of bacterial ligand stress 
(p=0.0001), however they were unable to maintain that rate of healing and a significant 
(p=0.0001) defect remained compared to the parental HeLa cells. The parental HeLa cells 
stimulated with bacterial ligands also had a significant defect remaining compared to the 
unstimulated HeLa cells (p=0.0001). The LPXN overexpressing cell line was difficult to 
assess as there were single cells within the defect tract which, in part, accounts for the 
wide SD bars. In summary, the wound healing assay indicates that although LPXN 
overexpression initially leads to a faster healing response wound healing over time is 
significantly impaired.  
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To quantify cytokine responses to changes in LPXN expression the BioLegend LEGENDplex 
Inflammation Panel was used to quantify cytokines secreted by Hela cells, either 
containing the LPXN overexpression plasmids, the LPXN knock out plasmids or parental 
Hela cells grown to confluency on fibronectin coated glass coverslips and on plain glass 
coverslips at 12 hours and 24 hours. Fibronectin was used to assess the requirement of 
the integrin signal to LPXN function, using a bacterial ligand cocktail of LPS to activate 
TLR2 and TLR4, peptidoglycan to activate TLR2, and MDP to activate NOD2. Hela cells did 
not grow on plain glass coverslips and the knock out cell lines grew poorly regardless of 
the growth environment (as described above) therefore these groups could not be 
analysed.  
3.6.3.1 MCP-1	
The pattern of MCP1 secretion by parental HeLa cells was a significant, but expected, rise 
in MCP1 secretion from 12 hours to 24 hours (p=0.0005). They show increased MCP-1 
secretion in response to bacterial antigens at 12 hrs post stimulation (p=0.0151), but not 
at 24 hours (Figure 3.12).and with a trend of more MCP1 secretion with bacterial ligand 
stimulation (p=0.0151 at 12 hours, no significant difference at 24 hours).  
 
Figure 3-13 Column graph showing secreted MCP1 in pg/ml of conditioned cell media averaged from 
quadruple replicates, each with duplicate technical replicates.  F+ = fibronectin coated glass slide, OE = LPXN 
overexpressing Hela cell  BS = bacterial antigen stimulation. Solid bars are non stimulated cells, dotted bars 
are stimulated with bacterial antigens. * p=<0.05 compared to 12 hour parental non stimulated hela sample, 
** p= <0.001 compared to 12 hour sample,**  p=<0.001 compared to the equivalent parental hela sample, 













































































Levels of MCP1 in the media was significantly lower from the LPXN over expressing cells 
grown without fibronectin at both 12 hours (p=0.0034) and 24 hours (p=0.0006) 
compared to the media from parental HeLa cell grown on fibronectin, the same was seen 
with media from bacterial antigen stimulated LPXN overexpressing cells grown without 
fibronectin compared to the media from parental HeLa cells; p = 0.0021, p=0.0006 
respectively.  
With fibronectin coating, MCP1 secretion into the media by LPXN overexpressing cells was 
significantly lower than both the parental HeLa cell lines and the LPXN overexpressing 
cells grown without fibronectin. At 12 hours, both the unstimulated and bacterial antigen 
stimulated LPXN overexpressing cells secreted <60% of the MCP1 than was expected 
(compared to parental HeLa cells) (p=0.0003 and p=0.0001). The bacterial antigen 
stimulation led to more MCP1 secretion at 24 hrs than 12 hours on the fibronectin coated 
slides, however it was still significantly lower than the level secreted by parental hela and 
the LPXN overexpressing cells lines without fibronectin (p=0.0001 for both). The data from 
the cells not grown on fibronectin indicate an integrin independent effect of the                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
LPXN overexpression, whilst data from cells grown on fibronectin indicate an integrin 
dependant effect. Together this indicated that LPXN may have an effect on MCP1 
secretion by epithelial cells, both in an integrin-independent and integrin-dependant 
fashion. 
It is unclear from this experiment whether LPXN overexpression affects the signal cascade 
for secretion or whether it downregulates MCP1 expression. We know that cell adhesion 
to fibronectin via integrins induces phosphorylation of the focal adhesion kinase (FAK) 
(362). Over expression of FAK increases expression of MCP-1 with a subsequent increase 
in protein levels, and knock out of FAC expression abolishes adhesion induced MCP-1 
expression as well as IL6 expression. FAK and NFKB inhibitors genistein and tosyl 
phenylalanyl chloromethylketone also inhibit MCP1 expression (363). LPXN binds to FAK 
and other phospho-tyrosine kinases such as PYK2 and in doing sequesters both LPXN and 
the kinases to the focal adhesion plaques thereby negatively regulating FAK functions. 
Knock out of FAK allows for LPXN shuttling to the nucleus to function as a transcription 
cofactor (351), knock out of FAK has also been shown to alter expression of other 
cytokines including IL6 (364). Therefore, it is possible that LPXN overexpression negatively 
regulates members of the FA, altering cytokine production as well as behaving as a 
transcriptional cofactor.  Given that MCP1 is upregulated by IL6, to confirm that the MCP1 
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response seen was not in response to IL6, the level of IL6 in the conditioned media was 
quantified. 
3.6.3.2 IL-6	
As shown in Figure 3-14, IL-6 was constitutively secreted by the parental HeLa cells with a 
trend (not significant) of decrease in secretion after 24 hours culture. Stimulation of 
parental cell lines with bacterial antigens did not significantly change constitutive IL6 
secretion at 12 or 24 hours. Interestingly in the absence of integrin signal (fibronectin -), 
more IL6 was secreted in the LPXN overexpressing cell lines (F- LPXN OE), with a trend of 
more secretion with bacterial antigen stimulation. The decrease in measurable IL6 at 24 
hours was again noted within the F- LPXN OE cell lines (p=0.0379), although this was not 
significant in the bacterial antigen stimulated F- LPXN OE cell lines. At 24 hours, the F- OE 
LPXN cell line secreted significantly more IL6 than the parental HeLa cells (p=0.0354).  
 
Figure 3-14 Column graph showing secreted IL6 in pg/ml of conditioned cell media averaged from quadruple 
replicates, each with duplicate technical replicates.  F+ = fibronectin coated glass slide, OE = LPXN 
overexpressing Hela cell  BS = bacterial antigen stimulation. Solid bars are non stimulated cells, dotted bars 
are stimulated with bacterial antigens. * p=<0.05 compared to 24 hour parental non stimulated hela sample, 
*p=<0.05 compared to the 12 hr F- LPXN overexpressing  sample, **p=<0.001 compared to the 12 hr F+ LPXN 
overexpressing sample. 
 
Analysis of the IL6 in the conditioned media of LPXN over expressing cell lines grown on 
fibronectin (F+ LPXN OE) gave a very different picture to the non integrin stimulated over 












































































comparable to constitutive levels, by 24 hours it had decreased to a barely detectable 
(160pg/ml) level (p=0.0046). With bacterial ligand stimulation, the measured IL6 was 
significantly lower at 12 hours than the non stimulated cultures (p=0.0002), although this 
increased and was comparable to constitutive levels by 24 hours suggesting a delayed 
response.  
Using Pearson correlation (Figure 3-15) we identified that MCP1 concentration measured 
across all the cell lines did not correlate with the measured IL6 concentration (r=0.2156, 
p= 0.1412). Therefore, the changes seen with MCP1 may not be in response to IL6, 
although more detailed analysis was required. When analysing the individual data points 
for each cell line the MCP1 concentration in the media from the LPXN OE F+ cell line 
correlated well with IL6 concentration (r=0.934 p= 0.0001), the LPCN OE F- cell line less 
well (r=0.57 p = 0.019) and the parental HeLa cells did not correlate at all (r= -0.206 p = 
0.443). This indicates IL6 involvement in the MCP1 response, but other factors may 
contribute.  To identify if the IL6 response was anomalous, other cytokines were measures 





Figure 3-15 Pearson Correlation Graphs assessing the correlation between MCP1 and IL6. A: Analysing all time 
point values for IL6 and MCP1 in parental Hela cells, LPXN over expressing cell lines grown without and without 
fibronectin. B Individual time point results for MCP/IL6 secreted from parental HeLa cells grown on fibronectin. 
C. Individual time point results for MCP/IL6secreted from LPXN overexpressing cell lines grown on fibronectin. 
D Individual time point results for MCP/IL6secreted from LPXN overexpressing cell lines not grown on 
fibronectin  
  













r = -0.206 p = 0.443














r = 0.934 p = <0.0001 













r = 0.57 p = 0.019 












r = 0.2156 p = 0.1412








As shown in Figure 3-16, IL8 was constitutively secreted at low level by the parental HeLa 
cell lines grown on fibronectin, with no significant changes in response to bacterial antigen 
stimulation. The LPXN overexpressing lines grown on fibronectin produced lower levels of 
IL8 than the parental HeLa controls, but it was only significant in the bacterial antigen 
stimulated lines at 12 hours (p=0.0003). The cell lines grown without fibronectin (without 
integrin activation), had higher levels of IL8 in the media compared to both the parental 
Hela cell lines and the LPXN overexpressing cell lines grown on fibronectin, however, due 
to variability these changes were not significant. The reduction in measurable IL8 at 24 
hours is expected, as post stimulation epithelial cells have maximal expression of IL8 at 4-
6 hours (365, 366). As expected, changes in IL6 and IL8 correlate r=0.92 p=<0.0001 (Figure 
3-17).   
 
Figure 3-16 Column graph showing secreted IL8 in pg/ml of conditioned cell media averaged from quadruple 
replicates, each with duplicate technical replicates.  F+ = fibronectin coated glass slide, OE = LPXN 
overexpressing Hela cell  BS = bacterial antigen stimulation. Solid bars are non stimulated cells, dotted bars 
are stimulated with bacterial antigens. ** p=<0.001 compared to 12 hour parental stimulated hela sample, 














































































Figure 3-17 Pearson Correlation Graph assessing the correlation between levels of  IL-8 and IL-6 secreted into 
media from parental HeLa cell lines and LPXN overexpressing cell lines grown with and without fibronectin at 
12 hours and 24 hour time points.  
In summary, LPXN overexpression reduces MCP1 secretion in epithelial cells, more so 
when the integrin signalling cascade is activated by fibrinogen. Part of this response may 
be due to a reduction in IL6 production. The trend of lower IL6 and IL8 production in LPXN 
over expressing cells with integrin activation may indicate that the cells are less able to 
respond to TLR and NOD2 stimulation, although more work is required to examine this 
further.  
3.6.4 Colon	biopsy	cytokine	responses		
Of the samples collected over 6 months, we utilised 9 sets of biopsies (a biopsy set is 3 
biopsies halved into IVOC system and 1 biopsy for baseline measurements) from normal 
colons, 10 sets of biopsies from quiescent UC patients, and 3 sets of biopsies from 
inflamed UC colons for cytokine analysis.  
3.6.4.1 Cell	type	by	cytokine	profile	
The minimum detectable concentration (MDC) of the Legendplex assay for each analyte 
was noted as per the Biolegend MDC in serum which was the closest validated equivalent 
to the biopsy samples containing cellular material (Table 3-3).  There were undetectable 
levels of IL17A, IL12p70 and IFNa in any of the colonic biopsies therefore the presence of 
activated T cells was not detectable by their cytokine profile in these biopsy samples. The 
detectable cytokine profile at baseline would be consistent with cells of the innate 
immune system including epithelial cells, macrophages, and dendritic cells (Figure 3-17).  












r = 0.92 r2 = 0.85
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Analyte MDC in Serum 
(pg/ml) 
Human IL1-B 0.9 
Human IFN-a 1.5 
Human IFN-y 1.1 
Human TNF-a 1.0 
Human MCP-1 1.1 
Human IL-6 1.0 
Human IL-8 1.0 
Human IL-10 0.8 
Human IL-12p70 0.6 
Human IL-17A 1.9 
Human IL-18 1.1 
Human IL-23 1.2 
Human IL-33 1.2 
Table 3-3 Minimum detectable concentration(MDC) of analytes in serum (pg/ml)based on results from 
Biolegend LegendPlex protocol.  
 
 
Figure 3-18 Logarithmic fold change from minimal detectable concentration of analytes at baseline (time zero) 











































































Using the polarised IVOC system to assess cytokines response, we were able to quantify 
the mucosal response to the mechanical stress of pIVOC in terms of cytokine production 
over 8 hours. The method and the manipulation of the biopsies to place them into the 
pIVOC system and maintain them for up to 8 hours produced a change in cytokine 
response over time. Apart from the static cytokines (IL18, IL23), the cytokine response 
increased over time in the IVOC system 
When analysed together as a group, the UC samples which were macroscopically 
quiescent did not differ significantly from the normal samples in the patterns of cytokine 
response. The inflamed samples differed at baseline in interferon gamma production 
compared to the quiescent UC samples (p=0.0004) and the normal samples 
(p=0.0002)(Figure 3-19). The UC inflamed samples had significantly altered TNF 
production compared to normal colons (p=0.04) and MCP1 production compared to 
quiescent UC samples (p=0.03). This data confirms that manipulation of biopsies produces 
a cytokine response, but other than in the expected and documented changes in IFN 
gamma, TNF and MCP1 production, there is no other significant difference seen in the 
cytokine response to pIVOC between the diseased and non-diseased samples. This 






Figure 3-19 Box Whisker plots of measured cytokines (normalised to protein content) in colonic biopsies in 
pIVOC from normal colons (n=63 individual samples analysed in duplicate from 9 patients), quiescent UC 
colons (UC)(n= 69 individual samples analysed in duplicate from 10 patients) and inflamed UC colons (UCI) 
(n= 27 individual samples analysed in duplicate from 3 patients ) over 8 hours. The cytokines were quantified 





To identify if the LPXN SNP rs10896794 had any effect on cytokine production, 11 patients’ 
samples (2 normal, 6 quiescent UC and 3 inflamed UC) were genotyped for the LPXN SNP. 
The samples were considered risk allele positive if they were homozygotes for the LPXN 
SNP risk allele (C<T). Heterozygotes are denoted (Y), and for those samples we were 
unable to ascertain a phenotype for that SNP in that sample (Table 3-4). All the genotyped 
samples had technical cytokine analysis duplicates which were reproduced on the 
legendplex analysis. To test the hypothesis that the LPXN SNP may have a role in altered 
response to bacterial stress, half of the samples underwent bacterial antigen stimulation. 
These results are only included in the analysis if the test was able to be reproduced with 
a technical replicate. Each of the analytes were normalized to the total protein in each 
sample to normalise for differing biopsy sizes.   
ID Disease 
Group 










55 M Nil T No 
16TB0398 Normal (IBS) 57 F Nil Y No 
16TB0405 UCQ 37 F 5ASA T No  
16TB0413   UCQ 63 F 5ASA Y No 
16TB0410 UCQ 45 M nil T 1ug + null 
controls 
16TB0409 UCQ 42 M 5ASA Y 1ug + null 
controls 
16TB0455 UCQ 58 M Azathioprine  T 10ug + null 
controls 
16TB0457  UCQ 60 F 5ASA Y 10ug + null 
controls 
16TB0274 UCI  51 M Nil Y No 
16TB0389 UCI 34 F 5ASA T No 
16TB0495 UCI 28 F 5ASA T No 
Table 3-4 Patients who had colonic biopsies genotyped for rs10896794.Patient samples are anonymised via 
the tissue bank (TB) ID code. T allele = risk allele, Y = T/C heterozygote at the SNP site. Age, gender and IBD 




Given the hypothesis that the LPXN risk allele has an effect on the NLRP3 inflammasome, 
IL-1b and IL-18 were analysed as downstream products of NLRP3 activation. Based on the 
LPXN over expressing cell line results; MCP-1, IL-6 and IL-8 were also analysed.  
3.6.4.2.1 IL-1Beta	
The LPXN risk allele in the normal colon had no significant effect on IL-1B production when 
compared to heterozygote controls (Figure 3-19). IL-1b production was significantly 
higher in LPXN heterozygote (LPXN T/C) quiescent UC samples (UCQ) than in LPXN risk 
allele homozygotes (LPXN T/T) at 6 and 8 hours. When comparing the normal samples to 
the UCQ samples; the T/T UCQ samples produced <50% of the IL1-B that the LPXN T/T 
normal samples did at the same time points (4,6,8 hours), with the reverse being true for 
the LPXN T/C samples. This indicates that the LPXN SNP risk allele may be affecting the 
production of IL1-B in the UCQ samples.  For the inflamed UC samples, the LPXN T/T 
samples contained more IL-1b at 6 hours and 8 hours (p=0.0006, p=0.0003) as compared 
to the LPXN T/C time matched pairs. The LPXN T/C samples produced lower levels of IL1-




Figure 3-20 IL-1B quantified using Legend Plex Assay. A; genotyped samples from normal colonic biopsies in a 
pIVOC which were homozygous for LPXN risk allele (Blue)or heterozygotes at the LPXN SNP site(red). SEM  bars 
shown. Two tailed t-test was not significant. B; IL-1B quantified from normal colonic biopsies in a pIVOC which 
were homozygous for LPXN risk allele (Blue)or heterozygotes at the LPXN SNP site(red). SEM  bars shown. C: 
IL-1b quantified from quiescent UC colonic biopsies in a pIVOC which were homozygous for LPXN risk allele 

















































































































In normal colonic biopsies IL-18 production did not differ significantly over 8 hours from 
each of the sample baseline levels. The LPXN risk allele homozygte samples had 
significantly more IL-18 compared to LPXN T/C heterozygote samples (p=0.0003 at 2 and 
6 hours, p=0.02 at 4 hours) (Figure 3.20). There was no significant difference between any 
of the UCQ samples either from baseline or between the LPXN T/T homozygotes or T/C 
heterozygotes. The LPXN T/C inflamed UC samples produced significantly less IL-18 at 4,6 
and 8 hours than the LPXN T/T samples. Interestingly, excluding the baseline inflamed 
samples, the IL-18 levels in the inflamed samples were directly comparable to those in the 
normal samples for both the LPXN T/C and LPXN T/T. This suggests changes in production 
of IL-18 seen with the LPXN SNP may not be directly involved with the acute inflammatory 
process in UC.  
3.6.4.2.3 IL-6	
The LPXN T/T had no significant effect on IL6 in the normal colons (Figure 3-22)compared 
to the LPXN T/C samples. Variability of the measured IL6 in UCQ samples meant that there 
was no significant difference between the LPXN T/C and LPXN T/T samples, however in 
the inflamed colonic samples there were significantly greater levels of IL6 production 
compared to the UCQ samples. Between the LPXN T/T and LPXN T/C inflamed samples 






Figure 3-21 IL-18 quantified using Legend Plex Assay A: normal colonic biopsies in a pIVOC which were 
homozygous for LPXN risk allele (Blue)or heterozygotes at the LPXN SNP site(red). SEM  bars shown. B: IL-18 
quantified from UCQ colonic biopsies in a pIVOC which were homozygous for LPXN risk allele (Blue)or 
heterozygotes at the LPXN SNP site(red). SEM  bars shown. C: IL-18 quantified from inflamed UC colonic 
biopsies in a pIVOC which were homozygous for LPXN risk allele (Blue)or heterozygotes at the LPXN SNP 
site(red). SEM  bars shown. Two tailed t-test; *= p<0.05 compared to same hour point in LPXN risk allele 











































































































Figure 3-22 IL-6 quantified using Legend Plex Assay A: IL6 quantified from normal colonic biopsies in a pIVOC 
which were homozygous for LPXN risk allele (Blue)or heterozygotes at the LPXN SNP site(red). SEM  bars 
shown. B: IL-6 quantified from UCQ colonic biopsies in a pIVOC which were homozygous for LPXN risk allele 
(blue)or heterozygotes at the LPXN SNP site(red). SEM  bars shown.C: IL-6 quantified from Inflamed UC 
colonic biopsies in a pIVOC which were homozygous for LPXN risk allele (blue)or heterozygotes at the LPXN 
SNP site(red). SEM  bars shown. Two tailed t-test; ** = p<0.001 campared to same hour point in LPXN risk 























































































































The trend in IL8 production in normal biopsies was directly comparable to IL6 production 
in normal biopsies, with significantly more IL8 being produced in LPXN T/T samples 
compared to LPXN T/C samples (Figure 3-23) (*p=0.04, **p=0.0009). Like IL6, the UCQ 
samples were the opposite to the normal samples, with LPXN T/C showing a greater rise 
in IL8 production over time compared to LPXN T/T (p=0.0024 at 4 hrs, p=0.0003 at 6 and 
8 hours). In the inflamed UC samples, there was significantly less IL8 produced in the LPXN 
T/T samples than the T/C samples, for the LPXN T/C samples there was double the amount 
of IL8 produced from the inflamed samples compared to the normal samples. There was 
no significant difference between the normal LPXN T/T samples and the inflamed UC LPXN 
T/T samples. This indicates that the LPXN T/T may reduce the pro-inflammatory 
production of IL8 in an inflamed colon.  
3.6.4.2.5 MCP1	
MCP-1 production was consistent higher in the LPXN T/T samples for all 3 types of colonic 
biopsy (normal, UCQ and UC inflamed) compared to the LPXN T/C samples (Figure 3-24). 
In the inflamed samples this reached significance, in the UCQ samples this did not. The 
results were analysed via a Pearson correlation to identify if the changes seen in MCP1 
production were due to or separate from changes in IL6 production (Figure 3-25). MCP1 
and IL6 production correlated for all samples except for the normal LPXN T/T colonic 
sample, indicating like in the cell line cytokine analysis that IL6 has a role in MCP1 cytokine 
changes seen with these results. However, although MCP-1 and IL6 levels did correlate, 
when taking into account the scale of production, all of the LPXN T/T samples produced 
more MCP-1 than the heterogeneous counterparts, but this is not the case for IL6 
production. This indicates that other factors are involved with MCP-1 production, such as 
the LPXN risk allele and patient specific features such as treatments and the presence of 








Figure 3-23 IL-8 quantified using Legend Plex Assay A: IL-8 quantified from normal colonic biopsies in a 
pIVOC which were homozygous for LPXN risk allele (Blue)or heterozygotes at the LPXN SNP site(red). SEM  
bars shown. B: IL-8 quantified from UCQ colonic biopsies in a pIVOC which were homozygous for LPXN risk 
allele (blue)or heterozygotes at the LPXN SNP site(red). SEM  bars shown.C: IL-8 quantified from Inflamed UC 
colonic biopsies in a pIVOC which were homozygous for LPXN risk allele (blue)or heterozygotes at the LPXN 
SNP site(red). SEM  bars shown. Two tailed t-test; *= p<0.05 compared to same hour point in LPXN risk allele 


































































































































Figure 3-24 MCP-1 quantified using Legend Plex Assay A: MCP-1 quantified from normal colonic biopsies in a 
pIVOC which were homozygous for LPXN risk allele (Blue)or heterozygotes at the LPXN SNP site(red). SEM  
bars shown. B: MCP-1 quantified from UCQ colonic biopsies in a pIVOC which were homozygous for LPXN risk 
allele (blue)or heterozygotes at the LPXN SNP site(red). SEM  bars shown.C: MCP-1 quantified from Inflamed 
UC colonic biopsies in a pIVOC which were homozygous for LPXN risk allele (blue)or heterozygotes at the 
LPXN SNP site(red). SEM  bars shown. Two tailed t-test; *= p<0.05 compared to same hour point in LPXN risk 























































































































Figure 3-25 Pearson correlation of MCP1 and IL6 in pg/ml in pIVOC samples over 8 hours of incubation. A: 
normal colonic samples heterogeneous at the LPXN SNP site. B: normal colonic samples homozygous for the 
risk allele at the LPXN SNP site. C: UCQ colonic samples heterogeneous at the LPXN SNP. D: UCQ colonic 
samples homozygous for the risk allele at the LPXN SNP site. E:UCI colonic samples heterogeneous at the LPXN 
SNP. F: UCl colonic samples homozygous for the risk allele at the LPXN SNP site. 
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To start to determine if a bacterial ligand stress was the driver of inflammation in patients 
with the LPXN risk allele, genotyped UCQ samples were analysed using “self” controls (half 
the biopsy stressed, the other half with no ligand stress).  These were single samples, 
therefore statistical analysis was not undertaken; this experiment was undertaken as a 
pilot experiment to ascertain if bacterial ligand stimulation was feasible in a polarised 
biopsy with a theoretically intact mucosal layer and its own microbiota.  
The markers of NLRP3 inflammasome activation, IL1-b and IL-18 both showed an initial 
heightened response to supra-physiological levels (10ug/ml) of bacterial ligand 
stimulation. The 1ug/ml LPS, PGN and MDP cocktail stimulation elicited a trend of higher 
IL-1b and IL18 compared to the non- stimulated controls (Figure 3-26).  
IL6, IL8 and MCP-1 production all had a trend of increased production in the supra-
physiologically stimulated samples (Figure 3-27) compared to their controls. More 




Figure 3-26 IL-1B and IL-18 production in UCQ samples containing the LPXN risk allele T/T. The figure shows 











































Figure 3-27 IL-6, IL-8 and MCP-1 production in UCQ samples containing the LPXN risk allele T/T. The figure 




























































































































The creation of multiple different LPXN expression cell lines was difficult. Low transfection 
rates of plasmids into intestinal epithelial cell lines was overcome by using an easier to 
transfect cell line (HeLa) and trialling multiple transfection reagents until the most 
effective for the plasmids used was found. 3 CRISPR plasmids were trialled with differing 
selection methods (antibiotic resistance, CD4+ expression for bead selection and GFP 
expression for flow-cytometry), the best performing in this circumstance were the 
antibiotic positive selection plasmids. It was decided to use the same selection technique 
for each of the plasmids to reduce the confounding effect of selection variables for both 
optimisation of the technique and results analysis.  
There were persistent difficulties with the LPXN knock out cell lines, as the transfection 
rates were slightly lower than the sham controls for reasons that are not clear, and the 
growth of the knock out cell lines was significantly slower which can be explained by the 
lack of LPXN, with the stress of the transfection and individual cells not surviving without 
other cells in contact with them. Optimisation led to the use of 50% conditioned cell media 
until the cell lines were growing in 6 wells which meant that after 6 weeks, we could 
analyse the LPXN knock out cells by qPCR, but were still unable to undertake wound 
healing as the cells would die before confluency. LPXN expression has not been 
characterised in Hela cells before, one paper undertook protein quantification in cell types 
using western blot which suggested that Hela did not contain LPXN. Using commercial 
antibodies, our qPCR results indicate that LPXN is expressed in Hela cells and has 
appreciable protein production as shown by Western blot.  
LPXN is a poorly understood LIM binding adapter protein whose role within the focal 
adhesion complex and role as a biomarker of cancer prognosis (breast and prostate) is 
just beginning to be evaluated. There have been 27 papers characterising the role of LPXN 
since 1998, compared to the 2747 papers since 1990 for Paxillin, a more ubiquitous LIM 
binding adapter protein.  
LPXN was identified as a potential mediator in the susceptibility to or pathogenesis of UC 
from the network analysis of the functional genomics of the UC risk susceptibility SNPs. It 
was unclear from the literature which cell type would have the predominant affect from 
the LPXN SNP.  We have shown that not only is LPXN present in epithelial cell lines, but 
knocking out LPXN in immortalised cell lines had a significantly detrimental effect on cell 
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growth. Overexpression of LPXN in Hela cell lines significantly reduced wound healing and 
with integrin activation significantly reduced the amount of inflammatory cytokines IL6, 
IL8 and MCP1 secreted into the media.  This indicates that LPXN overexpression may 
impact on the ability of epithelial cells to signal to other cells of the innate immune 
system. Where we would have expected an increased IL6 and IL8 response to bacterial 
stimulation, this was not seen in the overexpression cells lines with integrin activation, 
highlighting a potential inability of these epithelial cells to respond appropriately to 
bacterial stimuli.  
There are several intestinal epithelial cell models such as Caco2, HT29 and T84 – these are 
all immortalised colorectal cancer cell lines and whilst the Hela cells were easier to 
transfect they do not have ideal features of intestinal cells lines such as polarisation. 
Immortalised cell lines have been used in the literature as an in vitro model of colitis such 
as using DSS on caco2 cells (338)Specific cells such as dendritic cells and cell lines such as 
THP1 have been used to investigate pathogenesis pathways of colitis such as enteric cell 
education of dendritic cells (339) and identifying how carrageenan works on THP1 cells to 
cause the phenotype seen in carrageenan induced colitis mouse models(340).  Hela cells 
have not been used in this context, for obvious reasons, but this case have provided a 
good indicator for how an epithelial cell would respond to changes in LPXN expression. 
There are limitations to utilising over expression and gene silencing to ascertain the 
phenotype of a SNP, most pertinently, given that the phenotype is unlikely to be 
pronounced, creating severe perturbations in the expression of LPXN, an adaptor protein 
with significant roles in signalling cascades is likely to have a more pronounced effect than 
a single SNP within LPXN will do.  Future work on cell lines would include completion of 
the CRISPR-Cas9 homologous recombination technique to create immortal ‘SNP’ cell lines, 
other parallel techniques could include the creation of primary cell lines from genotyped 
individuals for further characterisation of the LPXN SNP within specific cell types such as 
enterocytes.  
3.7.2 Polarised	in	vitro	organ	culture	
The use of the polarised in vitro organ culture system overcomes the inherent problems 
of immortalised epithelial cell lines. The pIVOC is a snap shot of all the interacting cell 
types in the mucosa at the time of biopsy. It has been designed and used to examine 
adherence of and host responses to E.coli species (361, 367). We have utilised the 
technique to attempt to characterise the impact of genetic changes to the cellular 
response to mechanical stress and start to characterise the impact of bacterial ligand 
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stress. A limitation of this approach is that we have not shown that LPXN expression is 
altered in the genotyped biopsies that display SNP homozygosity. This could be  addressed 
by qPCR and should be a priority for future SNP assessment using pIVOC on genotyped 
samples.  
However, our results suggest that the LPXN risk allele in the cells present within the 
mucosa, may lead to altered cytokine response in normal colonic mucosa, quiescent UC 
mucosa and inflamed UC mucosa. An interesting question that needs to be answered 
raised by the data from patients with the normal mucosa but the LPXN T/T alleles who 
clearly had a different cytokine response to those with the T/C alleles, yet they do not 
have UC – what are the additional factors that translate a genetic mutation to a disease? 
The presence of a single SNP alone does not do this. Identification of other pertinent SNPS 
within the biopsies, such as the ATG16L1 T300A needs to be undertaken given the known 
effect of the SNP on IL1beta expression. Consistent with this would be further work to 
identify the synergistic effect of multiple SNPs and environmental factors such as the 
response to bacterial products needs to be done.  The quiescent UC patients with the 
LPXN T/T allele had a consistently dampened pro inflammatory and NLRP3 cytokine 
response (IL-6, IL-8, IL-1b, IL-18), and even when flooded with bacterial ligand stimulation 
did not raise a cytokine response that approached the inflamed samples cytokine 
response.  An explanation for this may be that all the patients with UCQ had well 
controlled disease, with minimal immune cell infiltrate within the mucosa and therefore 
the cells that would usually be recruited in an inflammatory response e.g. granulocytes 
and lymphocytes were unable to be recruited in the ex vivo sample. However, I would 
have expected the UCQ samples to respond in a similar manner to the normal samples if 
the SNP was the only variable.  
To conclude; we hypothesised that LPXN over expression in cell lines would reduce wound 
healing and dampen the cytokine response to bacterial ligand stimulation. LPXN over 
expression reduced wound healing and reduced the secreted cytokine and chemokine 
response from the cells. Consistent with this, the UC susceptibility SNP rs10896794, when 
homozygous for the risk allele, produced dampened cytokine responses in UCQ samples. 
Given that the aim of this experimental work was to validate an in silico prediction, these 
findings add weight to the suggestion that the non-coding SNP rs10896794 may impact 
on the pathogenesis and ongoing inflammation found in UC, but does not show this 
conclusively. The data indicates that there are multiple factors working synergistically to 
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produce the dysregulated inflammatory response seen in UC, therefore, further work to 
outline and identify the role of synergistic SNP effects on individual patients has been 
undertaken and is outlined in the next chapter.  
The role of the focal adhesion complex in UC pathogenesis remains intriguing with 
increasing interest in the role integrins play in IBD pathogenesis (164) and treatment,  
further work to examine this complex signalling cascade and the cross signalling with the 
NLRP3 inflamasome may provide new avenues for therapeutic options in patients with 
SNPs affecting the FAC.  
With regard to pIVOC with UC biopsies, with undergraduate students and in collaboration 
with the Hall group (QIB), further work has been undertaken looking at the effect of 
adding protective microbiota species on cytokine responses in UC and cytokine responses 







Overarching aim:  
To identify patient-specific pathogenic pathways to disease from 
their genotype 
4.1 Acknowledgements	
Given the large and complex nature of the UC Interactome and creating 58 individual 
patient interactomes, automation of the SNP workflow was necessary. This was 
undertaken by employing a software engineer supported by a Norwich Research Park 
Translation Fund, and working with bioinformaticians including David Fazekas, and Dr 
Paddy Sudhakar, from the Korcsmaros group.  The workflow was called the integrative 
SNP network platform (iSNP). Analysis and clustering of the networks was undertaken 
with Dr Dezso Modos, a collaborator from Professor Bender’s Group, Cambridge 
University. 
I am grateful to the UK IBD Genetics Consortium for allowing me access to their expertise, 
and data repository and I am especially grateful to Jeff Barrett, Miles Parkes and Dan Rice.  
4.2 Introduction	
There are multiple clinical subphenotypes of UC e.g. proctitis vs pancolitis, with or without 
extra-intestinal manifestations; it can even be argued that those who ‘fail’ treatments also 
have a different phenotype to those who have ‘burnt out’ disease and require no further 
pharmacological or surgical input, with graduations in between.  Whilst GWAS has 
highlighted SNPs associated with UC, not every patient has every SNP as evidenced by the 
significantly variable minor allele frequency. 
One of the major goals of GWAS research is to identifying the pathogenic mechanism of 
the genetic predisposition with early research focussed on <10% of SNPs which occur in 
exonic regions and alter the amino acid structure of the translated protein. It is clear, 
however, that complex genetic diseases such as UC these SNPs, although theoretically 
interesting, do not confer the pathogenic effect that was expected (368). Moreover, the 
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individual SNPs identified do not explain the missing heritability of UC (369) suggesting 
that there is a further unidentified factor in the ‘genetic predisposition’. >90% of UC 
associated SNPs are non exonic SNPs, which include intronic, intergenic or regulatory 
region SNPs. Functional interpretation of non-coding SNPs can be challenging (43).  Non 
coding SNPs can occur in functional DNA elements including long non coding RNAs 
(lncRNAs) (370, 371), microRNAs (miRNAs) (371, 372), miRNA binding sites on mRNA 
(373), and transcription factor binding sites (374). These functional DNA elements have a 
unique role in controlling cellular regulatory cascades in a dynamic, complex and 
temporally mediated manner (375). It has been hypothesised that SNPs within regulatory 
elements can function to fine tune the regulation. Validated pipelines such as CAUSEL 
(376) are evidence of the difficulty of identifying causal phenotypic effects from individual 
non-coding polymorphisms on gene regulation. 
4.3 Hypothesis,	Aims	and	Objectives	
What hasn’t been clear is if there is a summative or combined effect of regulatory gene 
changes caused by the presence of SNPs. We hypothesised that using a network biology 
approach to functionally annotate SNPs we could identify not only key pathogenic 
pathways to disease, but by using individual patient SNP genotypes, identify a mechanism 
to stratify patients based on their genotype and clinical parameters.  
I further hypothesised that individual patient genotypes have an impact on or correlate 
with their phenotype. This is not without precedent, for example; individual SNPs 
associated with an increased risk of pancreatitis with Azathioprine use has already been 
identified as well as SNPs associated with IBD prognosis (343). However in-depth analysis 
of individual patient SNP profiles and biological mechanisms and pathways affected by 
the UC associated SNPs is lacking.  
To test the hypothesis that there is a correlation between SNP function, associated SNP 
burden and disease, individual patient SNP profiles have to be constructed from publically 
available SNP datasets.  
The aims for this project were twofold: 
1. Utilise the iSNP workflow to identify key pathogenic pathways to disease from 
individual patient data - their ‘footprint’; 
2. Correlate the patient footprint with their clinical data. 
In order to do this, three objectives were identified: 
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1. Create individual footprints based on genomic data; 
2. Undertake unsupervised clustering and gene ontology analysis of the clustering; 
3. Undertake supervised clustering to identify if particular clinical phenotypes 
correspond with the clusters. 
4.4 Methods	
We obtained 58 individual Immunochip (IC) data sets as part of the UK IBD Genetics 
consortium, corresponding to a cohort of Norwich based patients with confirmed 
endoscopic and histological diagnosis of UC, all of whom are under the care of IBD 
physicians at the Norfolk and Norwich University Hospital. Two were excluded as their 
diagnosis had changed from UC to CD since the original data collection. Each patient notes 
were reviewed by an IBD physician to document the clinical parameters of demographics, 
disease site, disease treatments, extending back 20 years or to time of diagnosis 
depending or whichever was sooner, documented side effects of IBD treatment, 
extraintestinal manifestations and comorbidities.  
We extracted each individual patient immunochip data set from the PLINK based format. 
Patient specific UC associated SNPs were identified against a combined list of IC UC 
associated (finemapped) SNPs, and UC associated finemapped (FM)SNPs.  We utilised all 
of the finemapped SNPs with the highest PIC values, enriched to the colonic mucosa or 
with no enrichment. We identified GWAS UC associated SNPs if the IC SNP to GWAS SNP 
R2 value was <0.8. If GWAS SNPs were included (p=<5E-7), we linked their highest scoring 
(R2 = 1) linkage disequilibrium partners (via HapMap and 1000genomes) with them to 
undergo analysis en bloc. If the IC and FM SNPs overlapped and were concordant, both 
SNPs were put forward for analysis. If there was discordance, then both SNPs went 
forward, but were linked and analysed together.  
The SNPs from the patient matrix then underwent the automated iSNP workflow. The 
methodology of the SNP workflow remained the same as in Chapter 2, except that it used 
the most up to date versions of each database with the highest stringencies and was 
automated. Splice alteration, lncRNAs and mature miRNAS were not used within the 
methodology due to the potential high false positive rates.  
To correlate the anonymised patient data with the demographic and clinical data 
regarding IBD treatment, smoking, surgery that had already been collected as part of the 
original data collection, I worked with Dr Mark Tremelling at the Norfolk and Norwich 
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University Hospital to correlate the anonymised labels with the patient data. This data 
was then updated by myself as a clinician and re-anonymised and re-encrypted. The 
patient identifiable data remained at the Norfolk and Norwich University Hospital on a 
password protected spreadsheet, on a password protected computer that was only 
accessible via an ID swipe in system by clinical staff.  
The Patient SNP matrix was input with the functional annotation and first neighbours into 
initially Excel and then Access to create an interaction matrix. The Hamming distance was 
calculated between each patient. Unsupervised clustering analysis was undertaken, 
creating Tree Clusters based on the Hamming distance and average summarization.  
Supervised clustering with clinical data based on disease site, severity, treatment and 
comorbidities on the unsupervised clusters was then undertaken. Statistical significance 
was assessed using the Fisher Exact Test, in Microsoft excel.  
Gene Enrichment and Pathway analysis was undertaken using the Panther Classification 
System (377). Each individual patient interaction matrix uniprot IDs were uploaded to the 
Pantherdb web service. Statistical overrepresentation was undertaken using GO Biological 
Process and Bonferroni correction, reference list Homo Sapiens, P<0.05 was considered 
significant. Functional classification was undertaken and list converted to a Panther 
Pathway List.   
The network was analysed to identify the top 75% commonest first neighbour to the SNPs 
to identify converging pathways.  Each converging pattern underwent GIANT analysis for 
cell type specificity and gene ontology.   





Figure 4-1 Overview of the Norwich cohort iSNP workflow from retrieval of the SNP data using PLINK (top 
left), through extraction of disease associated SNPs, identification of transcription factor or miRNA binding 
sites and first neighbour proteins to creation of the combined UC-ome with subsequent clustering and 






The summary demographics are in Table 4-1. The numbers requiring a thiopurine (e.g. 
azathioprine) was as expected, however we had very low numbers of patients requiring 
biologic therapy within the cohort. The disease extent in terms of Montreal classification 
was as expected (E1 – proctitis, E2 – left sided disease, E3 – pancolitis).  Of the 385 SNPs 
71 were represented in the IC Norwich cohort. The range of SNP burden was 19-41 (mean 
28.5, median 28, mode 28).  
 
 
Given the low impact of the ELM results had on the UC interactome in chapter 2, the 
patient UC interactomes focused on transcription factor binding and miRNA binding sites. 
From the complete group we found two transcription factor binding sites, and 34 miRNA 
binding sites, 5 were in long non coding RNAs, 1 in a miRNA. The constructed network 
with the OmniPath interactors had 247 protein and 1297 edges (Figure 4-2). The network 
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5ASA n= 58 (100%) 
5ASA only n = 30(52%) 
Azathioprine n=27 
(47%) 
6MP n= 5 (8%) 
Methotrexate n =5(8%) 
Tacrolimus n=1 (2%) 
IV Methylprednisolone 
n = 7 (12%) 
Infliximab n = 3(5%) 
Ciclosporin n =2 (3%) 





function tests n =4 
(7%) 
 
Alopecia n= 2 (3%) 




consisted of one giant cluster and 9 single interactors which were not associated with the 
giant cluster and were excluded from future analysis.  The giant network contained two 
large hubs with the highest degrees of centrality; NFKB1 and PRKCB. These hubs, not 
unsurprisingly formed the two large modules within the giant cluster. There were also 18 
further SNP affected proteins that formed smaller modules within the giant cluster 
(Figure 4-3).  
 
 
Figure 4-2 Diagramatic representation of the Norwich Patient Cohort UC interactome created from integrating 
each patients annotated SNP burden with Omnipath.   The annotation of the SNPs focused on SNPs affecting 
transcription factor binding sites and miRNA binding sites. The diagram shows the SNPs as red boxes linked to 
the protein that they affect – such as NFKB1 highlighted by the red arrow. It also highlights the transcription 
factor targets and protein-protein interactions of the SNP affected proteins (green and grey lines respectively). 
There is clearly one large network (Giant cluster) and 9 SNPs which have no interaction with the larger 






Figure 4-3 Modularisation of the Norwich Cohort UC interactome Giant cluster using a patient example. 
Using modularisation techniques, the giant cluster was separated into different modules, each important to 
the network. There were two large modules, NFKB1 and PRKCB and multiple smaller modules within the 
giant cluster. The smaller modules comprised connecting nodes to the two large modules. In this patient 
example, the yellow colouring denotes the parts of the network the patient has, therefore they are PRKCB+ 
NFKB1- but contain many of the connecting nodes to NFKB1. As before, the squares are the SNPs, the circles 








Unsupervised clustering based on the Hamming distance between each patient 
dependant on their SNP burden identified that there were four distinct clusters or 
‘footprints’ of patients (Figure 4-4). Cluster 1 encompassed both large modules of the 
giant cluster; NFKB1 and PRKCB with their binding targets (n=22).  One patient was later 
excluded as they had a diagnosis of CD on the most recent histology. Cluster 2 was based 
around the NFKB1 node and binding targets (n=13). Cluster 3 was based around the 
NFKB1 and PRKCB binding targets and smaller modules, but not the major nodes 





Figure 4-4 Unsupervised clustering based upon the Hamming distance between patients. Hamming distance 
calculates how similar each string of information – in this case the SNPs and first neighbours in one patient is 
to the next string of information (SNPs and first neighbours) to the next patient. With the patients, there 





Figure 4-5 Patient network examples of Clusters A(1), B (2), C (3), and D(4), where yellow colouration 
identifies the nodes each particular patient has from within the interactome. Cluster 1 (A) is the 








Outside of the two large modules of NFKB1 and PRKCB, the clusters differed significantly 
with regard to the presence of SNPs affecting HDAC7, ZGPAT, C5orf66, MAML2 and 
DNMT3B with each cluster. In the Chi squared testing of % individual patients with 
individual proteins in their networks, Cluster 1 and 2, not unsurprisingly looked 
statistically similar for all proteins, except for ZGPAT, MAML2 and DMNT3B. Cluster 3 did 
not statistically differ from Cluster 1 in terms of non NFKB1 or PRKCB proteins, except for 
ZGPAT which appeared under-represented in cluster 1 (essentially Cluster 3 looked like 
Cluster 1 without the NFKB1 and PRKCB nodes). Cluster 4 (PRKCB node) and Cluster 2 
(NFKB1) differed the most significantly in terms of non-major node SNP involvement 
withDNMT3B and HDAC7 being under-represented in Cluster 2 and C5orf66 being over 






Figure 4-6 Percentage of patients within each cluster with SNPs in specific proteins crucial to the network. 
There are 2 NFKB1 SNPs. Nonewithstanding the NFKB1-PRKCB status of the clusters, other SNPs such as 
HDAC7, ZGPAT, C5ORF66, MAML2 and DNM3TB also significantly differ between cohort.s Only significant 






























































































The clusters are partly a function of the SNP volume of the patients; patients within 
clusters 1 or 2 (NFKB1 containing) had significantly more SNPs and therefore interaction 
partners than patients within clusters 3 or 4, due to the large number of targets of NFKB1 
and PRKCB. Cluster 3 contained the least number of SNPs and interacting proteins 
indicating there may be a minimum SNP burden to get the disease ( 
Figure 4-7). The majority of cluster 3 patients had a SNP in HDAC7 (86%), and/or ZNF831 
(62%) or CCNY (56%). 
Given the significant difference in SNP burden, further analysis of the unsupervised 
cluster was required in terms of gene ontology and pathway analysis, as well as a more 
in-depth analysis of the commonest convergent binding targets for each of the clusters. 
 
 
Figure 4-7 Box-Whisker plot showing the number of SNPs (hits) per cluster, identifying that clusters 1 and 2 












Gene ontology and Pathway enrichment analysis using Panther (377) identified 61 
commonly occurring significant pathways across all four clusters), with the apoptosis 
pathway featuring in all but 2 patients (Table 4.2). There is considerable commonality 
between the most frequently affected pathway enrichments between the clusters. 
Cluster 4 pathways predictably could be subsumed into cluster 1, however the frequency 
with which each pathway occurs within the clusters are subtly different as seen with 
analysis of the top ten pathways for each cluster (Figure 4.8). This highlights that although 




Table 4-2 Panther outputs for gene ontology for each cluster and the percentage of patients containing 






Table 4-3 Continued; Panther outputs for gene ontology for each cluster and the percentage of patients 








Figure 4-8 Diagram of the top 10 enriched gene ontology pathways across the clusters with an indicator of 
prevalence of each pathway within the cluster given by arrow thickness highlighting the commonality between 




The top ten pathways across all 4 clusters highlighted a total of 18 pathogenic pathways. 
These pathways have components identified as being involved in the aetiology of colitis 
– either mouse models or in human studies, but not necessarily from a genetic 
perspective as shown in the table below (Table 4-3).  
 
Table 4-4 Pathways identified by Panther from UC patients' clusters, with current literature references to their 
involvement in colitis. 
This gives confidence to the genetic underpinning we are trying to identify in UC, 











Gene ontology identified significant overlap between the clusters in terms of pathogenic 
pathways. To explore this further and identify SNP epistasis and convergent protein-
protein interactions within the first neighbours, we examined the top 66% commonest 
affected first neighbours.  The SNPs affected proteins (e.g. proteins whose regulation has 
been putatively affected by a SNP) that led to the convergent first neighbours within our 
cohort were NFKB1, PRKCB, IRF5, HDAC7, NR5A2, LSP1, CCNY, RGS14, GNA12 and ZGPAT. 
Analysing these against their minor allele frequency (Table 4-5), there was a wide variety 
of expected frequencies from 31% to 88%, with most below 50% highlighting the 
importance of the convergence of effects.  
Globally, these 10 SNP affected proteins had between 1 and 20 protein-protein 
interactions with 24 first neighbour proteins (Figure 4-8). These first neighbour proteins 
were chosen from the highest frequency of cross-hits with other SNP affected proteins, 
therefore each first neighbour protein had ³2 SNP affected proteins.  Figure 4-9 highlights 
the convergent first neighbours in the context of the unsupervised clusters.  Cluster 3 did 
not have any first neighbours with >2 hits, indicating a different mechanism of disease. 
Cluster 1 and 2 look very similar given the significant impact NFKB1 has on the network.  
 IC SNP Fine mapped 
SNP 
IC MAF Finemapped 
MAF 
LSP1 rs11041476 rs907611 NA 0.318 
NFKB1  rs1598859 rs3774959 NA 0.332 
NFKB1  rs3774937 rs3774959 0.332 0.332 
PRKCB1 rs7404095 NA 0.576 NA 
IRF5 rs4728142 NA 0.437 NA 
HDAC7 rs11168249 NA 0.461 NA 
CCNY NA rs12261843 NA 0.374 
RGS14 NA rs4976646 NA 0.404 
GNA12 rs1182188 rs798502 NA 0.7 
ZGPAT rs6062504 NA 0.702 NA 
NR5A2 rs2816958 NA 0.887 NA 
Table 4-5 Commonest SNP affected proteins in the Norwich UC cohort. Highlighted in yellow are the 
corresponding SNPs that appeared on Immunochip (IC) and in the patient cohort. Blue highlights indicate a 
finemapped SNP on Immunochip that was not in the Norwich cohort. Italics denote a minor allele frequency 
for the risk allele obtained from 1000 genomes, as the SNP was a finemapped UC SNP from the Broad Institute 






Figure 4-9 Diagram highlighting the 10 commonest SNPs in the entire Norwich UC cohort with their 
convergent binding partners. The size of the square denotes the commonality, blue outlines indicate a first 








To identify the role of the convergent proteins within the network, to further examine 
and test the hypothesis that there is a role of synergism between the SNPs that creates a 
SNP burden greater than the sum of the individual SNPs themselves, we undertook an 
enrichment analysis of the SNP affected proteins and convergent proteins in GIANT. In 
order to focus on the convergent proteins within the clusters, each patient footprint from 
within the cluster underwent subgroup analysis to identify if there were differences 
within the clusters which would bias or sway cluster-wide GIANT analysis.  Cluster 3 was 
excluded from this analysis as it did not have convergent nodes. An example subgroup 
within clusters can be seen in Cluster 1, which has networks which contain NFKB1 and 
PRCKB hub nodes, but within the cluster are patients who have IRF5 SNPs and those who 
do not.  This makes a significant difference to pathway enrichment as can be seen in 
comparing Table 4-6 with Table 4-7 .  
The enrichment was undertaken across 4 tissue/cell types: B lymphocytes, Colon, 
Dendritic cells and T lymphocytes. The tables (4-6 to 4-11) indicate the significance of 
each pathway from the patient gene set within each cell or tissue type.  Of note, 
regardless of the cell types, intracellular infections (viral infections, Toxoplasmosis, 
Legionellosis, TB, Leishmaniasis, Pertussis) featured in all the pathway enrichments 
(p=1.07E-11 to p=0.01). The pathways with the lower (but still significant) pathway 
enrichments came from smaller networks e.g. IW3134619: HDAC7, NFKB1, PRKCB and 
their first neighbours.  Also enriched were pathways involved with receptor signalling 
associated with extracellular infective ligand signalling, adaptive, and innate immune 
system processes, the NFKB1 pathway, STAT4 regulation, cancer processes. Interestingly, 
when NFKB1 was not present (Cluster 4), cellular processes such as Hippo signalling, TGF 
beta signalling, cell development, apoptosis and cellular junctions rose to the fore. There 
was no specific cell type of those tested that consistently showed the most significant 




















































































































































































































































































































Table 4-9 GIANT Enrichment analysis of Cluster 2: Patient example from HDAC7, IRF5, GNA12 and NFKB1 
































































































Table 4-10 GIANT Enrichment analysis of Cluster 4: Patient example from LSP1, HDAC7, CCNY and PRKCB 












































































Table 4-11 GIANT Enrichment analysis of Cluster 4: Patient example from HDAC7, GNA12, IRF5, PRKCB and 











































































Broadly  B cells, T cells, dendritic cells, neutrophils, macrophages and enterocytes have 
all been implicated in the pathogenesis of UC. It is unclear whether UC is specifically T cell 
driven, or as is more likely, multiple cell types involved with the pathogenesis of UC with 
SNPs have slightly different phenotypic effects depending on their cell type (as seen 
above). To identify the key cell players, a weight needs to be applied to the strength of 
the protein-protein interaction within specific cell types. This was undertaken using 
GIANT, and conditional formatting applied to identify high strength interactions. There 







The clusters were not significantly different with regard to severity of disease by 5 years 
or 10 years of diagnosis (e.g. requirement of thiopurines or above), nor site of disease. 
Some patients were excluded from the 10-year analysis as they had not yet reached this 
time point, reducing the sensitivity of the analysis further due to low numbers. The 
numbers were also too small to analyse for genomic effects on extra-intestinal 
manifestations. There was significant gender disparity between the groups with NFKB1 
hub disease being a disease predominately of males.  
We could however show that the clusters were significantly different in terms of the age 
the patients were diagnosed in ach cluster (Figure 4-10, with cluster 2 (NFKB1 
Predominant disease) being the youngest cohort by age of diagnosis, and cluster 3 
containing some of the eldest patients to be diagnosed of the cohort.  
If this was due to a critical mass of pathways affected, cluster 1 patients should have 
manifested the disease earlier, having the largest SNP burden, highlighting the potential 
importance of an environmental trigger within the cohort and the complexity of 
delineating phenotype from SNP interactions. The need for a further trigger is also 
suggested by cluster 3 having the lowest SNP burden in terms of convergent proteins. It 
could be hypothesised that an environmental trigger or other pathological pathway needs 
to be activated to develop the disease. This is a plausible conclusion as it was observed 
that the SNP in MAML2 was identified as being associated with severe disease in non- 
Figure 4-10 Age at manifestation of the disease across the clusters (footprints). Green is cluster 1, red is 




NFKB1 containing cohorts (cohorts 3 and 4, p=0.0001 via Fishers Exact test). The SNP in 
MAML2 is annotated to cause an increase in MAML2 expression. MAMAL2 is known to 
activate the Notch Receptor, thereby increasing NOTCH1 activation, which as part of the 
downstream effects, regulates the cell cycle and cellular proliferation. It also actives the 
inhibitor of the NFKB inhibitor (the IKK complex consisting of IKKB, IKKA and NEMO), 
which phosphorylates the inhibitor of NFKB (IkB) leading to a translocation of NFKB1 from 
the cytosol to the nucleus where it is transcriptionally active (Figure 4-11), as well as being 
a transcriptional activator of NFKB1.  
 
Figure 4-11 The NFKB1-MAML2 interaction. Diagram showing the interaction and convergence between UC 
associated SNP affected genes and the NFKB1 pathway. cNFKB1 = cytoplasmic NFKB1, nNFKB1 = nuclear 
NFKB1. All 5 SNPs are annotated to lead to an increase in NFKB1. 
This indicates that even without direct NFBK1 involvement via a SNP, these MAML2 
patients are activating the NFKB1 Pathway and this associated with more severe disease. 
The indicator of severity did not hold true for the MAML2 containing patients in cohort 1 
and 2, indicating that this pathway is only part of the pathogenesis, but warrants further 
























































Using patient specific data, we have shown that broadly, UC patients have different SNP 
burdens and different SNP convergence pathways, with the global effect on well 
documented pathways including pathogen handling and downstream immune response, 
cellular proliferation and apoptosis.  We have documented how the putative SNP effects 
on gene regulation can have a convergent effect on downstream pathways specifically 
the NFKB1 pathway. We have observed that this convergence, albeit in a small cohort, 
does not show cell specificity, but appears to be present in all cell types that were 
analysed, pertinent to UC. 
Our findings highlight the importance of other environmental factors that lead to the 
development of UC. The pathway enrichment indicates that this could be of viral, 
bacterial or parasite aetiology as all of these pathways were enriched. This is consistent 
with the current literature, showing that the tripartite of the epithelial barrier, the 
immune system and the human microbiota all have significant roles to play in the 
development of inflammatory bowel disease (378-380). Elucidating role of the virome in 
IBD is still in its infancy, however alteration in bacteriophage communities has been 
shown in IBD patients (139).  Our research indicates that viral handling of DNA and RNA 
viruses (specifically herpes simplex, influenza virus, measles virus and hepatitis C) may 
play a role in the pathogenesis in IBD. Epidemiological evidence suggested a role for 
persistent measles virus infection in CD, but no causal role for measles virus in IBD has 
been found(381-383). No causal role for influenza virus or hepatitis C virus has been found 
for IBD. Herpes simplex virus can cause colitis, but is usually a superinfection in an 
immunocompromised host(384, 385). One potential role for these viruses in IBD 
pathogenesis is via the common denominator that these viruses all have the capacity to 
infect dendritic cells (DC) and modulate the inflammatory response via IL12 to alter 
dendritic cell ability to stimulate T cells (386-393).  Hepatitis C, measles virus, influenza 
virus and herpes simplex all utilise an adhesion molecule called dendritic cell-specific 
intercellular adhesion molecule-3 Grabbing Non –integrin (DC-SIGN) (394-400). DC-SIGN 
is present on intestinal epithelial cells and epithelial cells with expression of DC-SIGN of 
can induce and control T cell differentiation and proliferation.  DC-SIGN expression was 
strongly correlated with disease severity in children with IBD (401). The role of viruses 
(both human specific and bacteriophage) in the pathogenesis of UC, is an area that 





Notch signalling (via the non-canonical pathway) is known to interact with multiple 
inflammatory responses including NFKB, hypoxia, epithelial-to-mesenchymal transition 
(involving TGF-beta), the Wnt signalling pathway and the mitogen activated protein 
kinase  (402).  TGF beta featured significantly in the pathway enrichment for cluster 4, but 
not clusters 1 or 2. Cluster 3 in the global gene ontology featured Wnt signalling as did 
cluster 2.  Within the intestinal mucosa, Notch activation is necessary for epithelial 
regeneration after an inflammatory injury when there is depletion of goblet cells (403). 
Conversely it decreases goblet cell number in response in MMP9 and p-ERK signalling in 
response to upregulation of Claudin 1, a structural protein of the tight junction which gets 
upregulated in an inflammatory state (404). We know from Chapter 2 that tight junction 
regulation is a key feature of the function of the UC associated SNPs.  
This is not the only pathway NOTCH impacts on from within the UC-ome; Notch has cell 
specific effects, for example, in macrophages NOTCH1 activation leads to the 
development of the inflammatory M1 phenotype (405, 406), and NOTCH1 deficiency has 
been shown to regulate the VEGF receptor and therefore downstream VEGF signalling 
(407), as well as inflammatory cytokine expression from macrophages including IL6 and 
IL12 (408). The VEGF pathway is a significant component of the pathways enrichment of 
both cluster 1 and 2. IL12 is impacted directly by SNPs in the UC-regulome, as well as the 
cytokine response and regulation in the pathway enrichment for clusters 1 and 2. In this 
way the Notch pathway is impacted in all 4 clusters.  
Notch signalling is required for intestinal epithelial homeostasis(409) and goblet cell 
number .  Goblet cell depletion is seen in UC (410) with overexpression of the Notch 
intracellular domain leading to depletion of secretory cells in intestinal crypt (411).  Notch 
impacts on mucosal immune function by regulating the production of cytokines that 
bridge the innate and adaptive immunity in the gut (412). It is plausible that Notch can 
therefore contribute to the development or maintenance of the mucosal inflammation 
that characterises UC by modulating mucosal immune function and controlling physical 








This was the first test of iSNP and larger cohorts are needed to utilise it to its full potential. 
We used the iSNP workflow to create individual footprints for each patient based on their 
genomic data and identify key pathogenic pathways to disease from that individual 
patient data including highlighting a potential role of intracellular pathogens in the 
aetiology of UC.  Using unsupervised, enrichment analysis of the data we have confirmed 
the role of the NFKB1 pathway, as well as identifying the Notch pathway as warranting 
further investigation for the cohort of patients who have the MAML2 SNP, and also as a 
pathogenic pathway to disease. This has been done and forms the basis of Brooks et al 
Systems genomics of UC: An integrative network analysis reveals the Notch pathway as a 
hidden player in disease pathogenesis under review. 
We have also added weight to the literature on multiple other pathways previously 
proposed as pathogenic including VEGF and PDGF pathways. We have begun to see how 
this method can be used to correlate the patient footprint with their clinical data, 










The focus of this PhD was to increase the understanding of the pathogenic pathways that 
underpin UC using a combination of systems biology, in vitro and ex vivo techniques. To 
encompass the above, the first part of this thesis explored the bioinformatics and network 
biology techniques used to annotate the function of UC and IBD associated risk alleles 
and identified their role within a larger interactome. This allowed stratification of a SNP 
for experimental validation using both in vitro molecular biology techniques and ex vivo 
organ culture, which was highlighted in the central portion of the thesis. The final section 
of this thesis utilised the bioinformatics techniques honed in chapter 2 to identify patient 
specific UC networks, cluster patients together based on their genetics and to identify the 
convergence of SNP effects, elucidating the different pathogenic pathways to disease 
based on a patient’s genetic landscape.  This chapter summarises the findings from these 
studies, their impact in a wider field, and future directions of work.  
Previously, GWAS and functional analysis of risk associated SNPs have looked for the 
identification of causal SNPs, with fine mapping, deep sequencing, and annotation of 
SNPs from within transcription factor binding sites or microRNA binding sites but very few 
have been ascribed to a definite causal variant with clear insight into the underlying 
disease pathogenesis. SNP epistasis has also been explored, identifying SNPs that affect 
interleukin production as working in concert. However, the hypothesis free global 
examination of multiple SNP functions with downstream protein-protein interactions has 
not been undertaken. As a result, the understanding of how SNPs may work in concert to 
drive pathogenesis is still poorly understood. In our study, the extensive, but exhaustive, 
functional annotation of SNPs utilising multiple validated techniques allowed us to create 
a UC interactome which could then be probed for pathogenic pathways, both novel and 
hypothesis driven.  
Overall, the UC interactome identified UC to be a disease of regulation with a significant 
number of SNPs annotated to be in splicing sites, miRNA binding sites in genes and long 
non-coding RNAs or TFBS. This is not surprising as >90% SNPs are present in non-coding 
regions that would represent sites of regulation. The identification of TFBS motifs is in 
accordance with previous studies which have identified transcription factor motif 
disruption in RTEL1/TNFRSF6B confirmed with epigenetic peaks (43). Whilst other studies 
utilise epigenetic peaks to confirm, we utilised enhancer regions to confirm the validity 




binding sites sequences for transcription factors which show the histone modifications 
that are identified in epigenetic peaks (413).  
The simplicity of using nucleotide complementarity to identify mRNA targets gives rise to 
bioinformatics tools which are based on complementarity to the seed, evolutionary 
conservation and free energy binding. The best algorithms have false positive rates of 20-
40%. Using the most stringent measures, we identified 107 miRNA binding sites from 56 
SNPs.  Creation and loss of miRNA binding sites by SNPs has been identified and validated 
previously (414, 415) at 3’UTR sites, but we also identified further sites in introns. These 
have been previously identified as imperfect centred, non-seed site, binding sites that 
mediate repression of target mRNAs and have been validated as genuine binding sites 
(416).  
We also showed that a significant number of SNPs were found in splicing sites. Validating 
splicing site mutations using in vitro experiments is costly and time consuming and may 
not be practical, however in silico prediction methods are regarded as essential for 
analysing these variants (417). We utilized 3 validated mechanisms for splice enhancing 
sites (418), but were limited in splice enhancing sites. There was also no way to predict 
the phenotypic effect of the individual splicing sites. Splicing mutations they cause highly 
penetrant Mendelian diseases such as a SNP in HMBS causes exon skipping leading to 
acute intermittent porphyria, is an example at the severe end of a spectrum of functional 
variants that produce a gradation of phenotypic effects. We aimed to elucidate the 
potentially mild phenotype of the significant number of exon and intron splicing sites 
using network biology. The genes affected by splicing sites were first neighbours of 
regulators within the tight junction network, the autophagy network and the apoptosis 
network, and were first neighbours of regulatory proteins, or regulatory 
kinases/phosphatases within the focal adhesion network.  
Unlike other studies using in silico methods, we did not find many deleterious effects of 
missense SNPs. This fits with UC being a disease of regulation, but it is at odds with the 
paradigm of missense mutations playing major roles in diseases such as cancer (419). it 
does fit with the concept that each risk associated locus only makes a small contribution 
to the disease phenotype, therefore subtle effects at a protein level can still be 
deleterious. ELM is a method, which utilises peptide motifs, but makes no assignation to 




motifs, which would otherwise be missed by high impact assessments such as Polyphen, 
SNPs3D or SNPeff.  
Consistent with the current GWAS literature, pathway analysis of the UC interactome 
indicated host-microbe interactions as a key global pathway (53, 171)but this is to be 
expected, as we are using the same proteins as was examined in these prior papers. What 
we have added with this section of the data is the potential key pathways and signalling 
cascades within host microbe interactions, that are regulated by multiple SNPs e.g. the 
tight junctions, autophagy and the focal adhesion complex. We have also identified, that 
unlike other functional annotation studies, when multiple modalities are examined there 
are hub SNPs that have multiple avenues of deleterious effect e.g. TFBS, MiRNA BS and 
splicing site alterations, which can have multiple impacts from gene expression, mRNA 
processing and mRNA repression depending on the dynamics of the cellular environment. 
This has to be taken in the context of wider IBD. There is a pathogenic overlap between 
CD and UC and by utilising IBD SNPs to create the UC interactome, we may have further 
illustrated the overlap. Future work, therefore analysing an equivalent CD cohort and 
comparing it against the UC cohort would both confirm the overlapping and highlight CD 
and UC specific pathways.  
Using these networks, we were able to stratify a SNP for validation, a putative TFBS SNP 
in LPXN. This was, by necessity, hypothesis based and was influenced by the available 
resources to experimentally validate said SNP.  There are validated pipelines for 
establishing the function of non-coding GWAS variants by fine mapping, epigenomic 
profiling, epigenome editing and then creating of isogenic cell lines for phenotypic 
characterisation (376), however we took a slightly different route. Utilising CRISPR-Cas9 
we created leupaxin knock out and over expression epithelial cell lines. This technique 
has been successfully utilised elsewhere to identify and validate regulatory SNPs in 
prostate cancer (420) and for identification and validation of drug resistant mutations in 
mammalian cells (421). Whilst we were not able to create a SNP cell line, we were able to 
show that LPXN overexpression in cell lines impairs wound healing and modulates 
cytokine response via an integrin mediated and TLR mediated effect. This has not been 
shown in epithelial cells before. We then went on to identify that the presence of the 
LPXN risk allele homozygosity may alterscolonic biopsy cytokine response to mechanical 
stress in the polarised in vitro organ culture system, as well as in response to bacterial 




required due to the presence of a mucus layer.  Further work looking at the response to 
TLR3 ligands such as Poly(I:C) or other PRR ligands and inflammasome inducers would 
elucidate the role of LPXN in the colonic mucosa further.  Given the data of SNPs working 
in concert, analysis of the several SNPs that affect the focal adhesion complex, in the 
pIVOC system would be advantageous to confirm this cumulative effect leading to a 
stronger phenotype. This however would require a significantly larger study, with both 
controls and UC patients. The focal adhesion complex provides a wealth of biomarkers 
for the oncology field (422), further work is needed to identify its role in the pathogenesis 
of inflammatory diseases such as UC, and thereby identifying potential biomarkers of 
disease progression, or treatment response. 
To extend this work further, we showed that it was possible to identify and visualize 
patient specific genetic footprints, and consistent with the literature have shown that it 
is the first neighbours (423), the protein-protein interactions who are hidden players in 
the disease pathogenesis. We have identified MAML2 as a potential severity marker in 
patients who don’t have UC associated NFKB1 SNPs, which via the Notch pathway can 
activate NFKB1. This work would benefit from validation in a larger patient cohort, which 
has been undertaken.  The work has also shown that despite the thousands on dynamic 
interactions that occur within a cell at any one time, the seemingly disparate SNP affected 
proteins converge on key regulatory proteins, some of which, like NFKB1, IL10, IL12a and 
IL23 are well known and explored, others such as the IRF family, RIPK2 require more work 
to characterise their role in UC. By clustering the patients based on their genetics, we 
have identified, in a small cohort, the minimum SNP burden and genetic footprint that 
leads to UC as shown in Cluster 3. 
We have also clearly shown that viral handling is a pervasive, significant theme from the 
gene enrichment across the entire patient cohort. Work recently published has identified 
Epstein Barr Virus as present within the colonic mucosa of UC patients, irrespective of 
their disease severity or treatment course(143). Further work identifying the mechanism 
of host genetics-virus interaction would be beneficial to understand this aspect of the 
disease instigation. 
This work would benefit from larger cohort studies, as the numbers were not large 
enough to make any significant contribution to identifying prognostic indicators or 
markers of disease severity, this is currently being undertaken. Nor was it large enough 




from large control cohorts to confirm that the pathways identified are valid and not just 
a function of the method used.  
This work is novel as it attempts to take a global overview of complex GWAS data and 
place the SNPS into a physiological, dynamic system in an attempt to explain genetic 
susceptibility, explain inter-person variability of disease processes and identify hidden 
players in the pathogenesis of UC that could be used for either biomarker identification 
or drug targeted/repurposing. From a pathogenesis perspective, the systems biology 
approach has provided a wealth of potential hypothesis driven avenues to pursue from 
the role of non enteropathogenic viruses such as EBV in the instigation of UC, the role of 
the focal adhesion complex in UC, to the role of the SNPS in colitis associated cancer. 
From a personalised medicine perspective, the ability to create individual patient’s 
genetic footprints opens the way for individualised drug targeting and disease 
modulation.  The approach has identified the importance of combining multiple 
modalities, to gain a clearer, yet more complex overview of the genetic landscape of 
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Ensembl (https://www.ensembl.org) Genome Database of the genome sequence  
for vertebrates of the genome sequence.  
dbSNP (ncbi.nlm.nih.gov) Free public archive/database of Single Nucleotide 
Polymorphisms hosted by the National Center for Biotechnology Information (NCBI) in 
collaboration with the National Human Genome Research Institute (NHGRI) 
JASPAR  largest open-access database of curated and non-redundant transcription 
factor binding profiles. The JASPAR core  database contains curated, nonredundant set 
of profiles, derived from published collections of experimentally defined transcription 
factor binding sites for eukaryotes.  
miRBASE archive of microRNA sequences and annotations. It is a primary repository for 
published microRNA sequence and annotation database. 
TARBASE v7.0  DIANA-TarBase v7.0 (http://diana.imis.athena-
innovation.gr/DianaTools/index.php?r=tarbase/index) Database of published 
experimentally validated miRNA:gene interactions.  
MiRANDA Target prediction software to identify potential microRNA target sites in 
genomic sequences.  
ELM (elm.eu.org) computational biology resource for annotation and detection of 
eukaryotic linear motifs 
Omnipath (omnipathdb.org) a comprehensive collection of literature curated human 
signalling pathways.  
ASSP (wangcomputing.com/assp/) sequence analysis tool for the prediction and 
classification of splice sites.  It predicts putative alternative exon isoform, cryptic and 
constitutive splice sites of internal (coding) exons. Non canonical splice sites are not 
detected.  
MES (gene.mit.edu/burgelab/maxent/Xmaxentsca_scoreseq.html) MaxEntScan is  




HSF (www.umd.be/HSF/) tool for calculating consensus values of potential splice sites 
Cytoscape (www.cytoscape.org) open source bioinformatics software platform for 
visualizing molecular interaction networks and integrating with gene expression profiles 
and other state data.  
Uniprot (www.uniprot.org) The Universal Protein Resource; comprehensive resource for 
protein sequence and annotation data.  
STRING (string-db.org) database of known and predicted protein-protein interactions. 
Ween organisms and interactions aggregated from other primary databases. The 
interactions include direct and indirect associations. The data comes from 
computational prediction, knowledge transfer between organisms and fro interactions 
aggregated from other databases.  
CHESEL Curated hexamer exonic splice enhancing ligands – the motifs curated and 
collated by De Haerty, Earlham Institute.  
FASTA  a suite of programs for searching nucleotide or protein databases with a query 
sequence. It performs a heuristic search of a protein or nucleotide database for a query 
of the same type.  
MirSVR a predicted target site scoring method. Allows for comprehensive modelling of 
miRNA target predicting functional non-conserved and non-canonical sites.  
ORegAnno (www.oreganno.org) The Open Regulatory Annotation database. Curated 
database of regulatory regions, transcription factor binding sites, regulatory variants 
and haplotypes.  
GeneCards  (www.genecards.org) searchable, integrated, database of human genes that 
provides concise genomic related information on all known and predicted human genes.  
UCSC Genome Browser (https://genome.ucsc.edu/) on-line genome browser hosted by 
the university of California, Santa Cruz. Allows access to genome sequence data 
integrated with a large collection of aligned annotations.  
Adhesome (adhesome.org) Literature based protein-protein interaction network that 
was developed from the biomedical literature of known interactions and cellular 








This appendix contains all the UC and IBD SNPs used to create the UC Interactome as 
described in Chapter 2.  This appendix also contains all the UC and IBD SNPs used to create 
the UC Interactome as described in Chapter 4.  These SNPs were identified from the 
original SNPs used in Chapter 2 that were present in the Norwich Patient cohort and are 
highlighted in yellow throughout the tables. 
The tables detail the risk allele used, the source of the SNP e.g. immunochip, broad 
institute fine mapping.  If the Broad institute data was used their PICS value was 
identified, or p-value if immunochip data was used. Tissue enhancers were identified if 
available. The SNP site annotation, gene name and Ensembl ID are included if relevant. 
The acronyms used in this appendix are as follows: 
Reverse strand rev 
Forward strand fwd 
Not applicable NA 
Immunochip data UC associated ICUC 
Sanger GWAS data UC associated  UCS 
Immunochip data IBD associated  ICIBD 
Sanger GWAS data IBD associated  IBDS 
Broad Institute UC finemapped index SNP BII 
Broad Institute UC finemapped SNP BIFM 
T helper 1 Cells Th1 
T helper 2 Cells Th2 
 
Please note that the Broad Institute index SNPs that are not identified on Immunochip or 
the Sanger GWAS data were identified from those enhancing to the colonic mucosa or 
non- enhancing.  The Broad institute finemapped SNPs were taken from the entire UC 
associated cohort if there was not a SNP within the subset of Broad Institute Index SNPs 










allele Source PICS P value SNP if FM Enhancer Annotation SNP/ID Gene Ensembl ID 
rs1182188 rev T C ICUC NA 1.23E-09 rs798502   intronic GNA12 ENSG00000146535 
rs1654644 fwd G T ICUC NA 6.05E-11 rs11672983   intronic KIR3DL2 ENSG00000240403 
rs3774937 fwd A G ICUC NA 2.23E-09 rs3774959   intronic NFKB1 ENSG00000109320 
rs3774959 fwd A G UCS BII BIFM 0.0664 NA rs3774959 Th1 intronic NFKB1 ENSG00000109320 
rs2816958 rev G A 
UCS ICUC BII  
BIFM 0.4543 1.98E-17 rs2816958 none intronic NR5A2 ENSG00000116833 
rs254560 rev A G 
UCS ICUC BII  
BIFM 0.3469 2.55E-09 rs254560 None intronic C5orf66 ENSG00000224186 
rs17229285 fwd C T 
UCS ICUC BII  
BIFM 0.2125 1.73E-18 rs17229285 none intronic lincRNA ENSG00000225421 
rs11168249 fwd C T IBDS ICUC NA 7.78E-09 rs11168249   intronic HDAC7 ENSG00000061273 
rs4743820 fwd T C IBDS ICUC  NA 3.60E-09 rs4743820   intronic lincRNA ENSG00000229694 
rs7134599 fwd A G 
IBDS ICUC 
BIFM BII 0.0503 8.51E-32 rs7134599 None intronic IFNG-AS1 ENSG00000255733 
rs6920220 fwd A G 
IBDS ICUC 
BIFM BII 0.2286 1.40E-21 rs6920220 none intronic lincRNA ENSG00000230533 
rs941823 rev C T 
IBDS ICUC 
BII BIFM 0.2447 2.95E-11 rs941823 colonic mucosa intronic lincRNA ENSG00000215483 
rs79755370 fwd A C BIFM 0.1769 NA rs11209026 none intronic IL23R ENSG00000162594 
rs11581607 fwd A G BIFM 0.1769 NA rs11209026 none intronic IL23R ENSG00000162594 
rs113935720 fwd C T BIFM 0.1769 NA rs11209026 none intronic IL23R ENSG00000162594 







SNP/ID Strand Risk Allele WT allele Source PICS P value SNP if FM Enhancer Annotation SNP/ID Gene Ensembl ID 
rs12261843 fwd G T BII BIFM 0.1173 NA rs12261843 none intronic CCNY ENSG00000108100 
rs6481950 fwd T C BIFM 0.1173 NA rs12261843 none intronic CCNY ENSG00000108100 
rs12254167 fwd G C BIFM 0.1173 NA rs12261843 none intronic CCNY ENSG00000108100 
rs1297265 fwd A G BII BIFM 0.1531 NA rs1297265 HEpG2 intronic lincRNA ENSG00000229425 
rs4657041 fwd C T BIFM 0.444 NA rs1801274   intronic FCGR2A ENSG00000143226 
rs254562 rev C T BIFM 0.1447 NA rs254560-A none intronic C5orf66 ENSG00000224186 
rs267939 rev C G BII BIFM 0.1752 NA rs267939 none intronic DAP ENSG00000112977 
rs267984 rev A T BIFM 0.0303 NA rs267939 none intronic DAP ENSG00000112977 
rs28671712 fwd A G BIFM 0.1403 NA rs28374715 none intronic CHP1 ENSG00000187446 
rs3024495 rev A G BIFM 0.4133 NA rs3024505 Th2 intronic IL10 ENSG00000136634 
rs11567701 fwd T G BIFM 0.034 NA rs3194051-G colonic mucosa intronic IL17R ENSG00000168685 






SNP/ID Strand Risk Allele WT allele Source PICS P value SNP if FM Enhancer Annotation SNP/ID Gene Ensembl ID 
rs11567699 fwd G C BIFM 0.034 NA rs3194051 colonic mucosa intronic IL17R ENSG00000168685 
rs1598859 fwd C T BIFM 0.0664 NA rs3774959 Th1 intronic NFKB1 ENSG00000109320 
rs9770544 fwd C G BIFM 0.4201 NA rs4722672 colonic mucosa intronic lincRNA ENSG00000253508 
rs543104 rev A G BIFM 0.0647 NA rs483905 colonic mucosa intronic MAML2 ENSG00000184384 
rs2425019 fwd A G BIFM 0.0996 NA rs6088765 none intronic MMP24 ENSG00000125966 
rs6584283 fwd T C BII BIFM 0.2242 NA rs6584283 colonic mucosa intronic lincRNA ENSG00000257582 
rs6911490 fwd T C BII BIFM 0.9378 NA rs6911490 none intronic ATG5 ENSG00000057663 
rs11757201 fwd C G BIFM 0.2286 NA rs6920220 none intronic lincRNA ENSG00000230533 
rs17264332 fwd G A BIFM 0.2286 NA rs6920220 none intronic lincRNA ENSG00000230533 
rs6927172 fwd G C BIFM 0.2286 NA rs6920220 none intronic lincRNA ENSG00000230533 
rs34902013 fwd G A BIFM 0.0503 NA rs7134599 None intronic IFNG-AS1 ENSG00000255733 
rs723403 rev C T BIFM 0.0503 NA rs7134599 None intronic IFNG-AS1 ENSG00000255733 






SNP/ID Strand Risk Allele WT allele Source PICS P value SNP if FM Enhancer Annotation SNP/ID Gene Ensembl ID 
rs2193041 fwd G A BIFM 0.0503 NA rs7134599 None intronic IFNG-AS1 ENSG00000255733 
rs12829089 fwd G T BIFM 0.0503 NA rs7134599 None intronic IFNG-AS1 ENSG00000255733 
rs200073939 fwd G C BIFM 0.0503 NA rs7134599 None intronic IFNG-AS1 ENSG00000255733 
rs12318183 fwd A C BIFM 0.0503 NA rs7134599 None intronic IFNG-AS1 ENSG00000255733 
rs1558743 fwd G T BIFM 0.0503 NA rs7134599 None intronic IFNG-AS1 ENSG00000255733 
rs1558746 fwd A G BIFM 0.0503 NA rs7134599 None intronic IFNG-AS1 ENSG00000255733 
rs12132298 fwd C T BIFM 0.1139 NA rs7554511 none intronic C1orf107 ENSG00000163362 
rs59655222 fwd C T BIFM 0.1139 NA rs7554511 none intronic C1orf108 ENSG00000163362 
rs41299637 fwd G T BIFM 0.1139 NA rs7554511 none intronic C1orf109 ENSG00000163362 
rs12131796 fwd A G BIFM 0.1139 NA rs7554511 none intronic C1orf110 ENSG00000163362 
rs7608697 fwd C A BIFM 0.1946 NA rs7608910 none intronic PUS10 ENSG00000162927 
rs7596362 fwd C T BIFM 0.1946 NA rs7608910 none intronic PUS10 ENSG00000162927 






SNP/ID Strand Risk Allele WT allele Source PICS P value SNP if FM Enhancer Annotation SNP/ID Gene Ensembl ID 
rs4560096 fwd G T BIFM 0.1946 NA rs7608910 none intronic PUS10 ENSG00000162927 
rs798502 rev A C BII BIFM 0.1681 NA rs798502 none intronic GNA12 ENSG00000146535 
rs11041476 fwd A G BIFM 0.1404 NA rs907611 colonic mucosa intronic LSP1 ENSG00000130592 
rs943072 rev G T BII BIFM   0.141 NA rs943072 colonic mucosa intronic lincRNA ENSG00000283573 
rs6940798 fwd A G BIFM 0.0742   rs943072 colonic mucosa intronic lincRNA ENSG00000283573 
rs2396087 fwd T C BIFM 0.141 NA rs943072 colonic mucosa intronic lincRNA ENSG00000283573 
rs2396088 fwd A G BIFM 0.141 NA rs943072-G colonic mucosa intronic lincRNA ENSG00000283573 
rs4273687 fwd G A BIFM 0.141 NA rs943072-G colonic mucosa intronic lincRNA ENSG00000283573 
rs9822268 fwd A G BII BIFM 0.1386 NA rs9822268 none intronic APEH ENSG00000164062 
rs11130213 fwd T C BIFM 0.1386 NA rs9822268 none intronic APEH ENSG00000164062 
rs2581817 rev G C BIFM 0.1017 NA rs9847710 none intronic SFMBT1 ENSG00000163935 
rs2564956 rev G A BIFM 0.1017 NA rs9847710 colonic mucosa intronic SFMBT1 ENSG00000163935 









allele Source PICS P value SNP if FM Enhancer Annotation SNP/ID Gene Ensembl ID 
rs6871626 fwd A C 
IBDS ICIBD 
BIFM BII 0.7608 1.43E-42 rs6871626 none intronic AC008697.1 ENSG00000249738 
rs7554511 fwd C A 
IBDS ICIBD 
BIFM BII 0.1139 1.24E-32 rs7554511 none intronic C1orf106 ENSG00000163362 
rs7608910 fwd G A 
IBDS ICIBD 
BIFM BII 0.1946 8.65E-32 rs7608910 none intronic PUS10 ENSG00000162927 
rs2823286 fwd G A IBDS ICIBD NA 9.28E-30 rs2823286  intronic lincRNA ENSG00000229425 
rs1893217 rev G A IBDS ICIBD NA 3.05E-26 rs1893217  intronic PTPN2 ENSG00000175354 
rs6062504 fwd G A IBDS ICIBD NA 1.09E-23 rs6062504  intronic ZGPAT ENSG00000197114 
rs12942547 fwd A G IBDS ICIBD NA 5.51E-22 rs12942547  intronic STAT3 ENSG00000168610 
rs11879191 fwd G A IBDS ICIBD NA 2.04E-18 rs11879191  intronic CDC37 ENSG00000105401 
rs2266959 fwd T G IBDS ICIBD NA 1.39E-16 rs2266959  intronic UBE2L3 ENSG00000185651 
rs3766606 rev G T BIFM ICIBD 0.1119 1.12E-15 rs35675666 colonic mucosa intronic PARK7 ENSG00000116288 
rs8005161 fwd T C IBDS ICIBD NA 2.35E-14 rs8005161  intronic GPR65 ENSG00000140030 
rs5763767 fwd A G ICIBD NA 2.70E-14 rs2412970  intronic HORMAD2 ENSG00000176635 









allele Source PICS P value SNP if FM Enhancer Annotation SNP/ID Gene Ensembl ID 
rs3851228 fwd T A IBDS ICIBD NA 1.08E-13 rs3851228  intronic TRAF3IP2-AS1 ENSG00000231889 
rs7657746 fwd A G IBDS ICIBD NA 2.76E-13 rs7657746  intronic KIAA1109 ENSG00000138688 
rs259964 fwd A G IBDS ICIBD NA 1.01E-12 rs259964  intronic ZNF831 ENSG00000124203 
rs17119 rev A G IBDS ICIBD NA 3.08E-11 rs17119  intronic lincRNA ENSG00000234261 
rs1517352 fwd C A IBDS ICIBD NA 3.28E-11 rs1517352  intronic STAT4 ENSG00000138378 
rs7495132 fwd C T IBDS ICIBD NA 9.48E-11 rs7495132  intronic CRTC3 ENSG00000140577 
rs11229555 fwd G T ICIBD NA 6.80E-10 rs10896794  intronic GLYAT ENSG00000149124 
rs7404095 fwd C T IBDS ICIBD NA 9.68E-10 rs7404095  intronic PRKCB ENSG00000166501 
rs13277237 fwd G A ICIBD NA 1.65E-09 rs1991866  intronic lincRNA ENSG00000229140 
rs10896794 fwd T C IBDS NA 6.10E-08 rs10896794   Intronic LPXN ENSG00000110031 











allele Source PICS P value SNP if FM Enhancer Annotation SNP/ID Gene Ensembl ID 
rs1801274 rev A G UCS 
ICUC 
BIFM 
0.444 1.44E-22 rs1801274  missense FCGR2A ENSG00000143226 
rs3749171 fwd T C IBDS 
ICUC 
NA 3.07E-21 rs3749171  missense GPR35 ENSG00000178623 
rs11209026 fwd G A ICIBD 
IBDS 
BIFM BII 
0.1769 8.12E-161 rs11209026 none missense IL23R ENSG00000162594 
rs3197999 rev A G ICIBD 
IBDS 
NA 1.01E-47 rs3197999  missense MST1 ENSG00000173531 
rs3742130 rev G A ICIBD NA 2.37E-14 rs9557195  synonymous GPR18 ENSG00000125245 
rs11230563 fwd C T IBDS 
ICIBD 
NA 9.03E-13 rs11230563  missense CD6 ENSG00000013725 
rs12103 fwd A G IBDS 
ICIBD 
NA 7.66E-13 rs12103  synonymous CPSF3L ENSG00000127054 
rs5771069 fwd G A BII BIFM 0.0956 NA rs5771069 colonic mucosa missense IL17REL ENSG00000188263 
rs10781499 fwd A G BII BIFM 0.2 NA rs10781499  synonymous CARD9 ENSG00000187796 




3  UC and IBD Associated SNPs utilised in Chapter 2 UC Interactome – Exonic SNPs. Highlighted are SNPs used in Chapter 4. 
SNP/ID Strand Risk Allele WT allele Source PICS P value SNP if FM Enhancer Annotation SNP/ID Gene Ensembl ID 
rs3208008 fwd A C BIFM 0.0478 NA rs2297441 colonic mucosa missense  RTEL1 ENSG00000258366 
rs1131095 fwd C T BIFM 0.1386 NA rs9822268 none synonymous  APEH ENSG00000164062 
rs13085791 fwd A C BIFM 0.1386 NA rs9822268 colonic mucosa synonymous MST1 ENSG00000173531 





allele Source PICS P value SNP if FM Enhancer Annotation SNP/ID Gene Ensembl ID 
rs17780256 fwd A C ICUC  
BIFM 
0.1314 1.89E-09 rs7210086-A none 3'UTR SLC39A11 ENSG00000133195 
rs2382817 fwd A C ICIBD IBDS NA 3.70E-12 rs2382817  5'UTR TMBIM1 ENSG00000135926 
rs727088 fwd G A ICIBD IBDS NA 4.65E-09 rs727088  3'UTR CD226 ENSG00000150637 
rs1126510 rev G A BIFM BII 0.3898 NA rs1126510 none 3'UTR PTGIR ENSG00000160013 
rs2297441 fwd A G BIFM BII 0.0769 NA rs2297441 colonic mucosa 3'UTR RTEL1 ENSG00000258366 
rs35675666 fwd G T BIFM BII 0.1119 NA rs35675666 colonic mucosa 5'UTR PARK7 ENSG00000116288 
rs10114470 fwd T C BIFM 0.0511 NA rs4246905 colonic mucosa 3'UTR TNFSF15 ENSG00000181634 











allele Source PICS P value SNP if FM Enhancer Annotation SNP/ID Gene Ensembl ID 
rs10797432 fwd C T UCS BIFM 
BII   
0.1121 5.18E-09 rs10797432 none DGV TNFRSF14 ENSG00000157873 
rs11150589 fwd T C UCS ICUC 
BIFM BII 
0.2236 6.04E-10 rs11150589 Th2 UGV ITGAL ENSG00000005844 
rs561722 rev C T UCS ICUC 
BIFM BII 
0.1751 5.15E-17 rs561722 none UGV NXPE2P1 ENSG00000255982 
rs6667605 fwd C T ICUC NA 2.62E-12 rs10797433  DGV  RP3-395M20.7 ENSG00000225931 
rs7210086 fwd A C BII BIFM 0.2636 NA rs7210086 none DGV SLC39A11 ENSG00000133195 
rs6451493 fwd T G BII BIFM 0.0382 NA rs6451493 colonic mucosa UGV lincRNA ENSG00000283286 
rs16940202 fwd C T BII BIFM 0.9638 NA rs16940202 colonic mucosa UGV lincRNA ENSG00000269667 
rs2155219 fwd T G BII BIFM 0.3783 NA rs2155219 colonic mucosa UGV pseudogene ENSG00000254755 
rs7562334 fwd A G BIFM 0.0422 NA rs11676348  DGV CXCR2 ENSG00000180871 










allele Source PICS P value SNP if FM Enhancer Annotation SNP/ID Gene Ensembl ID 
rs10228276 fwd G A BIFM 0.0528 NA rs4722672 none DGV HOTTIP ENSG00000243766 
rs10910092 fwd A G BIFM 0.1121 NA rs10797432 none DGV TNFRSF15 ENSG00000157873 
rs12598978 fwd T G BIFM 0.2236 NA rs11150589 th2 UGV ITGAL ENSG00000005844 
rs12716977 fwd T C BIFM 0.2236 NA rs11150589 th2 UGV ITGAL ENSG00000005844 
rs6451494 fwd C T BIFM 0.0382 NA rs6451493 colonic mucosa UGV lincRNA ENSG00000283286 
rs6883964 fwd G A BIFM 0.0382 NA rs6451493 colonic mucosa UGV lincRNA ENSG00000283286 
rs12655810 fwd T C BIFM 0.0382 NA rs6451493 colonic mucosa UGV lincRNA ENSG00000283286 
rs6888952 fwd G A BIFM 0.0382 NA rs6451493 colonic mucosa UGV lincRNA ENSG00000283286 
rs11742570 fwd C T BIFM 0.0382 NA rs6451493 colonic mucosa UGV lincRNA ENSG00000283286 
rs6890268 fwd T A BIFM 0.0382 NA rs6451493 colonic mucosa UGV lincRNA ENSG00000283286 
rs6871591 fwd A T BIFM 0.0382 NA rs6451493 colonic mucosa UGV lincRNA ENSG00000283286 
rs1445004 rev T C BIFM 0.0382 NA rs6451493 colonic mucosa UGV lincRNA ENSG00000283286 




rs7117324 fwd A G BIFM 0.1751 NA rs561722 none UGV NXPE2P1 ENSG00000255982 






allele Source PICS P value SNP if FM Enhancer Annotation SNP/ID Gene Ensembl ID 
rs34414754 fwd C A BIFM 0.1056 NA rs7524102 none UGV  ENSG00000279625 
rs3024505 rev A G ICIBD IBDS 
BIFM BII 
0.4133 6.66E-42 rs3024505 Th2 DGV IL10 ENSG00000136634 
rs907611 fwd A G ICIBD IBDS  
BIFM BII 
0.2159 2.70E-10 rs907611 colonic mucosa UGV LSP1 ENSG00000130592 
rs4656958 fwd G A ICIBD IBDS   NA 3.80E-09 rs4656958  UGV ITLN1 ENSG00000179914 
rs12946510 fwd T C ICIBD IBDS NA 4.10E-38 rs12946510  DGV IKZF3 ENSG00000161405 
rs10758669 fwd C A ICIBD IBDS 0.9823 1.29E-26 rs10758669 Th1 UGV JAK2 ENSG00000096968 
rs6087990 fwd C T ICIBD NA 1.20E-09 rs4911259  UGV DNMT3B ENSG00000088305 









SNP/ID Strand Risk Allele WT allele Source PICS P value SNP if FM Enhancer Annotation SNP/ID 
rs6017342 fwd C A UCS ICUC BIFM BII 1 1.43E-43 rs6017342 colonic mucosa non coding transcript variant 
rs2836878 fwd G A IBDS ICUC BIFM BII 0.179 4.62E-48 rs2836878 CD14+ cells RRV 
rs12568930 fwd T C IBDS ICUC BIFM 0.0569 1.26E-17 rs12568930 colonic mucosa RRV 
rs2838519 fwd G A BIFM BII 0.1914 NA rs2838519 colonic mucosa RRV 
rs2310173 fwd T G BIFM BII 0.5088 NA rs2310173 colonic mucosa RRV 
rs7282490 fwd G A BIFM 0.0678 NA rs2838519 CD20+ cells RRV 
rs4817986 fwd T G BIFM 0.179 NA rs2836878 CD14+ cells RRV 
rs4817987 fwd T C BIFM 0.179 NA rs2836878 CD14+ cells RRV 
rs913678 fwd T C IBDS ICIBD NA 4.59E-08 rs913678  RRV 
rs7282490 fwd G A IBDS ICIBD NA 2.35E-26 rs7282490  RRV 









SNP/ID Strand Risk Allele WT allele Source PICS P value SNP if FM Enhancer Annotation SNP/ID 
rs6426833 fwd A G UCS ICUC BIFM BII 0.4767 2.39E-68 rs6426833 colonic mucosa intergenic 
rs477515 rev G A UCS ICUC NA 6.96E-62 rs6927022  intergenic 
rs4380874 fwd T C ICUC  BII BIFM 0.7608 2.07E-26 rs4380874  intergenic 
rs2413583 fwd C T ICIBD IBDS NA 4.40E-33 rs2413583  intergenic 
rs17085007 fwd C T IBDS ICUC BIFM BII 0.703 1.38E-11 rs17085007 colonic mucosa intergenic 
rs17694108 fwd A G IBDS ICIBD NA 5.85E-15 rs17694108  intergenic 
rs9297145 fwd C A IBDs ICIBD NA 8.21E-12 rs9297145  intergenic 
rs559928 fwd C T IBDS ICIBD NA 4.19E-11 rs559928  intergenic 
rs4243971 fwd G T IBDS ICIBD NA 6.05E-10 rs6142618  intergenic 
rs4957048 rev C T BII BIFM 0.0634 NA rs4957048 none intergenic 




rs7809799 fwd G A BII BIFM 0.2779 NA rs7809799 colonic mucosa intergenic 
rs11676348 fwd T C BIFM BII 0.1055 NA rs11676348 none intergenic 
7 UC and IBD Associated SNPs utilised in Chapter 2 UC Interactome – intergenic SNPs. Highlighted are SNPs used in Chapter 4. 
SNP/ID Strand Risk Allele WT allele Source PICS P value SNP if FM Enhancer Annotation SNP/ID 
rs72703046 fwd C T BIFM 0.0634 NA rs4957048 none intergenic 
rs11955068 fwd T C BIFM 0.0634 NA rs4957048 none intergenic 
rs72703050 fwd C A BIFM 0.0634 NA rs4957048 none intergenic 
rs56410216 fwd A C BIFM 0.0634 NA rs4957048 none intergenic 
rs72703058 fwd A G BIFM 0.0634 NA rs4957048 none intergenic 
rs10737481 fwd T G BIFM 0.4767 NA rs6426833 none intergenic 


























Unique ID of 
each SNP 
miRNA or TF which has a 
binding site in the gene, 
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of the SNP 
Effected gene by 
changed TFBS or 
miRNA BS or the 
mID/name of lost 
mature miRNA itself 
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  UNIROT ID, MIMAT ID 
IDs are separated by 
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rs1131095 hsa-miR-369-3p mirna BS  P13798 APEH loss_up 
rs6911490 
  
ESE Q9H1Y0 ATG5 loss_up 
rs4129963
7 




hsa-miR-7159-5p mirna BS  Q3KP66 C1orf106 loss_up 
rs5965522
2 












ESE Q3KP66 C1orf106 gain_dow
n 


















ESE Q9H257 CARD9 loss_up 
rs1226184
3 
hsa-miR-6870-3p mirna BS  Q8ND76 CCNY gain_do
wn 
rs6481950 hsa-miR-433-5p mirna BS  Q8ND76 CCNY loss_up 




hsa-miR-6870-3p mirna BS  Q8ND76 CCNY gain_do
wn 


















ESS P30203 CD6 gain_up 
rs2837471
5 








ESE Q99653 CHP1 gain_dow
n 
rs12103 hsa-miR-7113-3p mirna BS  Q5TA45 CPSF3L gain_do
wn 
rs12103 hsa-miR-7113-3p mirna BS  Q5TA45 CPSF3L gain_do
wn 
rs7495132 P55317 FOXA1 TFBS Q6UUV7 CRTC3 gain_up 
rs7495132 O60806 TBX19 TFBS Q6UUV7 CRTC3 gain_up 
rs7495132 
  




ESE P51397 DAP gain_dow
n 
rs1801274 hsa-miR-204-5p mirna BS  P12318 FCGR2A gain_do
wn 
rs1801274 hsa-miR-6867-3p mirna BS  P12318 FCGR2A gain_do
wn 
rs4657041 A6NLW8 DUXA TFBS P12318 FCGR2A loss_do
wn 
rs4657041 P10276 RARA TFBS P12318 FCGR2A loss_do
wn 
rs1801274 Q9H0R8 ATG8 ELM P12318 FCGR2A gain 
rs1801274 P49840 GSK3 ELM P12318 FCGR2A gain 
rs1801274 P38398 BRCA1 ELM P12318 FCGR2A gain 
rs11229555 
  
ESE Q6IB77 GLYAT loss_up 
rs1182188 hsa-miR-4433a-3p mirna BS  Q03113 GNA12 loss_up 
rs1182188 hsa-miR-6880-5p mirna BS  Q03113 GNA12 loss_up 
rs1182188 hsa-miR-4510 mirna BS  Q03113 GNA12 loss_up 
rs1182188 hsa-miR-6760-5p mirna BS  Q03113 GNA12 loss_up 
rs1182188 hsa-miR-7847-3p mirna BS  Q03113 GNA12 loss_up 
rs1182188 
  
ESE Q03113 GNA12 loss_up 
rs3749171 
  


















Q06413 MEF2C TFBS Q9UKT9 IKZF3 gain_up 
rs3024495 hsa-miR-4647 mirna BS  P22301 IL10 gain_do
wn 
rs3024495 O14978 ZNF263 TFBS P22301 IL10 gain_up 
rs1156769
9 
Q99592 ZBTB18 TFBS Q96F46 IL17R loss_do
wn 




ELM Q6ZVW7 IL17REL loss 
rs5771069 
  








ESS Q5VWK5 IL23R gain_up 
rs1115058
9 








hsa-miR-548ay-3p mirna BS  P20701 ITGAL loss_up 
rs1115058
9 
hsa-miR-548at-3p mirna BS  P20701 ITGAL loss_up 
rs1271697
7 
hsa-miR-1268b mirna BS  P20701 ITGAL loss_up 
rs1271697
7 
hsa-miR-1268a mirna BS  P20701 ITGAL loss_up 
rs1115058
9 
P10914 IRF1 TFBS P20701 ITGAL gain_up 
rs7657746 hsa-miR-3183 mirna BS  Q2LD37 KIAA1109 loss_up 
rs7657746 hsa-miR-2114-5p mirna BS  Q2LD37 KIAA1109 loss_up 
rs7657746 hsa-miR-642a-5p mirna BS  Q2LD37 KIAA1109 loss_up 
rs7657746 hsa-miR-3184-3p mirna BS  Q2LD37 KIAA1109 gain_do
wn 
rs1654644 hsa-miR-625-5p mirna BS  P43630 KIR3DL2 loss_up 
rs1654644 hsa-miR-4716-3p mirna BS  P43630 KIR3DL2 loss_up 





























ESE P33241 LSP1 loss_up 
rs483905 hsa-miR-6839-5p mirna BS  Q8IZL2 MAML2 loss_up 
rs543104 
  








hsa-miR-6746-5p mirna BS  P26927 MST1 loss_up 
rs1308579
1 
hsa-miR-8085 mirna BS  P26927 MST1 loss_up 




ESE P19838 NFKB1 gain_dow
n 
rs2816958 hsa-miR-619-5p mirna BS  O00482 NR5A2 gain_do
wn 
rs2816958 hsa-miR-6513-5p mirna BS  O00482 NR5A2 loss_up 
rs1089169
2 








hsa-miR-3192-5p mirna BS  Q8N323 NXPE1 loss_up 
rs1089169
2 













ESS Q8N323 NXPE1 gain_up 
rs3766606 
  




ESE P17706 PTPN2 loss_up 
rs7596362 
  
ESE Q3MIT2 PUS10 loss_up 
rs7608697 
  
ESE Q3MIT2 PUS10 loss_up 
rs7608910 
  




rs3208008 hsa-miR-6759-5p mirna BS  Q9NZ71 RTEL1 loss_up 
rs2257440 hsa-miR-661 mirna BS  Q9NZ71 RTEL1 loss_up 
rs2297441 Q92826 HOXB13 TFBS Q9NZ71 RTEL1 gain_up 
rs2297441 P35453 HOXD13 TFBS Q9NZ71 RTEL1 gain_up 
rs3208008 
  
ELM Q9NZ71 RTEL1 loss 
rs3208008 
  
ESS Q9NZ71 RTEL1 gain_up 








ESE P40763 STAT3 loss_up 




hsa-miR-8073 mirna BS  Q92956 TNFRSF14 loss_up 
rs1091009
2 
hsa-miR-7157-3p mirna BS  Q92956 TNFRSF14 loss_up 
rs1079743
2 








ESE Q8N5A5 ZGPAT gain_dow
n 
 
 
